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ABSTRACT 
Neuroblastomas (NBs) are the most common solid extra-cranial tumours diagnosed in 
childhood and characterized by a high risk of tumour relapse. Like in other tumour types, 
there are major concerns about the specificity and safety of available drugs used for the 
treatment of NBs, especially because of potential damage to the developing brain. Many 
plant-derived bioactive compounds have proved effective for cancer treatment but are not 
delivered to tumour sites in sufficient amounts due to compromised tumour vasculature 
characterized by leaky capillary walls. Betulinic acid (BetA) is one such naturally-occurring 
anti-tumour compound with minimum to no cytotoxic effects in healthy cells and rodents. 
BetA is however insoluble in water and most aqueous solutions, thereby limiting its 
therapeutic potential as a pharmaceutical product. Liposomes are self-assembling closed 
colloidal structures composed of one or more concentric lipid bilayers surrounding a central 
aqueous core. The unique ability of liposomes to entrap hydrophilic molecules into the core 
and hydrophobic molecules into the bilayers renders them attractive for drug delivery 
systems. Cyclodextrins (CDs) are non-reducing cyclic oligosaccharides which proximate a 
truncated core, with features of a hydrophophilic outer surface and hydrophobic inner cavity 
for forming host-guest inclusion complexes with poorly water soluble molecules. CDs and 
liposomes have recently gained interest as novel drug delivery vehicles by allowing 
lipophilic/non-polar molecules into the aqueous core of liposomes, hence improving the 
therapeutic load, bioavailability and efficacy of many poorly water-soluble drugs. 
The aim of the study was to develop nano-drug delivery systems for BetA in order to treat 
human neuroblastoma (NB) cancer cell lines. This was achieved through the preparation of 
BetA liposomes (BetAL) and improving the percent entrapment efficiency (% EE) of BetA in 
liposomes through double entrapment of BetA and gamma cyclodextrin BetA inclusion 
complex (γ-CD-BetA) into liposomes (γ-CD-BetAL). We hypothesized that the γ-CD-BetAL 
would produce an increased % EE compared to BetAL, hence higher cytotoxic effects.  
 
Empty liposomes (EL), BetAL and γ-CD-BetAL were synthesized using the thin film 
hydration method followed by manual extrusion. Spectroscopic and electron microscopic 
characterization of these liposome formulations showed size distributions of 1-4 μm (before 
extrusion) and less than 200 nm (after extrusion). As the liposome size decreased, the zeta-
potential (measurement of liposome stability) decreased contributing to a less stable 
liposomal formulation. Low starting BetA concentrations were found to be more effective in 
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entrapping higher amounts of BetA in liposomes while the incorporation of γ-CD-BetA into 
liposomes enhanced the % EE when compared to BetAL, although this was not statistically 
significant. 
 
Cell viability studies using the WST-1 assay showed a time-and concentration-dependent 
decrease in SK-N-BE(2) and Kelly NB cell lines exposed to free BetA, BetAL and γ-CD-
BetAL at concentrations of 5-20 ug/ml for 24, 48 and 72 hours treatment durations. The 
observed cytotoxicity of liposomes was dependant on the % EE of BetA. The γ-CD-BetAL 
was more effective in reducing cell viability in SK-N-BE(2) cells than BetAL whereas BetAL 
was more effective in KELLY cells at 48-72 hours. Exposure of all cells to EL showed no 
toxicity while free BetA was more effective overall than the respective liposomal 
formulations 
 
The estimated IC₅₀ values following exposure to free BetA and BetAL were similar and both 
showed remarkable statistically significant decrease in NB cell viability, thus providing a 
basis for new hope in the effective treatment of NBs. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1    Development of Cancer 
The human body comprises of many different cells all proliferating and differentiating under 
the control of various related regulatory mechanisms. Some of these mechanisms involve 
several cell checkpoints which are responsible for detecting and correcting irregularities in 
deoxyribonucleic acid (DNA). In spite of these processes, DNA damage could occur through 
diet, hormonal imbalances, tobacco use, radiation exposure, environmental factors and certain 
infections (Cretney et al., 2007). In the event of DNA damage, normal cells would trigger a 
DNA repair mechanism but failure to do this, results in genomic instability (Gotter, 2009).  
Apoptosis or programmed cell death is initiated to ensure that cells are abolished and cannot 
multiply. A failure to execute apoptosis can cause the progression of abnormal cell 
proliferation which is one of the most prominent characteristics of cancer (Gotter, 2009). 
Cells can divide uncontrollably and out-compete the normal cells for nutrients thereby 
displacing normal cells and forming masses of purposeless tissues called tumours (Cooper, 
2000; Quail and Joyce, 2013). Tumours could be benign (non-cancerous) or malignant 
(cancerous). Benign tumours lack the ability to invade other areas of the body whereas 
malignant tumours have the ability to metastasise to other parts of the body through the 
lymphatic system or the bloodstream (Maccauro et al., 2011). 
1.2    Tumour Vasculature 
Tumour cells, similar to normal cells in the human body require nutrients, oxygen and the 
ability to eliminate harmful metabolic waste products and carbon dioxide. Stages involved in 
initial tumour growth depend on diffusion of nutrients; however when a tumour reaches a size 
of approximately 2 mm³, diffusion from surrounding blood vessels becomes limited and may 
lead to hypoxia and nutrient deficiency (Rong et al., 2006). This results in the development of 
vasculature within the tumour through recruitment of endothelial cells and angiogenic factors 
to construct new blood vessels from existing blood vessels to the site of the tumour; a process 
termed angiogenesis (Danhier et al., 2010; Yoo and Kwon 2013). The increase in blood 
supply generates highly disorganised and abnormal vasculature marked with regions having a 
rich blood supply and others with low blood supply (Danhier et al., 2010; Goel et al., 2012). 
Poor vasculature results in dead end vessels with incomplete endothelial linings causing leaky 
 
 
 
 
2 
 
and highly permeable tumour vessels (Dudley, 2012; Goel et al., 2012). Important hallmarks 
of malignant cell growth have been identified to include: self-sufficiency in growth signals, 
insensitivity to antigrowth signals, unregulated proliferation potential, an increase in blood 
supply to the tumour, metastasis, evading the immune system, reprogramming of energy 
metabolism and importantly, evasion of apoptosis (Hanahan and Weinberg, 2000; 2011).   
1.3     The Nervous System  
The nervous system (NS) is a highly sophisticated organ system comprising a network of 
specialised cells called neurons (Stahl, 2008). The brain is composed of approximately 86 
billion neurons (Azevedo et al., 2009) which are the essential information-processing units of 
the NS, responsible for receiving and transmitting electrical and chemical signals between 
different parts of the human body (Stahl, 2008). They are categorized into three types (Figure 
1.1): inter-neurons (which constitute the majority of neurons in the brain, conduct thought 
processes, vision and perception of surroundings); motor neurons (receive impulses from the 
brain to cause muscular contraction and gland secretion) and sensory neurons (receive 
information from sense organs and relay it to the brain) (Kandel et al., 1995; Lodish et al., 
2000; Martini, 2006). 
 
Figure 1.1 Schematic illustration of the structure of three different types of neurons: a) Multi-polar inter-
neurons, b) Motor neuron and c) Sensory neuron, with their major components. Arrows indicate the direction of 
the conduction of action potentials (Adapted from Lodish et al., 2000). 
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A typical neuron constitutes three essential parts (Figure 1.1, p. 2): Cell body/soma (which 
contains the nucleus and cytoplasm), dendrites (which receive electrochemical stimulation 
from other neural cells) and axons (which conduct electrical impulses away from the soma, 
towards other neurons, muscles or glands) (Kandel et al., 1995; Martini, 2006). Motor and 
sensory neurons have long axons covered by a myelin sheath, which assists in the speed of 
neural impulses (Morell and Quarles, 1999). The spaces in between myelin sheaths where 
axons are exposed are called ‘Node of Ranvier’ (Figure 1.1). Neurons can communicate in 
three different ways: electrical synapse, emphatic interaction and chemical synapse, with the 
latter being the most predominant form of communication within the brain (Kendal et al 
1995). When a signal is received by dendrites, it is transmitted to the soma via an 
electrochemical signal and passes through the axon to the axon terminals, which form 
junctions with other cells (Figure 1.1). Pre and post synaptic neurons are in close proximity to 
each other and are separated by a gap junction called the synapse. Once signals arrive at the 
axon terminals of a pre-synaptic neuron, neurotransmitters (acetocholine, dopamine, 
serotonin, etc.) are released to transfer electrochemical signals to post-synaptic neurons 
(Purves et al., 2001; Martini, 2006).  
The NS is divided into two parts: the central nervous system (CNS) and the peripheral 
nervous system (PNS) (Figure 1.2): 
 
 
 
 
 
 
 
 
 
Figure 1.2 Flowchart representing the divisions and sub-divisions of the NS (Adapted from 
http://classconnection.s3.amazonaws.com/420/flashcards/1094420/jpg/nervous_system_organization132805608
1853.jpg with modifications). 
 
Nervous system (NS) 
Peripheral Nervous System 
(PNS): Relays information 
to CNS and body 
Somatic Nervous System (SNS): 
Communicates with sense organs 
and voluntary muscles 
Autonomic Nervous System 
(ANS): Communicates with 
internal organs and glands 
Sensory (afferent) 
Nervous System 
(SENS): 
Sensory input 
Motor (efferent) 
Nervous System 
(MNS): Motor 
output 
Sympathetic 
Nervous System 
(SYNS): ‘Fight or 
flight’ 
Parasympathetic 
Nervous System 
(PSNS): Control 
activities in the 
body at rest  
Central Nervous System 
(CNS): Brain and spinal 
cord 
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The CNS comprises of the brain and the spinal cord, located and protected by the skull and 
the vertebral column. The CNS receives information from the human body and coordinates 
sensory data and motor commands (Shepherd, 1987; Bear et al., 2006). The PNS constitutes 
all the nerves which relay information from the brain to the rest of the body (Shepherd, 1987; 
Bear et al., 2006). The PNS connects the CNS to sensory organs (e.g., eyes, ears, muscles, 
glands and blood vessels) and is further sub-divided into the somatic nervous system (SNS) 
and the autonomic nervous system (ANS) (Figure 1.2, p. 3) (Martini, 2006). 
The ANS, also called the visceral NS or involuntary NS, consists of two main sub-divisions: 
the sympathetic nervous system (SYNS) and the parasympathetic nervous system (PSNS) 
(Figure 1.2, p. 3) (Martini, 2006; McCorry, 2007). The PSNS is responsible for control of 
digestion activities when the body is at rest, it also includes salvation, urination, defecation, 
sexual arousal and lacrimation (tear production) (McCorry, 2007). The SYNS allows the 
body to manage under stressful conditions and also controls the ‘fight-or-flight’ response 
(Martini, 2006). The SYNS consists of nerve fibres that run along the spinal cord, clusters of 
nerve cells called ganglia and nerve-like cells found at the medulla of the adrenal gland 
(Martini, 2006; McCorry, 2007). The main function of the SYNS is to allow the dilation of 
the pupils, inhibit salvation, relaxing of the bronchi of the lungs, acceleration of the heart, 
inhibits digestive activity, stimulates glucose by the liver, secretion of epinephrine and 
norepinephrine from the kidneys, relaxes the bladder and contracts the rectum (Bear et al., 
2006; Martini, 2006; McCorry, 2007). 
1.4    Central Nervous System (CNS) Cancers 
More than 100 brain tumour types based on clinical presentation, genetics, histopathological 
features and malignancy have been recognized by the World Health Organization (WHO) 
(Fuller, 2008). Brain tumours are the second most common cancers in men (ages 20-39) and 
the fifth most common cancers in woman (ages 20-39). An estimated 23,380 new brain and 
other NS cancer cases were projected for 2014 in America, with more males being affected 
than females (12,820 men versus 10,560 females) (Siegal et al., 2014). In the paediatric age 
group, tumours of the CNS account for 30% with the majority of other cases belonging to the 
groups of lymphomas, sarcomas, or embryonal tumours like nephroblastoma, 
hepatoblastoma, and neuroblastoma (Stiller, 2004). CNS embryonal tumours originate in 
embryonic cells that remain in the brain after birth and could potentially spread through 
the cerebrospinal fluid to other parts of the brain and spinal cord (Shalaby et al., 2014). The 
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global burden of CNS diseases is expected to increase to 14% in 2020 (Blasi et al., 2007). 
Most NS tumours are difficult to treat with a low survival rate. They are known to grow 
aggressively, metastasize profusely and are resistant to current treatments (Van Meir et al., 
2010; Westphal and Lamszus, 2011). Any brain tumour is life-threatening because of its 
invasive and infiltrative nature within the limited intracranial cavity. 
1.5    Neuroblastoma (NB) 
Neuroblastomas (NBs) are the most common extra-cranial solid brain tumours to be 
diagnosed in infancy and childhood (Nuchtern, 2012), accounting for 7-8 % of all childhood 
cancers and affecting 10.2 per million children under the age of 15 years old in the USA 
(Cheung and Dyer, 2013). Approximately 75 % of diagnosed cases present with metastases, 
increased aggressiveness and chemo-resistance in children older than one year old (Kaatsch, 
2010). Significant strides have been achieved in identifying prominent molecular and genetic 
markers for NB, however this disease remains one of the major challenges confronting 
paediatric oncology especially since the five year survival rate for patients presenting with 
high risk NB tumours remains below 40 % (Maris et al., 2007; Jiang et al., 2011). Children 
treated for high-risk NB also have the greatest risk of treatment-related complications, 
including severe hearing loss, infertility, cardiac toxicity, and secondary cancers related to the 
use of high-dose chemotherapy (Brodeur et al., 2011). 
NB belongs to a group of embryonal tumours, which is characterised by a failure of precursor 
cells to exit from a proliferative phase and enter the differentiation process (Grimmer and 
Weiss, 2006). NB has been numerously reported to originate from the neural crest element of 
the SYNS during embryology (Acosta et al., 2009; Jiang et al., 2011; Cheung and Dyer, 
2013; Marshal et al., 2014). 
1.5.1 NBs and Neural Crest Development  
The formation of the CNS in embryology is called neurulation (Copp, 2005). The first step in 
neurulation is the formation of a neural plate which forms at the cranial end (the future brain 
region) of the embryo and grows towards the caudal end (the future spinal cord region). 
Neural crest (NC) development takes place in roughly the third week of embryogenesis, 
where the lateral edges of the neural plate border elevates and move together to form the 
neural fold which fuse together to form the neural tube (Figure 1.3, p. 6) (Copp, 2005; Bhatt 
et al., 2013). The NC is masses of tissue located at the edges of the lateral plates of the 
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folding neural tube and constitutes multipotent NC cells (Simões-Costa and Bronner, 2013). 
Once the neural tube has completely fused, the process of neurulation is complete. NC cells 
start to populate the dorsal part of the neural tube (Figure 1.3) (Simões-Costa and Bronner, 
2013).  
 
Figure 1.3 The process of neurulation. The Neural crest (NC) development occurs in the third week of 
embryogenesis, where the lateral edges of the neural plate border elevate and form the neural fold which fuses 
together to form the neural tube. NC cells then migrate laterally along the sympaticoadrenal lineage of the 
SYNS and form a variety of diverse cell types (Adapted from Wislet-Gendebien et al., 2012). 
A group of NC cells are programmed to undergo an epithelial-to-mesenchymal transition 
(EMT) (Simões-Costa and Bronner, 2013). EMT is a process whereby polarised epithelial 
cells undergo multiple biochemical changes allowing it to acquire a mesenchymal cell 
phenotype, which includes improved migratory capacity, invasiveness and elevated resistance 
to apoptosis (Kalluri and Neilson, 2003; Kalluri and Weinberg, 2009). EMT is completed by 
the degradation of underlying basement membrane and the formation of mesenchymal cells 
that can migrate away from the neural tube (Figure 1.3) (Theveneau and Mayor, 2012). 
Migratory NC cells start to migrate laterally along migratory pathways and form a variety of 
diverse cell types, including PNS neurons, PNS glia, Schwann cells, cartilage and bones, 
melanocytes in the skin, smooth muscles and connective tissue (Figure 1.3) (Theveneau et 
Mayor, 2012; Wislet-Gendebien et al., 2012). Cells populate the primordia of the sympathetic 
ganglia and the adrenal gland, and finally differentiate into the sympathoadrenal lineage of 
Neural tube 
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sympathetic neurons and adrenal chromaffin (endocrine) cells (Mora and Gerald, 2004; Park 
et al., 2008; Taneyhill, 2008; Kulesa et al., 2009; Bhatt et al., 2013).  
The guidance of NC cells along migratory routes and the control of processes involved in cell 
proliferation and differentiation into sympathoadrenal lineage is highly dependent on 
extracellular signals from the microenvironment and intracellular signalling events that 
induce the complex process of NC formation (Gammill and Bronner-Fraser, 2003; Huber, 
2006). Disturbances within these precisely controlled processes, especially the maintenance 
of proliferation and differentiation at specific points can initiate the transformation of NC 
cells to give rise to neuroblastic tumours (Mora and Gerald, 2004). The Sonic Hedgehog and 
Wnt signalling pathways, fibroblast growth factor and bone morphogenic protein (BMP 
proteins) are required for proper NC development and have been implicated in NB 
development (Schneider et al., 1999; Martinez-Morales et al., 2005; Dupin et al., 2007; Shahi 
et al., 2008). 
Therefore NB can be considered as a malignant tumour of pre-cursor or undifferentiated 
neuroectodermal cells derived from the NC (Kamijo, 2012). Embryonic migration of NC 
cells relate the fact that NB can occur anywhere along the sympaticoadrenal lineage of the 
SYNS, however 65 % of primary NB tumours arise in the abdomen with the medulla of the 
adrenal gland being predominantly associated (Park et al., 2008). The paraspinal ganglia are 
also commonly associated with NB (Maris, 2010) and it can also develop in other nerve 
tissues such as PNS nerves, neck (5%), chest (20%), pelvis (5%) abdomen and from mental 
disorders such as Hirschsprung’s disease, congenital central hypoventilation syndrome and 
neurofibromatosis type 1 (Rohrer et al., 2002; Maris et al., 2007). CNS NBs are rarer and 
occur in 5-10% of recurring NB cases (Matthay et al., 2003). CNS NB form in 
the nerve tissue of the cerebrum or the layers of tissue that cover the brain and spinal cord 
(Matthay et al., 2003; Yariş et al., 2004). CNS NBs may be large and spread to other parts of 
the brain or spinal cord (Kramer et al., 2001; Matthay et al., 2003). Presenting symptoms of 
NBs depend largely on the location of the primary tumour and presence of metastasis.  
1.5.2.   Genetics of NB 
Familial (hereditary) NB is rare and heterogeneous, accounting for less than 5% of all NBs 
(Maris et al., 2002; Maris et al., 2007; Jiang et al, 2011). Two of the most common genes 
associated with hereditary NBs are paired-like homeo-box 2b (PHOX2B) gene and anaplastic 
lymphoma kinase (ALK) oncogene (Jiang et al., 2011). Germline mutations in the PHOX2B 
 
 
 
 
8 
 
gene on chromosome 4p13 was the first predisposition mutation gene identified in NB 
(Mosse et al., 2004; Trochet et al., 2004). PHOX2B encodes a homeo-domain transcription 
factor responsible for cell cycle exit and neuronal differentiation and is an important factor in 
the development of NC-derived autonomic neurons and proliferation of immature 
sympathetic neurons (Raabe et al., 2008). PHOX2B has two polyalanine repeat sequences, 
but the non-polyalanine repeat mutations that are usually associated with NB-Hischsprung 
disease and congenital hypoventilation syndrome (Mosse et al., 2004; Trochet et al., 2004). 
Therefore a disturbance in PHOX2B-regulated differentiation pathway in the 
sympathoadrenal lineage of the NC is associated with NB tumour progression (Raabe et al., 
2008). 
The lymphoma ALK gene is expressed in the developing sympathoadrenal lineage of the NC 
and regulates the balance between proliferation and differentiation through multiple cellular 
pathways (Motegi et al., 2004, Schönherr et al., 2010). Inherited changes in the ALK 
oncogene seem to account for most cases of hereditary NB (Mosse et al., 2008 and Jiang et 
al., 2011). Approximately 8% of all NB tumours are associated with ALK abnormalities, 
including the somatic cases (Cheung and Dyer, 2013). NB cell lines and primary tumours 
containing high expression levels of ALK showed high PHOX2B expression suggesting that 
PHOX2B can directly regulate ALK gene expression, showing a connection between these 
two pathways that are mutated in familial NB (Bachetti et al., 2010).  
LMO1 (LIM domain only 1) was recently linked to NB tumours (Wang et al., 2011). Wang 
and colleagues over expressed LMO1 in SK-N-BE(2c) NB cell line which caused an increase 
in cell proliferation rate. Additionally, LMO1 copy number analysis in NB tumours showed 
copy number gain in 12.4 % of the tumours, which was shown to be associated with 
increased LMO1 expression (Wang et al., 2011). 
The majority of NB is non-familial (sporadic) (Cheung and Dyer, 2013). Three genetic 
subtypes: 1A, 2A and 2B are used based on their genomic outline. Low stage tumours 
(subtype 1) present with many abnormalities and a near triploid DNA content.  Subtype 2A or 
2B are characterized by an unbalance of chromosome 17, 17q gain, present in more than 50% 
of the cases. Subtype 2A contains 11q deletions, commonly together with 3p deletions 
(Cheung and Dyer, 2013).  DNA alterations have been reported at chromosome arms 1q 160–
162, 2q 163, 4p 164, 9p 165, 14q 166 and 19q 167 (Cheung and Dyer, 2013).  Chromosomal 
deletions indicate tumour suppressor genes while chromosomal gains may cause presence of 
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oncogenes (Cheung and Dyer, 2013). Subtype 2B tumours present with MYCN 
amplification, often together with 1p deletions (Cheung and Dyer, 2013). 
The proto-oncogene MYCN is a helix-loop-helix transcription factor that regulates growth, 
differentiation, angiogenesis, metabolism and apoptosis in the developing CNS (Wakamatsu 
et al., 1997). Expression of MYCN is a strong intracellular stimulus for ventral migration of 
NC cells. It is present in moderate levels in the nuclei of all trunk NC cells before and during 
migration and several signalling pathways regulates its expression (Grimmer and Weiss, 
2006). MYCN is most commonly associated with sporadic aggressive NB tumours and 
occurs in approximately 22-25% of NB tumours and is associated with poor outcome 
(Althoff et al., 2015).  
1.5.3 Classification of NB Cancer 
"International NBs Staging System" (INSS) (Table 1.1 and Figure 1.4, p. 10) was initiated to 
determine the stages of NBs according to its anatomical presence at diagnosis. 
Table 1.1 International NBs Staging System (INSS) for NB with risk classification (Brodeur 
et al., 1988; Brodeur, 2003; van Noesel and Versteeg et al., 2004; Maris et al., 2007): 
INSS 
staging 
Description Risk classification 
Stage 1 The tumour is confined to the area of origin. Low risk 
Stage 2A The cancer remains localized to the area of origin, but NB cells may be 
present in the lymph nodes enclosed within the tumour. The lymph nodes 
outside the tumour may be free of cancerous cells. 
Low risk/ 
Intermediate risk 
Stage 2B Cancer has spread from point of origin and lymph nodes surrounding the 
tumour. Surgery may be used remove the tumour. 
Low risk/ High risk 
Stage 3 Surgical intervention is often complicated as the tumour infiltrates across 
the midline with or without regional lymph node involvement; or 
unilateral tumour with contra-lateral lymph node involvement; or 
midline tumour with bilateral lymph node involvement. 
Intermediate 
risk/High risk 
 Stage 4 The tumour has spread to distant sites such as distant lymph nodes, skin, 
bone marrow or other organs, however the criteria does not match that of 
stage 4S. 
Intermediate risk/ 
High risk 
Stage 4S Stage 4S: The child is younger than one year old and the cancer 
originated from one side of the body but may disseminate to the lymph 
nodes on the same side but not on the opposite side. Less than 10% of 
the bone marrow cells are cancerous. The cancer can be disseminating to 
the other organs but it is limited to liver, skin or bone marrow. 
 
Low risk/ High risk 
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Figure 1.4 International Neuroblastoma Staging System (INSS) for NB based on anatomical presence 
(Source: http://www.nant.org/Patients_and_Families/neuroblastoma.php).  
1.5.4   Current Diagnosis and Treatment of NB Cancer 
A multidisciplinary approach is commonly applied for the diagnosis and therapy of this 
cancer. Diagnosis is usually confirmed with imaging techniques such as magnetic resonance 
imaging (MRI) scan, computed tomography (CT) scan or positron emission 
tomography (PET) scan, with surgical tissue extraction for further lab analyses also done 
(Sharp et al., 2011).  
A strong independent prognostic factor in NB is age. Children under the age of 18 months 
have localized tumours, allowing for easier diagnosis while in older children; NB has 
metastasized making diagnosis increasingly difficult, eluding to the fact that diagnosis of 
patients with high risk NB have a poor survival rate (Maris et al., 2007; Cohn et al., 2009). 
Treatment usually involves a combination of chemotherapeutic drugs since removing the 
entire tumour is difficult however due to the high infiltrative nature, surgical intervention is 
necessary to assist in reducing the tumour size and radiotherapy usually follow shortly after 
(Wen and Kesari, 2008). Low risk groups such as NB stage 1 and stage 2 tumours are 
localized and can be treated successfully by surgical intervention followed by chemotherapy 
treatment (Jiang et al., 2011). Stage 4S NBs risk group without MYCN amplification may 
regress spontaneously and require no treatment (Jiang et al., 2011). The reported survival rate 
of patients with low risk NB is greater than 95% (Alvarado et al., 2000; Simon et al., 2004; 
Park et al., 2008).  
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Intermediate risk groups such as stage 3 and 4 also rely on surgery and combination 
chemotherapy (Jiang et al., 2011). Radiation may be used to remove residual tumours and 
patients who respond poorly to initial treatments and experience recurrence are treated with 
an aggressive form of chemotherapy (Jiang et al., 2011). Approximately 70–90% cure rate is 
associated with this risk group (Matthay et al., 1999; Schmidt et al., 2000; Park et al., 2008).  
High risk groups with unfavourable biological features and those with MYCN amplification 
at stage 4S are more challenging to treat as the cancer has metastasized (Matthay, 1995; 
Castleberry et al., 1997; Brodeur, 2003). At this late stage patients have poor prognosis and 
approximately 20-50% of high risk NB cases show a low response to high-dose 
chemotherapy and also demonstrates multi drug resistance (Maris and Matthay, 1999). High 
risk NB is treated with chemotherapy, surgery, radiation, bone marrow or hematopoietic stem 
cell transplant among other methods (Maris, 2010). Despite all these available treatments, the 
overall cure rate for high-risk patients was only about 30 % during the past two decades 
(Matthay et al., 1999; Pearson et al., 2008; Zage et al., 2008).  
Common chemotherapeutic drugs used singly or in combination for the treatment of NBs 
includes Cyclophosphamide/ifosfamide, Cisplatin/carboplatin, Vincristine, Doxorubicin 
(Adriamycan), Etopside, Topotecan, Busulfan and Melphalan (Simon et al., 2007; Kushner  
et al., 2010; Bagatell et al., 2011; London et al., 2011; DuBois et al., 2012; French et al., 
2013;  Kushner et al., 2013). Patients in the paediatric age group with high-risk NB can be 
treated with 13-cis-retinoic acid (isotretinoin) to reduce the risk of recurrence after high-dose 
chemotherapy and stem cell transplant (Veal et al., 2013; Sonawane et al., 2014). A 
monoclonal antibody called ch14.18 attaches to the ganglioside GD2, a substance found on 
the surface of many NB cells (Navid et al., 2010; Yang et al., 2010). This antibody can be 
given in conjunction with cytokines (immune system hormones) such as GM-CSF and 
interleukin-2 (IL-2) and is now part of the routine treatment for many children with high-risk 
NB also after a stem cell transplant (Navid et al., 2010). 
Some of the drugs used to treat NBs are known to have toxic side effects. Short term side 
effects include hair loss, mouth sores, loss of appetite, diarrhoea, compromised immune 
system, nausea and vomiting. Cyclophosphamide and ifosfamide are known to damage the 
bladder and reproductive organs thereby affecting fertility (Emadi et al., 2009). Doxorubicin 
is frequently associated with cardiotoxicity, while cisplatin and carboplatin induce 
nephrotoxicity and hearing loss (Kumar et al., 2012; Schacht et al., 2012). The most common 
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side effect of 13-cis-retinoic acid is drying and cracking of the lips and nosebleeds 
(Scheinfeld and Bangalore, 2006). Vincristine may induce neuropathy and ch.14.18 cause 
severe nerve pain and leaking of fluid in the body which could lead to a decrease in blood 
pressure, increase in heart rate, shortness of breath, swelling and allergic reactions (Wang et 
al., 2000; Yang et al., 2010). 
The long term toxic side effects to adjacent brain structures usually include cognitive deficits 
and epilepsy due to neuronal damage (Wen and Kesari, 2008), growth reduction, thyroid 
function disorders, learning difficulties and an increased risk of secondary cancers affecting 
survivors of high-risk NB (Brodeur et al., 2011). 
Table 1.2 Therapeutic strategies for different risk groups of NBs (Maris, 2010) 
Variable Category 
 Stage 1 
Low risk 
Stage 2 
 Intermediate risk 
Stage 3 
High risk 
Stage 4S tumours  
High risk 
Treatment Surgery Moderate-intensity 
chemotherapy; Surgery 
Multimodal therapy Supportive care 
Survival rate 
(%) 
> 98 90-95 40-50 >  90 
 
1.6    Challenges in Treating CNS and Brain Cancers 
The delivery of drugs in CNS cancers is mainly limited by the presence of anatomical 
barriers: the blood–brain barrier (BBB), blood–cerebrospinal fluid barrier (BCSFB) and the 
cerebrospinal fluid brain barrier (CSF) (Engelhardt and Sorokin, 2009) (Figure 1.5, p. 13). 
These barriers are essential for the normal function of the CNS as it separates brain 
extracellular fluids in the CNS from circulatory blood and provides transport processes for 
essential nutrients, ions and metabolic waste products (Redzic, 2011; Khanbabaie and 
Jananshahi, 2012). Other specialized barriers such as the blood-tumour-barrier (BTB) also 
hamper CNS drug delivery. 
 
1.6.1   Blood-Brain Barrier (BBB) 
The BBB is located at the blood capillaries of the brain and is formed by capillary endothelial 
cells (Figure 1.5, p. 13), astroglia, pericytes and perivascular mast cells (Schulz  and 
Engelhard, 2005; Abbott et al., 2006). This barrier is approximately 200 nm thick separating 
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over a billion capillaries from the brain tissue, the surface area of these capillaries being 
approximately 20m² (Pardridge, 2005).  
 
Figure 1.5 Sagital section of the brain indicating the location of anatomical barriers. The specialized barriers 
of the CNS include: (a) Blood-brain-barrier (BBB), (b) blood–cerebrospinal fluid barrier (BCSFB) and the (c) 
cerebrospinal fluid brain barrier (CSF) (Saim, 2012). 
The capillary endothelial cells are held together by complex tight junctions which are 
interconnected side-by-side by tight adherens junctions (Figure 1.5) thereby preventing the 
passage of small molecules and ions through spaces between cells by diffusion or active 
transport (Martini, 2006; Stamatovic et al.,. 2008). The main integral proteins present at tight 
junctions include: occludin, claudins and junctional adhesion molecules (JAMs) (Stamatovic 
et al., 2008). The compact network of interconnections confers the highest trans-endothelial 
electrical resistance (approximately 500 Ωcm²), higher than that of systemic endothelia (3-33 
Ωcm²) (Butt et al., 1990; Burke et al., 1999).  
Nutrition transport of ions, amino acids, vitamins and proteins through the brain endothelium 
is induced by several molecular transport systems in the plasma membrane (Visser et al., 
2005). This barrier is highly selective and controls the entry of compounds into the brain 
(Upadhyay, 2014). Crossing of any molecule through the BBB is dependent upon its 
physicochemical properties and pharmacokinetic profile in plasma (Balda and Matter, 1998; 
Upadhyay, 2014). A large amount of drugs or molecules such as nucleic acids, peptides, 
proteins and antibiotics fail to cross the BBB, but substances such as alcohol, caffeine, 
nicotine, anaesthetics and glucose can cross rapidly (Martini, 2006). Only molecules with a 
(c) 
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mass lower than 400–600 Da and hydrophilic compounds with a mass lower than 150 Da, can 
cross the BBB via passive diffusion (Visser et al., 2005; Santaguida et al., 2006). Most 
molecules cannot cross the BBB due to these factors, including the majority of anti-cancer 
drugs; however drugs such as anxiolytics, antipsychotics selective serotonin reuptake 
inhibitors and opiates can cross (Pardridge, 2005; Upadhyay, 2014). Even drugs, small 
molecules or solutes that can cross the BBB are confronted with many degrading enzymes 
present inside endothelial cells. These enzymes recognize and rapidly degrade most peptides, 
including naturally occurring neuropeptides (Misra et al., 2003). In addition, capillary 
endothelial cells have a high concentration of drug efflux transporter proteins such as P-
glycoprotein (P-gp) (Thuerauf and Fromm, 2006) and multidrug resistance-associated 
proteins (MRPs) (Borst et al., 2000) which hampers penetration of many therapeutic agents 
into the brain parenchyma. 
1.6.2   Blood-Cerebrospinal Fluid Barrier (BCSFB) and CSF-Brain Barrier 
Regions of the CNS located adjacent to the cebral ventricles of the brain called the 
circumventricular organs (CVOs) do not possess the BBB. These regions comprise the pineal 
gland, median eminence, organum vasculosum of the lamina terminalis, neurohypophysis, the 
area postrema, subfornical organs, the subcommisural organ and choroid plexus (CP) 
(Khanbabaie and Jahanshahi, 2012). The BCSFB is situated at the CP epithelial cells which 
are responsible for secreting cerebrospinal fluid (CSF). Unlike BBB capillaries, BCSFB 
capillaries are fenestrated and have no tight junctions (Figure 1.5, p.13); therefore there are 
no astrocytes in contact with endothelial cells. The endothelium does not form a barrier for 
the movement of small molecules; instead the BCSFB at the CP is formed by epithelial cells 
and tight junctions that connect them (Redzic, 2011; Khanbabaie and Jahanshahi, 2012). 
Similar to the BBB, transport across the BCSFB is selective with only small molecules such 
as ions, potassium, calcium and chloride crossing in a controlled environment (Martini, 
2006). Diffusion, facilitated diffusion and active transport into CSF from CSF to blood occur 
in the CP (Johanson et al., 2008). The CP epithelial cells offer low resistance (150–200 
Ωcm²) in comparison with capillary endothelial cells from the BBB (Saito and Wright, 1983). 
Consequently, substances move from the blood into the CSF in a molecular weight-
dependent manner and irrespective of their movement across the BBB such as 
azidothymidine (AZT), which rapidly enters CSF across the CP epithelium but cannot cross 
the BBB easily (Dykstra et al., 1993). Therefore the presence of drugs in the CSF 
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compartment does not neccsearily guarantee penetration into the brain parenchyma.  Unlike 
at the BBB, where solutes that have crossed the capillary barrier undergo rapid distribution 
throughout the brain parenchyma, the penetration of solutes from CSF to brain parenchyma is 
accomplished through diffusion which decreases rapidly with distance, e.g., the highest 
penetration of brain-derived neurotrophic factor (BDNF) is approximately 0.3 mm from the 
ependymal surface of the brain (Mak et al., 1995). The estimated volume of CSF in the 
human brain is 140 ml and in a healthy adult the CSF is replaced 4–5 times a day (Mak et al., 
1995). CSF produced by the CP progresses from the lateral ventricles to the third ventricle 
and then into the fourth ventricle of the brain. The CSF then passes from the foramina of 
Luschka and Magendie to the cisterna magna and then into the cranial and spinal 
subarachnoid spaces and is finally absorbed into the bloodstream across the arachnoid villi. 
Therefore drugs that are injected into the CSF are removed quickly via bulk ﬂow through the 
CSF ﬂow pathway as a result of the high turnover rate of CSF (Johanson et al., 2008). 
One of the most challenging steps in neuroscience researches and therapy is the ability to 
penetrate these permeability barriers for delivering anti-cancer drugs to the CNS (Khanbabaie 
and Jahanshahi, 2012). 
1.6.3   Challenges Associated with Chemotherapeutic Drugs 
In addition to the anatomical barriers presented by the CNS, which contributes largely to the 
diminished therapeutic value of many potent anticancer drugs, in comparison with normal 
brain vasculature, tumour vasculature of the brain comprises abnormal blood vessels; 
distended capillaries with leaky walls, leading to inconsistent drug delivery into the brain 
(Van Meir, et al., 2010). Localized hypoxia can lead to tumour resistance as a result of 
irregular blood flow. Drug metabolizing enzymes that are situated in the cerebral 
microvasculature mainly provide a protective role aginst exogenously administered 
molecules (Borst et al., 2000; Thuerauf and Fromm, 2006).  
The difficulty in NS and CNS tumours therapy is also greatly impacted by the lack of 
specificity of anticancer drugs to pathological diseased sites, resulting in very low amount of 
administered drug that can ultimately reach the brain (Begley and Brightman, 2003). This 
also contributes to the systemic toxicity associated with chemotherapeutic agents. Drugs with 
short distribution half-lives can lead to sub-therapeutic levels of chemotherapy and may result 
in a minimal probability of circulating the drug through the tumour vascular bed (Medina et 
al. 2004). For the anticancer agent anthracycline, drug-induced congestive heart failure, 
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alopecia, mucositis, nausea and vomiting are the major concerns due to its very poor 
prognosis (Drummond et al. 1999). Myelosupression and cardiotoxicity are considered dose-
limiting factors in conventional cancer treatment with free doxorubicin (Drummond et al. 
1999). Tumour cells may become resistant to conventional treatments and the brain becomes 
susceptible to damage, also the brain has a limited ability for self-repair which decreases with 
age (Wang et al., 2013). Avoidance of systemic toxicity through chemotherapeutic drugs and 
radiation is crucial especially in the paediatric age group; combating drug resistance, 
improving drug delivery to the diseased sites thereby reducing side effects are essential in 
combating NB. The importance of anti-cancer drug delivery to patients with NB especially in 
CNS related NB, is important as the neurons in the CNS shows limited regenerative capacity. 
Therefore damaged neurons are not capable of dividing and replacing themselves under 
normal circumstances and as a result this comprises the CNS greatly (Buga et al., 2011). 
Consequently, there has been little advancement in the development of effective therapeutic 
agents for NB cancer in the past decades. However, a great deal of research has aided in our 
molecular understanding of the pathogenesis involved in NB cancer. Most antitumor 
therapies such as chemotherapy, radiation or immunotherapy act through the induction of 
apoptosis in cancer cells (George et al., 2010). It has been proposed that one of the 
mechanisms contributing to the aggressive behaviour of advanced-stage NB in older children 
is resistance to the extrinsic apoptosis pathway activation (George et al., 2010). Hence, recent 
years has focused on assessing the mitochondrial pathway for drug-induced apoptosis 
treatments for cancers such as NB (Ferrin et al., 2011; Posadas et al., 2012).  
1.7   Apoptosis (Programmed Cell Death) 
Apoptosis is a highly specialized form of controlled cell death which is executed in an 
orderly manner (Palai and Mishra, 2015). It occurs during development and aging of cells to 
maintain cell proliferation in tissues. It differs to necrosis which is also a type of cell death 
but occurs after cell injury, whereas apoptosis is constant and required to maintain the 
homeostasis of cell proliferation and cell death (Sankari et al., 2012). 
Apoptosis occurs through two main pathways the intrinsic (mitochondrial pathway) and 
extrinsic (death receptor pathway). A third pathway involving T-cell mediated cytotoxicity 
called the perforin/granzyme pathway also exists (Thornberry and Lazebnik, 1998; Fischer 
and Schulze–Osthoff, 2005). The intrinsic and extrinsic pathways depend on the specific 
triggering by signals to begin an energy-dependent cascade of molecular events, while 
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Granzyme A works in a caspase-independent fashion in the perforin/granzyme pathway 
(Elmore, 2007). All the pathways converge at the execution pathway resulting in the 
characteristic biochemical and physical changes such as membrane blebbing, cell shrinking, 
nuclear fragmentation, condensation of the chromatin network and chromosomal DNA 
fragmentation (Figure1.6 and Figure 1.7). The final stages of apoptosis are marked by the 
formation of apoptotic bodies which are engulfed by phagocytes (Gotter, 2009).  
 
Figure 1.6 Characteristic cellular changes that normally occur during apoptosis. This includes changes in 
reactive index, cell shrinkage, chromatin condensation, membrane blebbing and DNA fragmentation. Apoptotic 
bodies form and are phagocytised by neighbouring cells (https://www.promega.com/resources/product-guides-
and-selectors/protocols-and-applications-guide/apoptosis/). 
 
Figure1.7 The three main pathways involved in apoptosis: Extrinsic Pathway (death 
receptor), Intrinsic Pathway (mitochondrial pathway) and  Perforin/Granzyme Pathway 
(Adapted from Elmore, 2007). 
1.7.1   Extrinsic Pathway 
The extrinsic pathway is activated by the binding of death ligands to death receptors (Rubio-
Moscardo et al., 2005; Elmore, 2007). The death receptors possess an intracellular domain 
which causes the recruitment of adaptor proteins, such as tumour necrosis factor (TNF) 
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receptor associated death domain (TRADD), Fas-Associated death domain (FADD) adaptor 
molecule and cysteine proteases like caspase-8 (Schneider and Tschopp, 2000; Wong, 2011). 
When the death ligand binds to its death receptor, it forms a death-inducing signalling 
complex (DISC). This activates pro-caspase-8 which then processes downstream effector 
caspases and cleaves specific substrates causing cell death (Elmore, 2007; Wong, 2011; 
Sankari et al., 2012).  
1.7.2   Intrinsic Pathway 
Stimuli such as cell damage by toxins, free radicals, radiation, DNA damage, the absence of 
certain growth factors, hormones and cytokines that lead to failure of suppression of death 
programs, causes changes in the inner mitochondrial membrane (Elmore, 2007). 
Consequently, this causes the opening of the mitochondrial permeability transition pore 
resulting in the loss of the mitochondrial transmembrane potential and the release of pro-
apoptotic proteins from the intermembrane space into the cytosol (Saelens et al., 2004). 
These pro-apoptotic proteins are cytochrome c, Smac/DIABLO and HtrA2/Omi (Du et al., 
2000; van Loo et al., 2002; Garrido et al., 2006).  
Apoptotic events occurring in mitochondria are regulated by the activity of members of the 
B-cell leukemia/lymphoma 2 (Bcl-2) families of proteins and tumour suppressor protein p53 
(Cory and Adams, 2002). Bcl-2 family members are divided into three groups based on the 
presence of 1-4 Bcl-2 homolog domains. Proteins containing all four domains are anti-
apoptotic e.g. Bcl-2, Bcl-x, Bcl-XL, Bcl-XS, Bcl-w and BAG. They reside in the outer 
mitochondrial membrane and control cytochrome c release from the mitochondria via 
alteration of mitochondrial membrane permeability. The other groups are pro-apoptotic 
proteins such as Bax, Bak, and BH-only proteins such as Bid, Bad, Noxa, Puma and Bim 
(Ola et al., 2011). 
When cytochrome c is released into the cytosol, it binds to the C-terminal of Apaf-1, a 
cytosolic protein with an N-terminal-recruitment domain (CARD) (Zou et al., 1997), thus 
facilitating the association of dATP with Apaf-1, exposing the N-terminal CARD through 
which caspase-9 is recruited, creating an “apoptosome”. Caspase-3 is then recruited to the 
apoptosome, where it is activated by caspase-9 (Bratton et al., 2001). Caspase-3 cleaves key 
substrates and promotes the execution phase (Chinnaiyan, 1999; Hill et al., 2004). 
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Second Mitochondrial-Derived Activator of caspase (Smac)/DIABLO and High Temperature 
Requirement Protien-A2 (HtrA2)/Omi indirectly promote apoptosis by inhibiting inhibitors 
of apoptosis proteins (IAP) activity (Salens et al., 2004; Schimmer, 2004). The IAP family of 
proteins are important apoptosis regulators because they can regulate both the intrinsic and 
extrinsic pathways (Deveraux and Reed, 1999; Silke et al., 2002; Elmor, 2007).  
Apoptosis Inducing Factor (AIF), endonuclease G and Caspase-Activated DNAse (CAD) are 
a second group of pro-apoptotic proteins released from mitochondria. AIF causes DNA 
fragmentation into approximately 50-300 kilobase pieces and condensation of peripheral 
nuclear chromatin referred to as “stage I” condensation (Susin et al., 2000; Joza et al., 2001). 
The endonuclease G cleaves nuclear chromatin to produce oligonucleosomal DNA fragments 
(Li et al., 2001). CAD is then released from the mitochondria and translocates to the nucleus 
where it causes oligonucleosomal DNA fragmentation and more pronounced chromatin 
condensation, called “stage II” condensation, after cleavage by caspase-3 (Enari et al., 1998; 
Susin et al., 2000). 
A sensor of cellular stress and a critical activator of the intrinsic pathway is p53. This protein 
could lead to the expression of BH3-only molecules Puma and Noxa (Villunger et al., 2003) 
or could directly activate Bax transcriptionally or functionally (Johnstone et al., 2002; Chipuk 
et al., 2004). 
1.7.3   Cancer and Apoptosis 
As seen in Figure 1.7 (p. 17) the different pathways occur simultaneously and overlap at 
certain stages, showing cross-talking between pathways. Therefore these pathways are 
dependent on each other and an imbalance in the expression of genes in the apoptotic 
pathways can promote the transgression of cellular homeostasis, resulting in diseases such as 
cancer (Cory and Adams, 2002; Elmore, 2007; Sankari et al., 2012). Drugs inducing 
apoptosis remain the principal chemotherapeutic choice in medical oncology, with more than 
half of anti-cancer drugs coming from natural origins, such as plants (Gotter, 2009). These 
therapies usually induce apoptosis by inducing cellular stress leading to the intrinsic 
activation of apoptosis through p53 or upstream of the mitochondria.  
The pathways involved are complex and cancer cells often become resistant to conventional 
therapies through developing escape-mechanisms in the signalling cascade (Bouillet et al., 
1999; Puthalakath et al., 1999; Orr et al., 2003). Approximately half of all human tumours 
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have acquired p53 mutations and the rest have deactivated the p53 pathway such as 
increasing p53 inhibitors or decreasing its activators (Green and Kroemer, 2009). Therefore, 
treatments that rely solely on p53-dependent apoptosis might not function and a novel class 
of anti-cancer agents directly targeting the mitochondria and not just depending on p53 may 
hold great promise in overcoming drug-resistance in tumours. Betulinic Acid (BetA) is 
potentially one such anti-cancer agent (Mullauer et al., 2010). 
1.8)   Betulinic Acid (BetA) 
Natural products have been used to combat human diseases for decades and play an 
increasing role in drug discovery and development (Ji et al., 2009). Two important known 
classes of naturally-derived compounds used in clinical settings and research are vinca 
alkoids and taxanes, with products such as Velban and Navelbine already on the market 
(Risinger et al., 2009; Mullauer et al., 2010). Taxanes and triterpenoids belong to the 
terpenoids class of successful naturally-derived compounds approved in 1992 by the US Food 
and Drug Administration (FDA) and is used for various cancers including ovarian, lung and 
breast cancers (McChesney et al., 2007). Triterpenoids (also referred to as isoprenoids), are 
the largest group of natural compounds consisting of six isoprene units and can be isolated 
from many different plant sources (Hill and Connolly, 2013). They can be sub-classified into 
several groups and many of them or their synthetic derivatives are currently being 
investigated for various diseases, especially the anti-cancer agents (Bishayee et al., 2011). 
One highly promising class of natural compounds from the triterpenoids is BetA (3β-
hydroxy-lup-20(29)-en-28-oic acid) which is the oxidized derivative of Betulin (Bet) (Figure 
1.8, p. 21). BetA is a natural plant-derived pentacyclic triterpenoid present in a large diversity 
of plants (Dehelean et al., 2012). Both Bet and BetA have been studied extensively and have 
shown a great number of pharmacological benefits, with BetA being more effective (Şoica et 
al., 2012). BetA is most commonly found in the bark of the white birch tree (Betula alba), 
due to the high betulin content of up to 22% (Fulda and Kroemer 2009). Other known sources 
of BetA include trees and shrubs such as Ziziphus spp. (Rhamnaceae), Syzygium spp. 
(Myrtaceae), Diospyros spp. (Ebenaceae) and Paeonia spp. (Paeoniaceae) (Cichewicz and 
Kouzi, 2004). 
The chemical structures of Bet and BetA differ at the C-28 position (Figure 1.8, p. 21) and 
many different extraction techniques have been proposed to isolate BetA from Bet. After 
extraction, the white crystalline solid form of BetA has a molecular formula of C₃₀H₄₈O₃ 
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with a molecular mass of 456.3603 g mol−1 and demonstrates limited solubility in organic 
alcohols (Tolstikov et al., 2005; Cheng et al., 2011; Dehelean et al., 2012). It has low 
solubility in water, petroleum ether, dimethylformamide, dimethyl sulfoxide, and benzene; 
however it is highly soluble in pyridine and acetic acid and has a melting temperature of 
between 316-318 °C (Cichewicz and Kouzi, 2004; Cheng et al., 2011). 
  
 
Figure 1.8 Birch trees (A) from which BetA is commonly extracted to give a white crystalline solid (B) and 
the chemical structures of BetA and Bet (C) 
(http://plantextract8988.en.ec21.com/Birch_Bark_Extract_Powder_Betulin--5520266_5520364.html; 
Moghaddam et al., 2012). 
1.8.1   Medicinal Properties of BetA 
BetA extracted from the white birch bark has a long tradition in folk medicine for treatment 
of stomach and intestinal problems by Native Americans and in certain parts of Russia 
(Yogeeswari and Sriram, 2005; Alakurtti et al., 2006; Dehelean et al., 2012). It is a unique 
compound as it demonstrates many different biological activities and medicinal properties 
such as anti-inflammatory (Alakurtti et al., 2006; Moghaddam et al., 2012), anti-bacterial 
(Chandramu et al., 2003; Eiznhamer and Xu, 2004; Fontanay et al., 2008), anti-malarial 
(Bringmann et al., 1997; Steele et al., 1999; de Sá et al., 2009), antheminitic (Enwerem et al., 
2001), antinociceptive (Kinoshita et al., 1998), anti-HSV-1 and inhibition of human 
immunodeficiency virus (HIV) (Dang et al., 2009; Moghaddam et al., 2012). BetA has also 
A B 
C 
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demonstrated anti-cancer abilities (Chintharlapalli et al., 2007; Fulda and Kroemer, 2009; 
Mullauer et al., 2010; 2011; Moghaddam et al., 2012). 
1.8.2   BetA Anti-tumour Effects and Effects on Healthy Cells 
BetA only gained attention in cancer research in 1995, when Pisha et al., (1995) identified it 
as a specific inducer of apoptosis in melanoma cells. Since then, the capacity of BetA to 
induce apoptosis has been demonstrated in vitro for a wide variety of prevalent cancers such 
as leukaemia (Ehrhardt et al., 2004; Raghuvar et al., 2005), ovarian cancer (Zuco et al., 
2002), cervix cancer (Xu et al., 2014), prostate cancer (Reiner et al.,2013), lung cancer (Hsu 
et al., 2012), breast cancer (Damle et al., 2013), colorectal cancer (Chintharlapalli et al., 
2011), glioblastoma (GB) cancer as well as other head and neck cancers including NB 
(Thurnher et al., 2003; Fulda and Kroemer, 2009; Mullauer et al., 2010). BetA shows little to 
no toxicity to healthy cells (Zuco et al., 2002; Mullauer et al., 2010). 
1.8.3   Apoptotic Effects of BetA 
Numerous studies have attempted to elucidate the molecular mechanisms of BetA-mediated 
antitumor activity and have shown that BetA-induced apoptosis differs from that caused by 
other anticancer agents (Figure 1.9, p. 23). Common anti-cancer agents activate the death 
receptor pathway of apoptosis or induce cellular stress such as cytokine withdrawal or DNA 
damage, resulting in activation of the apoptotic signalling cascade via p53 and/or BH3-only 
proteins. BetA does not involve p53 or death ligands but directly induces mitochondrial 
damage (Figure1.9, p. 23), leading to Bax/Bak independent release of cytochrome c (Fulda 
and Kroemer, 2009; Mullauer et al., 2010) overcoming resistance that a tumour cell could 
have gained upstream of the mitochondria. The formation of the mitochondrial transition pore 
complex causes inhibition of STAT3, JAK1 and JAK2 (Shanmugam et al., 2012). BetA also 
causes the inhibition of topoisomerases 1 and 2 and the activation of nuclear factor-kB (NF-
kB) (Mullauer et al., 2010; Pandey et al., 2010). 
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Figure 1.9 Comparison of the induction of apoptosis by conventional anti-cancer drugs compared to BetA. 
The majority of anti-cancer agents induce cellular stress such as cytokine withdrawal or DNA damage, 
resulting in activation of the apoptotic signalling cascade via p53 and/or BH3-only proteins. BetA induces 
apoptosis independently of p53, by directly inducing mitochondrial damage resulting in the release of 
cytochrome C (Adapted from Mullauer et al., 2010). 
1.8.4   BetA Induces Apoptosis in Brain Cancer Derived Cell Lines 
Fulda et al., (1997) first identified BetA as a new cytotoxic agent against neuroectodermal 
tumour cells including NB, medulloblastoma (MB), GB and Ewing’s sarcoma cells. They 
showed that BetA exerted a cytotoxic effect on different NB and GB cell lines that was 
independent of p53 and caused the release of cytochrome c or AIF from mitochondria into 
the cytosol induced activation of caspases and nuclear fragmentation leading to cell death 
(Fulda et al., 1997; 1998; 1999). 
BetA regulates Bcl-2 family proteins in a context-dependent manner (Fulda, 2008; Fulda and 
Kroemer, 2009). Treatment with BetA resulted in up-regulation of the pro-apoptotic Bcl-2 
family protein Bax in NB, GB and melanoma cells, whereas Bcl-XS was found at high levels 
in BetA-treated NB cells. The alterations in the balance of Bax/Bcl-2 proteins were suggested 
to have caused apoptosis in NB, GB and melanoma cells treated with BetA (Fulda et al., 
1997; Wick et al., 1999). Expression levels of anti-apoptotic Bcl-2 remained unchanged upon 
incubation with BetA in NB cells while an increase in Bcl-2 protein levels was reported in 
GB cells (Fulda et al., 1997; Wick et al., 1999).  
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Generation of reactive oxygen species (ROS) upon treatment with BetA has been reported to 
be involved in initiating mitochondrial membrane permeabilization (Fulda et al., 1999; Fulda 
and Kroemer, 2009). Glioma cells exposed to BetA induced ROS generation, which was 
blocked by Bcl-2 or the antioxidants N-tert-butyl-a-phenylnitrone (PBN) and N-acetyl-
cysteine (NAC). Expression levels of Bcl-2 and Bax increased after BetA application; 
however levels of Bcl-Xs and Bcl-XL were not affected. Furthermore, ROS formation was 
dependent on new protein synthesis and was crucial for caspase activation (Wick et al., 
1999).  
BetA has also been reported to modulate activity of the transcription factor NF-kB (Fulda, 
2008). BetA was identified as a potent activator of NF-kB in a number of cancer cell lines 
including SHEP neuroblastoma cell line (Kasperczyk et al., 2005). The activation by NF-kB 
has been found to be involved in decreased phosphorylation of inhibitor of NF-kB kinase 
(IKK) with subsequent proteasome degradation as well as increased translocation of the NF-
kB subunit p65 to the nucleus (Takada and Aggarwal, 2003).  
Interestingly, NB cells that showed resistance to CD95-or doxorubicin-triggered apoptosis 
remained sensitive to treatment with BetA, and BetA exhibited potent antitumor activity on 
primary tumour cell cultures from all NB (4/4) and all MB (4/4) (with an ED₅₀ of 3-15µg/ml 
for both) and most GB patients (20/24) (with an ED₅₀ of 5-16 µg/ml) ex vivo (Fulda et al., 
1998b). 
1.8.5   Use of BetA for Drug Delivery  
BetA has demonstrated the ability to initiate apoptotic pathways in cancer cells and show a 
favourable therapeutic window in which it could even overcome anticancer drug resistance or 
used in combination treatments, which could improve the efficacy of anticancer therapy, 
especially since it shows low cytotoxicity in normal cells (Zuco et al., 2002; Mullauer et al., 
2010). 
Pisha et al., (1995) published the first in vivo study of BetA which described a method for 
enhancing its solubility by co-precipitating BetA with polyvinylpyrrolidone (PVP) and 
intraperitonally delivering it to nude mice bearing subcutaneous human melanoma 
xenografts. Complete lack of toxicity was observed with tumour regression using a 500 
mg/kg body weight dose, indicating a broad therapeutic window (Pisha et al., 1995). A few 
other studies addressing the in vivo efficacy of BetA have since followed, all indicating a 
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potent anti-tumour effect with no systemic toxicity (Zuco et al., 2002; Chintharlapalli et al., 
2007; Rajendran et al., 2008; Mullauer et al., 2011). 
Due to its lipophilic properties, BetA cannot be dissolved and administered in most aqueous 
solutions (Mullauer et al., 2011), posing a difficulty in its in vivo efficacy and hampering its 
formulation into a pharmaceutical product. Many studies have tried to modify BetA 
derivatives to enhance their solubility such as modifications at the C-3 and C-28 positions 
which demonstrated potential in addressing the solubility challenges (Liu et al., 2004; Huang 
et al., 2007; Rajendran et al., 2008). However, since the lipophilic character of BetA is likely 
to be crucially involved in its pluripotent mechanism of action, permitting its broad activity 
profile, newer formulations of BetA are needed (Mullauer et al., 2011). With the advent of 
nanotechnology, nanoscale drug delivery systems for cancer have greatly improved the 
efficacy of many anti-cancer drugs. 
1.9 Nanotechnology for Cancer Treatment 
Considered as one of the key technologies of the 21st century, nanotechnology holds many 
promises for the future in various scientific disciplines including offering numerous novel 
possibilities for the treatment of cancer. Nanotechnology employ particles in the 1-100 nm 
size range in at least one dimension making them attractive for medical purposes 
(Khanbabaie and Jananshahi, 2012; D’Souza, 2014). The size of nanoparticles (NPs) offers 
unique and important features such as surface to mass ratio which is much larger compared to 
that of their bulk size (Parveen et al., 2012). NPs based on their size can cross biological 
barriers through small capillaries and into individual cells (Fisher and Ho, 2002; Lockman et 
al., 2002). Most importantly, NPs can be surface-functionalized with targeting moieties such 
as antibodies, aptamers, peptides, etc, for surface proteins on diseased cells, thereby allowing 
efficient drug accumulation at the target site and reducing unwanted side effects and the 
toxicity posed by most anti-cancer therapeutic agents (Parveen et al., 2012). Cancer 
nanotherapeutic systems are being implemented to decrease the limitations associated with 
conventional cancer drugs, most importantly the lack of specificity as nanotherapeutics offers 
a safer platform than using viral vectors to deliver therapeutic agents directly to diseased cells 
(Mamo et al., 2010). Other advantages associated with NPs for cancer drug delivery include: 
improving hydrophobic drugs and molecules, increased aqueous solubility of drugs, 
protecting of drugs from degradation, sustained drug release, improving drug bioavailability, 
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improving pharmokinetic and pharmocodynamic properties and offering appropriate form for 
all routes of administration (Parveen et al., 2012).  
1.9.1   Drug Delivery to Cancer Cells Using Nanoparticles (NPs) 
To deliver anticancer drugs through NP systems, two main approaches exist: Passive 
targeting and active targeting (Figure 1.10) (Parveen et al., 2012). Passive targeting takes 
advantage of the leaky vasculature in tumour tissues caused by angiogenesis as blood vessels 
are known to be poorly defined (Alexander-Bryant et al., 2013). Blood vessels in tumours are 
irregularly shaped, leaky and show abnormal blood flow (Peer et al., 2007). Endothelial 
junctions are gaps in the endothelium which control the passage of macromolecules from the 
blood to tissue (Alexander-Bryant et al., 2013). In normal vasculature, endothelial junctions 
range from approximately 5-10 nm in width (Haley and Frenkel, 2008), however in tumour 
tissues, this size increases to a range of 100-780 nm depending on the tumour type (Folkman 
and Shing, 1992; Baban and Seymour, 1998). NPs are naturally attracted to this localized 
area compared to normal cells and due to their small size; they can easily enter these gaps 
into the extracellular vascular space. This phenomenon is referred to as the enhanced 
permeability and retention (EPR) effect and can be exploited for passive drug targeting 
(Figure 1.10) (Maeda et al., 2000; Peer et al., 2007). 
 
Figure 1.10 Schematic diagram showing passive and active targeting approaches for NP drug delivery. Active 
targeting requires surface functionalization for cell-specific recognition binding while passive targeting takes 
advantage of the diseased leaky tumour vasculature for EPR effect (Adapted from Peer et al., 2007). 
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Active targeting requires surface functionalization of receptor specific ligands that can 
promote cell-specific recognition binding (Thorpe, 2004). This is dependent on the targeting 
moiety of the NPs which should be abundant and show high specificity for the diseased cells. 
The active targeting can be accomplished by molecular recognition of the diseased cells by 
different molecules that are over expressed at the surface of diseased site via the ligand-
receptor, antigen-antibody interactions, and peptides or by targeting through aptamers etc., 
(Parveen et al., 2012).  
Numerous biological barriers exist for NPs to successfully reach the intended disease sites 
such as extracellular and intracellular barriers (Desai, 2012). Extracellular barriers are 
primarily concerned with stability of the NPs as the innate immune system destroys all 
foreign objects. Therefore, stabilization of these NPs with biocompatible proteins such as 
human serum albumin or polymers such as polylactide or polycaprolactone etc. is 
fundamental in offering a ‘stealth mode’ for targeted or non-targeted drug delivery systems 
and assists in preventing agglomeration of NPs when inside the human body. Aggregates or 
clusters usually form if NPs are not steric stabilized or bio-functionalized for human 
applications. Intracellular barriers pose a difficulty for drug delivery systems through 
endosome entrapment and the ability to escape the recticular endothelial system (RES) (Guo 
and Huang, 2011). Smaller-sized NPs have a relatively long circulation time because they can 
avoid the RES uptake more easily and can penetrate deep into tissues through fine capillaries, 
thus allowing for better control of therapeutic drug delivery (Gupta et al., 2006). 
1.9.2   Nanocarriers for Therapeutic Delivery 
 
Figure 1.11 Different types of nano-drug delivery systems (Mai and Meng, 2013). 
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Many different types of nanocarriers have been developed over the past decades and some of 
these are shown in Figure 1.11 (p. 27). The main requirements for these carrier systems are: 
stability, biocompatibility, biodegradability, low toxicity, and the ability to protect drugs or 
nucleic acids from rapid degradation or excretion as well as high target specificity for 
targeted drug delivery (Markovsky et al., 2012). Based on their classification, some of the 
types shown in Figure 1.11 will be discussed below in detail (Table 1.3): 
Table 1.3 Different types of nanocarrier systems  
Nanocarrier 
system 
Structure        Characteristics Examples  
Polymeric 
NP 
(polymeric 
drug 
conjugates) 
Drugs are conjugated to the 
side chain of a linear 
synthetic or semi synthetic  
polymers with a linker 
(cleavable bond) (Sanchis et 
al., 2010) 
Biodegradable, passive and active drug delivery, 
controlled release polymer technologies where 
natural or synthetic polymers combines with a 
drug in  such a way that the drug is encapsulated 
within the polymer system for release in a 
predetermined manner e.g. by temperature, pH 
or the presence of specific biological analytes  
Opaxio (Li and Wallace, 
2008, Sanchis et  al., 
2010) 
Polymeric  
Micelles 
Amphiphillic block co-
polymers self-assemble and 
form micelles with a 
hydrophobic core and a 
hydrophilic shell (Adams et 
al., 2003). 
Self-assembling, biocompatible, non-toxic, 
carrier for non-polar drugs, controlled drug 
release and targeting capabilities and high cargo 
loading (Nakanishi et al., 2001; Al-Zubaidi et 
al., 2014). 
Genexol-PM (PEG-poly 
(D, L-lactide) 
(Nasongkla et al., 2006). 
Dendrimers Monodispersed symmetric 
macromolecules with nm 
size dimensions constructed 
around an internal cavity 
surrounded by many hyper-
branched structures of 
reactive end groups (Malik 
et al., 1999). 
Multifunctional-dendrimers can be modified 
with several molecules such as imaging contrast 
agents, targeting ligands, or therapeutic drugs, 
rendering a dendrimer-based multifunctional 
drug delivery system (Svenson and Tomalia 
2005). The internal cavity can also encapsulate 
drugs (Svenson and Tomalia 2005). 
PAMAM-platinate 
(Malik et al., 1999). 
Magnetic 
NPs (MNPs) 
 
Nm sized particles with 
magnetic properties which 
can be manipulated using 
magnetic fields 
Gold NPs and supramagnetic NPs (e.g. ferrite-or 
magnetite (Fe3O4)-based spherical particles) 
can be applied to improve MRI imaging, 
magnetic drug delivery and localized photo- 
thermal  induced therapy by heating the specific 
area where these NPs accumulate and 
consqeuntly leading to the destruction of 
diseased cells (Mody et al., 2014).     
MNPs for improving 
imaging for cancer 
diagnosis and 
hyperthermia treatment 
of cancer treatment 
(Kumar and Mohammad, 
2011; Yigit et al., 2012). 
Carbon 
nanotubes 
(CNTs) 
NPs composed of benzene 
rings forming graphene 
sheets folded to produce a 
tube. It can be single walled 
or double walled depending 
on their application 
(Rastogi et al., 2014). 
CNTs can be made biocompatible through 
chemical modifications. Sidewall or tips of 
CNTs allows attachment of several molecules at 
once, therefore a higher therapeutic load 
compared to the other NPs. It also has similar 
applications as the MNPs in terms of drug 
delivery and photo-thermal therapy (Rastogi et 
al., 2014). 
Antifungal agent or 
anticancer drugs have 
been covalently linked to 
CNTs (Parveen et al., 
2012). 
Quantum 
dots (QDs)  
 
Semi conductor crystals 
with nm size dimensions 
possessing conductive 
properties based on size 
(Cho et al., 2007) 
QDs are imaging modalities due to their 
quantum size characteristics which lead to size-
tuneable band gaps thereby enhancing the 
photonic function (Yong et al., 2012). 
QDs are capable of 
detecting cancer 
biomarkers (Wagner et 
al., 2010). 
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1.9.3   Toxicity Associated with NPs 
The predicted benefits of NP drug-delivery systems are numerous as they are already 
resolving most of the common problems experienced with conventional drugs and beginning 
to replace them (Table 1.3, p. 28). However, to exploit the full potential of nanotechnology in 
nanomedicine, attention should also focus on safety and toxicity issues regarding these carrier 
systems. The toxicity factor surrounding most of these NPs, especially the non-degradable 
NPs are an uncertainty which hampers clinical success. 
Non-degradable NPs used for drug delivery may show persistence and localization at the site 
of the drug delivery, but in some many cases it results in chronic inflammatory response (De 
Jong and Brom, 2008). Cationic NPs including gold and polystyrene have been shown to 
cause haemolysis and blood clotting (Gupta and Gupta, 2005; De Jong and Brom, 2008). 
Studies with carbon nanotubes (CNTs) showed that platelet aggregation was induced by both 
single and multi-walled CNTs (Radomski et al., 2005). Quantum dots (QDs) composed of 
heavy metal compounds may prove difficult for the body to degrade and the accumulation in 
the body may lead to cytotoxic effects (Sahoo and Labhasetwar, 2005).  
The efficiency of NP carriers is dependent on their design, application and materials used. 
Overloading of the NPs may cause problems and hydrodynamic size also affects NP 
clearance rate from circulation (Moghimi et al., 2001). Materials, used for coating and 
immobilization approaches are important as many studies show that the coating thickness and 
hydrophobicity can significantly affect the magnetic properties of magnetic NPs (MNPs) 
(LaConte et al., 2007; Duan et al., 2008). It has been reported that small NPs (20 nm) are 
excreted by the renal system (Banerjee et al., 2002), medium sized NPs (30–150 nm) 
accumulate in the bone marrow, heart, kidney and stomach while large NPs (150–300 nm) 
have been found in the liver and spleen (Veiseh et al., 2010). These results require a novel 
way of handling the toxicology of NPs.  
Liposomes are the first drug-carrying nano-carriers to reach cancer clinics (Figure 1.11). The 
first liposomal drug to gain approval by the FDA in 1995 was Doxorubicin (Doxil/Caelyx) 
and has since been used to treat a wide variety of advanced stage cancers such as  ovarian 
cancer, metastatic breast cancer and AIDS-related Kaposi's sarcoma (Perche and Torchilin, 
2013). Other approved liposome encapsulated anti-cancer drugs include Vincristine 
(Marqibo) and Paclitaxel (Lipusu), with many ligand targeting liposomes for targeted drug 
delivery being in phases I, II and III of drug development stages (Perche andTorchilin, 2013). 
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1.10   Liposomes  
Since the discovery of liposomes by Dr Bangham and colleagues in 1965, liposomes have 
generated much enthusiasm due to their unique potential to improve the delivery of current 
drugs (Paliwal et al., 2011; Monteiro et al., 2014). They are self-assembled, closed colloidal 
structures composed of one or concentric phospholipid bilayers surrounding a central 
aqueous core (Parveen et al., 2012). Liposomes offer simultaneous loading of hydrophobic 
(non-polar) molecules/drugs into the phospholipid bilayer while hydrophilic (polar) 
molecules/drugs can be encapsulated in the aqueous space (Figure 1.12), thus allowing 
unlimited therapeutic cargo loading (e.g., anti-cancer drugs, DNA, peptides vaccines, 
enzymes and imaging agents to be loaded into this assembly) (Perche and Torchilin, 2013).  
 
 
Figure 1.12 Schematic illustration of a liposome. The phospholipid bilayer creates a hydrophobic region for 
entrapping non-polar molecules/drugs, while the aqueous core creates the hydrophilic region for encapsulating 
polar molecules/drugs. Liposomes may have one or more than one phospholipid bilayer, depending on the size, 
type and method of preparation of the liposome (Adapted from Lopes et al., 2013 with a few modifications). 
Liposomes have been reported to be biocompatible, degradable in vivo, have low 
immunogenicity and excellent safety profiles in humans. They offer increased pharmokinetic 
and pharmodynamic properties and it is relatively inexpensive for mass production, which 
makes them superior as a NP for therapeutics (Allen and Cullis 2013; Ait-Oudhia et al., 
2014). Additionally, liposomes can be surface coated with targeting agents for targeted drug 
delivery (Kelly et al., 2011; Tiwari et al., 2012; Allen and Cullis 2013; Monteiro et al., 2014) 
Some of the advantages of liposomes include: 
• Passive and active targeting to tumour tissues (Torchilin, 2010) 
 PHOSPHOLIPID BILAYER:  LIPOSOME: 
Aqueous 
core 
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• Increased efficacy and therapeutic index (Chuang et al., 2011) 
• Increased drug loading and stability of encapsulated agents (Nallamothu et al., 2006; 
Gubernator, 2011) 
• Improved pharmacokinetics and pharmocodynamics (Drummund et al., 1999; 
Gubernator, 2011) 
• Decreased toxicity due to biodegradability (Mufamadi et al., 2011; Akbarzadeh et al., 
2013) 
1.10.1   Phospholipolipids and Liposomes 
Phospholipids (PL) are a class of amphipahtic molecules composed of hydrophilic (polar) 
head groups and hydrophobic (non-polar) hydrocarbon tail groups (Figure 1.12, P. 30) and 
can have a structural backbone such as glycerol or sphingomyelin (Cooper and Hausman, 
2009). They are present in high levels of all cell membranes of living matter and can orient in 
a variety of supramolecular structures in aqueous solutions through the hydrophobic 
interactions of the hydrocarbon chains (Kent, 1995; Monteiro et al., 2014). 
Biocompatible phospholipids and sphingolipids are mainly used to prepare liposomes. 
Phospholipids could comprise of different head and tail groups that can influence the surface 
charge and bilayer permeability of liposomes (Perrie and Rades, 2010). Common 
phospholipids used in liposome preparations are provided in Table 1.4. 
Table 1.4 Examples of common phospholipids used in the preparation of liposomes 
Name of phospholipid The esterfied group Net charge at pH 7 
Phosphatidylcholine (PC) CH₂CH₂N⁺(CH₃)₃ Zwitterionic 
Phosphatidylethanolamine (PE) CH₂CH₂NH₃⁺ Zwitterionic 
Phosphatidylglycerol ( PG) -CH₂CHOHCH₂OH Negative 
Phosphatidylserine (PS) CH₂CHNH₃⁺COO Negative 
 
PLs could be naturally-occurring such as egg/ soy phosphatidylcholine (EPC) or synthetic 
such as dipalmitoylphosphatidylcholine (DPPC) (Monteiro et al., 2014) shown in Figure 
1.13. Synthetic PLs are more stable than natural PLs because they can be produced from 
natural PLs with improved features. Modifying the non-polar and polar-regions of PLs permit 
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the formation of an unlimited variety of well-defined and characterized PLs (Monteiro et al., 
2014). 
 
Figure 1.13 Chemical structure of dipalmitoylphosphatidylcholine (DPPC) lipid. DPPC is a16 alkyl chain 
lipid which consists of a hydrophilic head group with a quaternary ammonium moiety choline linked to a 
glycerol via a phosphoric ester (Brandl, 2001). The permanent positive charge on the choline of the head group 
counteracts the negative charge of the phosphate to produce a neutral hydrophilic head group (Philippot and 
Schuber, 1994). 
 
Natural or synthetic phosphatidylcholine (PC) is the most widely employed phospholipid for 
preparing liposomes due to its stability and capacity to act against changes in pH or salt 
concentrations in the product and or the biological environment (Perrie and Rades, 2010). It 
is also the most predominant PL found in natural membranes, located in the outer leaflet of 
the cell membrane and accounting for 50-90% of cell membrane phospholipids (Kent 1995; 
Li and Vance 2008). PCs in mammals are usually synthesized from the DAG branch of 
phospholipid synthetic pathway and transferred to carbon-3 via the action of the choline: 1, 2-
diacylglycerol cholinephosphotransferase (Li and Vance, 2008). It consists of a hydrophilic 
head group with a quaternary ammonium moiety choline, which is linked to a glycerol via a 
phosphoric ester (Brandl, 2001). The permanent positive charge on the choline of the head 
group counteracts the negative charge of the phosphate to give neutral hydrophilic head 
group (Philippot and Schuber, 1994).  
1.10.2   Phase Transition Temperature (Tc) 
Phase transition temperature (Tc) is the temperature above the lipid boiling point, which is 
required to change the lipid from an ordered gel phase, where the hydrocarbon chains are 
closely packed and extended, to a disordered liquid crystalline phase, where the hydrocarbon 
chains are randomly oriented (Mozafari et al., 2008; Monteiro et al., 2014). 
Factors affecting the Tc include hydrocarbon chain length, degree of saturation of the 
hydrocarbons, charge and polar head group species (Mozafari et al., 2008). When a double 
bond exists between two carbon atoms in a hydrocarbon chain, the chain is said to be 
unsaturated, whereas hydrocarbon chains without double bonds are said to be saturated. The 
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length and degree of saturation of the lipid chain influence the gel liquid-crystalline Tc. As 
the hydrocarbon length is increased, van der Waals interactions become stronger requiring 
more energy to disrupt the ordered packing, therefore the phase Tc increases (Monteiro et al., 
2014). Tc is lowered by decreased chain length and by unsaturation of the hydrocarbon 
chains and the presence of branched chains and bulky head groups (e.g., cyclopropane rings) 
(Szoka and Papahadjopoulos, 1980; Small, 1986). Liposomes cannot form at temperatures 
below Tc of the lipids and selecting a high transition lipid where the lipid vesicle would 
always be in the gel phase would contribute to an ideal non-leaky packaging system (Patel 
and Panda, 2012).  
Tc of liposomes is crucial as it determines the permeability, fusion, aggregation, 
deformability and protein binding which all contributes to stability of liposomes and 
behaviour in vitro and in vivo (Mozafari et al., 2008).  
1.10.3   Characteristics of Liposomes 
1.10.3.1   Liposomal Size  
The size of a liposome usually ranges from approximately 20 nm upwards and may be 
composed of one or numerous bilayers, each with a thickness of approximately 4 nm 
(Maherani et al., 2011) or 20-100 nm (Yang et al., 2011) as reported in literature. Size 
characteristics of liposomes and the number of bilayers present, depend on the method of 
preparation (Cornell, 2000). 
Table 1.5 Classification of liposomes based on size and number of bilayers (Elhissi et al., 
2006; Raman et al., 2010; Swaaya and deMello, 2013) as shown below: 
 
Vesicle Types Abbreviation  Diameter Size Number of lipid bilayers 
Small unilamellar vesicles SUV Diameter of 20-100 nm One lipid bilayer 
Large unilamellar vesicles LUV Diameter of  > 100 nm One lipid bilayer 
Giant unilamellar vesicles GUV Diameter of  > 100 nm One lipid bilayer 
Multilamellar vesicles MLV Diameter of   0.1-20 µm. Four to twenty lipid bilayers 
Multivesicular vesicles MVV Diameter of  > 1 µm. Multicompartmental  structure 
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Figure1.14 Schematic illustration of the classifictaion of different liposomes based on size and number of 
bilayers (Adapted from Swaaya and deMello, 2013 with a few modifications). 
The size of a liposome is crucial, as it will influence the rate of the opsonisation (process 
whereby the immune system recognises foreign particles and recruits immune cells called 
phagocytes to engulf and destroy these foreign particles) and clearance by the RES after 
intravenous administration and their ability to remain in blood vessels and exploit the EPR 
effect for delivering anti-cancer drugs (Liu et al., 1995). Liposomes with a diameter of less 
than 150 nm have been reported to be suitable for efficient drug delivery (Takeuchi et al., 
2001). Lamellarity refers to liposomes that have more than one lipid bilayer and the number 
of lipid bilayers present in liposomes influences the encapsulation efficiency and drug release 
kinetics, therefore intracellular fate is affected by the size and lamellarity (Laouini et al., 
2012). Based on their composition and size, liposomes have the potential of transporting 
drugs or small molecules through blood vessels and biological barriers promoting efficient 
transport. Liposomes with a diameter of 100 nm or less can undergo free diffusion through 
the BBB by receptor mediated or absorptive mediated transcytosis (Prathyusha et al., 2013). 
If the size and composition of liposomes are not considered thoroughly before intravenous 
administration, larger liposomes (> 200 nm in diameter) can become coated by serum 
proteins such as opsonins, which would result in opsination and ultimately phagocytosis by 
the RES and would most likely accumulate in the liver (> 300 nm) and spleen (< 40 nm) 
(Maurer et al., 2001; Immordino et al., 2006). Small liposomes would have a lower density of 
opsonins on the membrane surface which would result in lower uptake by the macrophages 
and a greater chance to evade the RES and remain in the circulation longer before reaching 
the target site (Liu et al., 1995), however NPs less than 10 nm have a greater propensity for 
renal clearance (D’Souza, 2014). 
 
 
SUV 
LUV 
GUV MLV MVV 
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1.10.3.2   Liposomal Stability 
Liposome stability consists of physical, chemical and biological stability. Physical stability 
indicates mostly the quality of the size and the charge present on the surface of liposomes as 
this should be considered for aggregation (Popovska et al., 2013). The ability of liposomes to 
maintain the surface charge for extended durations during storage adds to the high physical 
stability of the formulation and shelf life. Cationic liposomes can be stable at 4°C for long 
periods of time, if properly sterilized (Laouini et al., 2012). Chemical stability entails the 
prevention of both the hydrolysis of ester bonds in the phospholipids bilayers and the 
oxidation of unsaturated sites in the lipid chain (Prathyusha et al., 2013). Oxidation of 
phospholipids in liposomes occurs in unsaturated fatty acyl chain-carrying phosphlipids. The 
chains are oxidised via a free radical chain mechanism in the absence of particular oxidants. 
The ester groups of the phospholipids can be hydrolyzed in the presence of water, producing 
lysophospholipids, a high concentration of which commonly leads to an increased 
permeability of the lipid bilayer and a destabilization of the system (Prathyusha et al., 2013). 
Chemical instability can lead to physical instability and leakage of encapsulated drug from 
the bilayers and fusion and aggregation of vesicles.   
Approaches that can be taken to increase liposomal stability (Akbarzadeh et al., 2013) are as 
follows:  
a) Storing liposomes at low temperatures, protection from light and adding antioxidants 
such as α-tocopherol and butyl hydroxy toluene in order to minimize oxidation of 
liposomes. 
b) Avoidance of high temperature and excessive shear forces. 
c) Working under nitrogen or argon will minimize the oxidation of lipids during the 
preparation process and maintain low oxygen potential. 
d) The hydrolysis of ester bonds can be reduced by optimising the pH, temperature, ionic 
strength, chain length and the amount of cholesterol incorporated into the bilayers. 
1.10.3.3   Addition of Cholesterol (Chol) in Liposome Formation 
The addition of the cholesterol (Chol) in the lipid bilayer improves the overall structural 
integrity and stability, and forms a highly ordered rigid membrane with fluid-like 
characteristics (Lee et al., 2005; Monteiro et al., 2014). It does this by filling up holes present 
in the membrane, by reducing the permeability of the membrane to water soluble molecules 
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and decreasing the fluidity or increasing the microviscosity of the bilayer making it less 
permeable, thereby preventing drug leakage from the liposome and creating a more 
hydrophobic region (Monteiro et al., 2014). This could reduce binding of opsonins on the 
liposomes and may improve stability and retention of liposomes in vivo (Maurer et al., 2001). 
Liposomal formulations containing Chol and phospholipids are referred to as ‘conventional 
liposomes’ (Monteiro et al., 2014). 
 
Figure 1.15 Chemical structure of cholesterol (Chol). Chol consists of four hydrocarbon rings, making it 
strongly hydrophobic and hydroxyl (OH) group attached to the end of the Chol makes that part weakly 
hydrophilic (http://www.sigmaaldrich.com/catalog/product/sigma/c8667?lang=en&region=ZA). 
Chol molecular structure (Figure 1.15) consists of four hydrocarbon rings which aids in 
making it strongly hydrophobic. The presence of the hydroxyl (OH) group attached to the end 
of the Chol makes that part weakly hydrophilic therefore it inserts itself in the bilayer of 
liposomes with its OH-group towards the aqueous core, and the rigid hydrophobic tail toward 
the phospholipid bilayers (Cooper and Hausman, 2009; Perrie and Rades, 2010). Chol can be 
added to the lipid bilayers at concentrations up to 1:1 molar ratio, however Chol at higher 
molar ratios causes low encapsulation of drugs and the fact that it is readily oxidized could 
create problems for lipid based drug products (Nallamothu et al., 2006; Torchilin and 
Weissig, 2003). 
1.10.3.4   Surface Charge and Membrane Characteristics  
Surface charge of the liposome is influenced by the lipids used in the liposome formation. 
The surface charge can be modified to suit applications; an example would be to use 
negatively or positively charged phospholipids which induce electrostatic repulsion and 
stabilization against liposome aggregation (Ogihara et al., 2010).  
Most biological cell membranes, including cancer cells exhibit a negative charge; neutral-
charged liposomes with tightly packed membranes seem to remain in circulation for longer 
periods of time and display higher drug retention when compared to charged systems 
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(Honary and Zahir, 2013). Certain plasma proteins have an affinity for liposomes, and the 
affinity is enhanced if the liposome is charged.  
Cationic systems interact quickly with various components in systemic circulation and thus 
have shorter half-lives in vivo (Maeda, 2000). Cationic liposomes can be more cytotoxic than 
neutral or anionic liposomes. This is due to the positive charge of the liposomes which allows 
non-specific interactions with cell membranes. However, anionic liposomes activate platelets 
but cationic or neutral liposomes do not (Ilinskaya and Dobrovolskaia, 2013). Cationic 
liposomes are less toxic in vitro than in vivo; studies suggest that reactive oxygen 
intermediates may be involved in the toxicity (Dokka et al., 2000; Audouy et al., 2002; Wu et 
al., 2004; Chien et al., 2005). Studies indicate that anionic liposomes containing negatively 
charged lipids such as PS and PG are quickly taken up by macrophages and thus disappear 
from the circulation in a short time (Liu et al., 1995; Massing and Fuxius, 2000).   
Therefore liposomes for drug delivery systems must maintain stability while in circulation for 
a prolonged period of time before reaching the intended site and avoid the RES in the 
process. In order to achieve this, liposomes can be coated with the commonly used 
polyethylene glycol (PEG) (Torchilin, 2005). PEG is a FDA approved hydrophilic polymer 
varying in molecular weight due to the number of monomer repeat units. Sterric stabilization 
of liposomes with PEG was one of the main advances in liposome development (Monteiro et 
al., 2014). PEG serves as a steric barrier with the flexible chains forming “brushes” which 
extends out from the surfaces of liposomes and changes the surface properties of liposomes. 
This prevents interaction of phagocytes and creates the desired “stealth layer” to produce the 
so-called ‘stealth liposomes’ or ‘PEGylated liposomes’ (Monteiro et al., 2014). PEG has 
good solubility properties in aqueous media and has been used to coat many NP, as it does 
not form any metabolites, has a low toxicity profile and does not accumulate in the RES 
(Perrie and Rades, 2010). 
1.10.4   Liposomal Release of Contents  
Liposomes have evolved since their discovery with many different stimuli being exploited to 
trigger the release of the encapsulated cargo from liposomes into cells, including temperature 
(Torchilin, 2005, Ponce et al., 2006), pH (Simões et al., 2004), light (Troutman et al., 2009), 
redox potential (Ong et al., 2008), magnetic fields (Amstad, et al., 2011), near infra-red and 
ultrasound (Hagtvet et al., 2011 and Nappini et al., 2011) and targeting molecules each with 
its own specific advantage depending on the applications (Torchilin, 2005). 
 
 
 
 
38 
 
1.10.5   Liposome Interaction with Cells 
Liposomes can enter cells via different mechanisms or a combination of mechanisms (Vyas 
and Khar, 2002). The entry of liposomes or their contents into cells is dependent on the type 
of liposomes as shown in Figure 1.16. They can be 1) non-targeting liposomes or 2) targeting 
liposomes:  
 
Figure 1.16 Different mechanisms of liposome-cell-interaction for non-targeting liposomes and targeting 
liposomes (Adapted from Torchilin, 2005). 
1.10.5.1   Non-targeting Liposomes 
Liposomes containing drugs can adsorb onto the cell surface (Figure 1.16, a and b). 
Adsorption on the surface of the cell can occur by physical attractive forces which causes the 
release of liposomal contents into the cells. This process may or may not involve 
internalisation of the liposome into the cell. In fusion (fusogenic liposomes), liposomes come 
into close proximity with the cell membrane and mixing of plasma membrane cell lipids 
occurs (Figure 1.16, c). This causes liposomal contents to automatically be released into the 
cell cytoplasm. Drugs can be released into the cytoplasm or can be destabilized by certain 
membrane components when adsorbed on the cell surface so that the released drug can enter 
the cells via micropinocytosis (Figure 1.16, d). Due to similar lipids found in the bilayer of 
liposomes, cell membranes can recognise these lipids, leading to lipid exchange (Figure 1.16, 
e). Internalisation by endocytosis (Figure 1.16, f) occurs when liposome come into close 
contact with the cell surface, cells form endosomes (Figure 1.16, g) through invagination of 
the plasma membrane, taking up the liposome which would then fuse with the lysosome to 
1) Non-targeting liposomes 2) Targeting liposomes 
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form secondary lysosomes, allowing for cellular digestion of the lipids and release of its 
contents into the cytoplasm, where they are reduced by oxy-redoxy systems inside the cell 
(Figure 1.16, h) (Torchilin, 2005). 
1.10.5.2   Targeting Liposomes 
Liposomes loaded with drugs and accessorised with targeting molecules such as antibodies, 
peptides, aptamers etc (Figure 1.16, a, p. 38) can be cell-specific and interact with a specific 
recognition sites present on the surface of the diseased cell (Figure 1.16, b). Endocytosis 
occurs and the liposome is encapsulated into an endosome (Figure 1.16, c) to allow the drug 
to be released into the cytoplasm (Figure 1.16, d) (Torchilin, 2005). 
1.10.6   Production Process of Liposomes 
The production process of liposomes includes (Akbarzadeh et al. 2013): 
1) Method of liposome preparation  
2) Liposome size reduction 
3) Purification 
4) Characterization  
1.10.6.1   Methods of Liposome Preparation 
A number of different methods have been established based on the scale of the production, 
drug encapsulation, administration route and drug physiochemical properties, etc. 
(Akbarzadeh et al., 2013). Based on the different drug loading methods of preparing 
liposomes, two main approaches are used: passive loading methods and the active loading 
methods (Figure 1.17, p. 40) (Akbarzadeh et al. 2013; Popovska et al., 2013).  
In the passive loading method the drug is encapsulated by introducing an aqueous phase of a 
water-soluble drug or an organic phase of lipid-soluble drug before or during the steps 
involved in the manufacturing of liposomes (Popovska et al., 2013). In this process, owing to 
the same drug concentration across the bilayer of the liposomes, the percentage of 
encapsulation depends on the affinity of the drug to the lipid membrane, the lipid 
composition of the membrane, the volume of internal aqueous phase, the concentration of the 
liposomes formed and the drug-to-lipid ratio (Muppidi et al., 2012). For lipid-soluble drugs 
with high affinity to the lipid membrane, the passive loading method can yield a high 
entrapment efficiency of drugs (Akbarzadeh et al. 2013).  
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Figure 1.17 Different methods of liposome preparation. Liposomes can be entrapped with drugs/molecules 
through passive loading techniques (drug/molecules are loaded during the process of preparation) or active 
loading techniques (drug/molecules are loaded after the liposome has been prepared) (Prathyusha et al., 2013). 
In active loading technique, the drugs are loaded after the liposome has been formed by 
creating diffusion gradients for ions or drugs across the external and internal aqueous phases 
such as K⁺-Na gradient and H⁺ gradient (Popovska et al., 2013). The drug is able to permeate 
through the lipid bilayers into the liposome following the concentration gradient until 
equilibrium between the interior and the surrounding medium is attained (Gregoriadis, 2007). 
The amount of hydrophobic drug that can enter into a liposome depends on the packaging 
arrangement of lipids in the lipid bilayer. Polar drugs interact with the polar head groups of 
phospholipids and are sequestered by the liposomes but amphiphilic molecules are difficult to 
retain inside liposomes as they can rapidly permeate through lipid bilayers (Maherani et al., 
2011). Active loading has certain advantages since the active agent is not yet present during 
the preparation of the liposome but the method is restricted to a small range of drugs that 
behave as weak amphipathic bases or acids and can permeate bilayers in the uncharged state, 
but not in the charged state (Maherani et al., 2011). 
1.10.6.1.1   Thin Film Hydration Method 
Thin film hydration method is the original method proposed by Bangham and is the simplest 
method for preparing liposomes on a research scale (Wagner and Vorauer-Uhl, 2011).  
Methods of liposome 
preparation 
Passive loading techniques Active loading techniques 
Mechanical dispersion 
methods 
Solvent dispersion methods Detergent removal methods 
Examples include: Thin film 
hydration by hand shaking/ 
non-hand-shaking, micro-
emulsification, sonication, 
French pressure cell, 
membrane extrusion and 
freeze thawed method 
Examples include: Ethanol 
injection method, double 
emulsion vesicles, reverse 
phase evaporation method 
and stable pluri lamellar 
vesicles 
 
Examples include: Detergent 
removal from mixed 
micelles, dialyses, column 
chromatography and ultra-
centrifugation methods 
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Figure 1.18 Flow diagram of liposome formation using thin film hydration method (Adapted from Lopes et 
al., 2013, with a few modifications). 
The method (Figure 1.18) involves dissolving lipid compositions, with or without 
hydrophobic drugs in an organic solvent (chloroform only or chloroform: methanol mixtures) 
in a round bottom flask. The solvent is removed by a rotary evaporation at above Tc to 
produce a thin dry lipid film on the wall of the round-bottom flask (Figure 1.18, a, b, c). The 
thin film is hydrated by adding a hydration solution with/without the hydrophilic drugs to be 
encapsulated (Figure 1.18, d). The flask is then heated above Tc and stirred or vigorously 
shaken for a few hours (Figure 1.18, e). Liposomes are formed when thin lipid films are 
hydrated and detach during agitation and self-close into vesicles to form large MLVs (over 1 
µm in diameter) (Figure, f). This method can yield an entrapment efficiency of approximately 
40% and a heterogeneous sized population of multilamellar vesicles (MLVs) (Akbarzadeh et 
al., 2013; Lopes et al., 2013; Prathyusha et al., 2013). Further sizing techniques are employed 
to create the desired size (Figure 1.18, g). 
1.10.6.2   Size Reduction Methods 
Sizing of liposomes requires energy input such as sonic energy (sonication) or mechanical 
energy (extrusion). The sonication method is a common method used for producing small 
unilamellar vesicles (SUVs) with diameters of roughly 15-25 nm. Two sonication techniques 
that exist are probe sonication and bath sonication (Akbarzadeh et al., 2013). The 
disadvantage of sonication is the low internal encapsulation efficiency caused by damage to 
a) 
b) c) d) 
e) f) g) 
Hydrophilic drugs in 
hydrating solution 
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the phospholipid structure, metal pollution from the probe tip as well as heterogeneous size 
distribution (presence of MLV along with SUVs) (Dua et al., 2012; Akbarzadeh et al., 2013; 
Popovska et al., 2013). 
Extrusion methods are based on the principle of passing MLV through filters with specific 
sizes to obtain a liposome population with a mean diameter size the same as the filter pore 
size. It was first introduced in the 1970s in order to reduce the size of liposomes for 
biological applications (Johnson et al., 1971). It is the most common method of sizing 
liposomes and producing unilamellar vesicles (ULVs) on a research scale (Mokhtarieh et al., 
2013). Extrusion is more advantageous than sonication as a variety of lipid mixtures can be 
extruded without lipid degradation; it’s possible to eliminate organic solvents or detergents 
from the final preparations and to produce homogenous populations of SUVs in the size 
range of 50-150 nm (Akbarzadeh et al., 2013). There are many commercial products 
available for extruding liposomes but the most common extruder used is the Avanti large and 
mini extruders (Figure 1.19).  
 
 
Figure 1.19 Avanti® Mini-Extruder. Extruder compartments include two gas-tight glass syringes, membrane 
compartment and a heating block (A). The more times the lipsome suspension passes though the membrane, the 
more homogenous the lipid solution becomes, as noted by the whitish colour of liposome suspension before 
extrusion and the more transparent liposome suspension after extrusion (B) 
(http://www.avantilipids.com/index.php?option=com_content&view=article&id=533&Itemid=297). 
A 
B 
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The extruders is made of stainless steel and Teflon, and has two glass gas tight syringes on 
either ends, one syringe is loaded with the liposome suspension and when pressure is applied 
the liposome suspension passes through the size specific filter pores for the required amount 
of passes to obtain a mean distribution of SUVs at a specific size range (Figure 1.19, A). An 
odd number of passes is used to finish on the opposite side, leaving everything that never 
made it through the filter in the first syringe. As the liposome suspension passes through the 
membranes repeatedly, the colour will become more transparent (Figure 1.19, B). The 
extruding process takes place on a heating block at above the Tc. 
1.10.6.3   Purification Methods 
Purification of liposomes is an important step as it removes low molecular weight material 
that was not entrapped into liposomes. Liposomes are normally purified by size exclusion 
chromatography, gel filtration chromatography, dialysis and centrifugation methods 
(Akbarzadeh et al., 2013). 
1.10.6.4   Characterization of Liposomes 
Characterization of liposomes focuses on the evaluation of certain physio-chemical and 
biological parameters (Table 1.6). Taking the physical and chemical parameters into account, 
determines the safety profiles and final behaviour of liposomes both in vitro and in vivo.  
Table 1.6 Different characterization techniques for liposomes  
Characterization  Some of the methods/instrument used for characterization 
Size, shape and surface 
morphology 
Photon correlation spectroscopy (PCS) using Zetasizer NanoZS, Transmission electron 
microscopy (TEM), cryo-TEM, atomic force microscopy (AFM) and scanning electron 
microscopy (SEM) 
Surface charge  Free flow electrophoresis, zeta potential measurement using a Laser Doppler 
electrophoresis (LDE) or Zetasizer NanoZS 
Lamellarity Nuclear magnetic resonance (NMR), Electron paramagnetic resonance (EPR) TEM and 
small angle X-ray scattering 
Tc Differential scanning calorimetry (DSC) and NMR 
Phospholipid 
quantification  
Lipid phosphorus content (Bartlett method) 
Lipid oxidation  Spectroscopy, thin layer chromatography (TLC), high-performance liquid chromatography 
(HPLC), gas-liquid chromatography 
Encapsulation percentage Mini column centrifugation, gel exclusion, spectrophometry, fluorescence spectroscopy, 
enzyme based methods, HPLC,  fluorescence spectrophotometer 
Drug release Diffuse cell/ dialysis and HPLC 
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1.10.7 Liposomal Encapsulation of Lipophilic Drugs 
The water solubility of lipophilic drugs or compounds incorporated into the conventional 
liposome bilayer is often limited in terms of drug-to-lipid ratio (Dhule et al., 2012). It has 
also been reported that some lipophilic drugs may interfere with the bilayer formation, 
limiting the dose which can be incorporated into the liposome (Chordiya and Senthilkumaran 
et al., 2012). Furthermore, both incomplete and rapid release has been reported for lipophilic 
drugs entrapped within liposomes (Otero-Espinar et al., 2010). In recent years, many 
different strategies have been employed to increase the overall entrapment of lipophilic drugs 
or molecules for aqueous encapsulation into liposomes, one such strategy is the use of 
cyclodextrins and liposomes. 
1.11 Cyclodextrins (CDs) 
Cyclodextrins (CDs) are torus-shaped supramolecular crystalline cyclic oligosaccharides with 
at least 6 D-(+) glucopyranose units attached by glucosidic bonds allowing amphoteric 
properties of a hydrophophilic outer surface and a lipophilic interior (Laza-Knoerr et al., 
2010). 
 
Figure 1.20 Molecular structure of β-cyclodextrin. Cross-section of a cyclodextrin molecule is provided, 
showing the arrangement of a glucose unit and conical representation showing the hydrophilic exterior and 
hydrophobic cavity (http://www.chemiedidaktik.uni-wuppertal.de/disido_cy/cyen/info/03_physical_cy.htm). 
The glucopyranose units are present in a chair conformation and the hydrophilicity of the 
outer surface of CDs is due to the presence of hydroxyl groups orientated to the cone exterior 
with the primary hydroxyl groups of the sugar residues at the narrow and wider edges (Figure 
1.20). The central cavity is formed by the skeletal carbons and ethereal oxygen’s of glucose 
residues, which gives the CD molecule a hydrophobic inner cavity for appropriately sized 
non-polar molecules for forming host-guest complexes. The van der Waals, hydrogen bonds 
 
 
 
 
45 
 
and hydrophobic effects facilitate the formation of stable complexes of lipophilic/poorly 
water-soluable drug molecules in the non-polar cavity of CDs (Nasir et al., 2012). 
Consequently, CDs has been employed in numerous applications in a variety of fields, 
including the pharmaceutical industry and novel drug delivery systems (Nasir et al., 2012).  
1.11.1   Advantages of CD Complexation 
It is estimated that 30 different pharmaceutical products containing drug CD complexes is 
available worldwide (Tiwari et al., 2010). Some of the advantages of CDs complexation in 
pharmaceutical products (Otero-Espinar et al., 2010; Nasir et al., 2012) include:  
• Improved aqueous solubility of many poorly water soluble drugs 
• Enhanced bioavailability of drugs  and decreased toxic effects associated with drugs 
• CDs inclusion complexation helps to alleviate the irritancy of the drugs that normally 
irritate the stomach, skin or eye 
• CDs conceal the unpleasant odour and bitter taste of drugs 
1.11.2   Types of CDs 
CD is usually classified based on several parameters such as the amount of glucopyranose 
units present, internal cavity diameter and molecular mass etc. There are over 1500 types of 
CD derivatives mentioned in literature (Szejtli, 1998; Blanford, 2014); common parent CDs 
is highlighted in Figure 1.21 and Table 1.7 (p. 46). 
 
Figure 1.21 Three of the most common types of cyclodextrins (CDs). CDs are often classified based on the 
glucose units present: α-, β-, and γ-CDs (with 6, 7 or 8 glucose units respectively) 
(http://unam.bilkent.edu.tr/~uyar/images/Research_fig2.png). 
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Table 1.7 Characteristics of natural cyclodextrins (CDs) (Nasir et al., 2012). 
Parameters Α-CD (α-CD) Β CD (β-CD) γ-CD (γ-CD) 
Empirical formula C₃₆H₆₀O₃₀ C₄₂H₇₀O₃₅ C₄₈H₈₀O₄₀ 
Glucose units 6 7 8 
Molecular mass 973 1135 1297 
Cavity diameter 0.47-0.53 nm 0.60-0.66 nm 0.75-0.83 nm 
 
The parent CDs are natural, non-reducing, crystalline, homogeneous, and non-hygroscopic 
having limited aqueous solubility due to strong intermolecular hydrogen bonding in the 
crystal lattice (Hakkarainen et al., 2005). To improve their physiochemical properties and 
inclusion capacity, chemically modified derivatives of these parental CDs have been prepared 
which are amorphous, non-crystallisable with enhanced aqueous solubility, physical stability, 
and microbiological stability and reduced parent toxicity (Szente and Szejtli, 1999).  
1.11.3   CD Complexation Techniques 
The complexes are formed when a “guest” molecule (non-polar drug/molecule) is partially or 
fully included inside a “host” molecule (CD) with no covalent bonding (Astraya et al., 2009; 
Anjana et al., 2013). Some common techniques used include: solid dispersion or co-
evaporated dispersion, neutralization method, kneading method, precipitation method, spray 
drying or automization method and certain melting techniques (Anjana et al., 2013). 
1.11.4   BetA and CDs 
The water solubility of BetA is poor (0.02μg/ml) (Jäger et al., 2007), however the solubility 
of Bet and BetA was recently greatly improved by CD complexation, which created a stable 
complex, improving the in vitro and in vivo properties of the active compound (Dehelean et 
al., 2011a; Şoica et al., 2014). Natural and semi-synthetic CDs have been involved in 
triterpene complexation with good solubility and the best results were obtained with γ-CD 
derivatives (Dehelean et al., 2008). Glucose derivatives have the added benefit of being able 
to cross the BBB actively, through saccharide receptors and channels; in particular glucose 
channels (Upadhyay, 2014). Therefore, the derivatives shown have additional advantages for 
the treatment of tumours located in the brain. 
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1.11.5   Liposomes and CDs 
It has been reported that some lipophilic drugs may interfere with the lipid bilayer formation 
during the preparation of liposomes, limiting the dose which can be incorporated into the 
liposome. Furthermore, both rapid release and incomplete release have been reported for 
lipophilic drugs formulated in liposomes (Otero-Espinar et al., 2010). CDs and liposomes 
have been used in recent years as drug delivery vehicles (Table 1.8). By forming water 
soluble complexes, CD would allow insoluble drugs to accommodate in the aqueous phase of 
liposomes, thereby increasing the amount of insoluble drugs entrapped in liposomes 
improving the bioavailability and therapeutic efficacy of many poorly water solube drugs and 
may also offer a prolonged or controlled drug release (Arun et al., 2008; Chordiya and 
Senthilkumaran, 2012; Nasir et al., 2012). Problems associated with intravenous 
administration of CD complexes such as their rapid removal into urine can be avoided by 
their entrapment in liposomes (Arun et al., 2008). 
Table 1.8 CDs and liposomes as drug delivery vehicles  
Drug/ anti-cancer 
agent 
Type of 
CD 
Effect Reference 
Asialofetuin γ-CD Increased gene transfer activity Motoyama 
et al., 2011 
Benzocaine, Butamben HPβCD Enhanced intensity and duration of anesthetic effect Maestrelli et 
al., 2010 
Curcumin (water 
insoluable chemical 
compound) 
2HP-γ-
CD 
Increased efficiency and potential drug delivery vehicle 
for the treatment of various cancers 
Dhule et al., 
2012 
Colchicine  βCD Sustained drug release and improved target specificity Singh et al., 
2010 
Fluocinolone acetonide Several 
different 
CDs 
Sustained-release profile over prolonged periods of 
time for ocular inflammatory disease  
Vafaei et al., 
2014 
Irinotecan SBECD Improved irinotecan retention resulting in a highly 
active liposomal irinotecan formulation demonstrating 
prolonged release and protection against hydrolysis 
Li et al., 
2011 
Prilocaine (anesthetic) HPβCD Efficient encapsulation of prilocaien (PRL) base in 
aqueous vesicle core, increased anesthetic effect 
duration and reduced initial lag time in comparison 
with PRL in the lipophilic phase or PRL hydrochloride 
in aqueous core.  
Bragagni et 
al., 2010 
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1.12 Justification of Current Research 
Despite the best available treatment, tumour relapse is often observed in most patients 
diagnosed with high grade NBs. Treatment for NB cancer in the paediatric age group is 
crucial due to the developing brain as it is expected that two out of three survivors of the 
childhood cancer will ultimately develop at least one serious health problem within 20 to 30 
years after the initial cancer diagnosis (Modak and Cheung, 2010). More than half of children 
diagnosed with high-risk NB will either not respond to conventional therapies or relapse after 
treatment, necessitating the development of novel treatments (London et al., 2011). 
Cancer nanotechnology research is the most expanding interdisciplinary research that is using 
state of the art techniques to overcome limitations associated with early diagnosis and 
effective drug delivery systems for cancer. Liposomes are the first nano drug-delivery 
systems to reach cancer clinics, making them the most superior NP for nano-based drug 
delivery systems and are continuously being improved to better suit applications. They have 
the potential revolutionary impact into the understanding, visualization and therapeutic 
applications for NB cancer. 
1.13 Aims  
The aim of the study was to develop a NP drug delivery system for treating NB brain cancer 
cell lines with BetA. We proposed that BetA be incorporated into liposomes (BetAL) (Figure 
1.22, p. 49), but due to its lipophilic nature, entrapment will occur only in the bilayers and 
this could pose a limitation when downsizing liposomes as the remaining entrapped BetA 
could be too poor to have potent cytotoxic efficacy. To improve BetA encapsulation within 
the aqueous core, BetA complexation with γ-CD was suggested to produce a γ-CD-BetA 
inclusion complex (Figure 1.24, p. 50). Double loading of BetA and the γ-CD-BetA inclusion 
complex into liposomes was expected to create a novel drug delivery system for BetA (γ-CD-
BetAL) (Figure 1.25, p. 50). 
 
 
 
 
 
 
 
 
 
 
49 
 
 
 
Figure 1.22 Schematic illustration of the BetAL delivery system 
 
  
  
Figure 1.23 Schematic illustration of the Empty liposome (EL) delivery system. 
 
 
 
1,2-dipalmitoyl-sn-glycero-3-
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Figure 1.24 Schematic representation of γ-CD-BetA inclusion complex. 
 
Figure 1.25 Schematic illustration of the γ-CD-BetAL delivery system. 
1.14 Objectives 
The objectives of the study were to prepare free BetA, empty liposomes (EL), BetAL and γ-
CD-BetAL and evaluate: 
1) Physical and chemical characteristics of the liposome designs 
2) Effects on cell viability in SK-N-BE(2) and Kelly NB cell lines in vitro 
1.15 Hypothesis 
We hypothesize γ-CD-BetAL would produce a higher entrapment efficiency compared to 
BetAL and therefore a higher cytotoxic effect in comparison to BetAL.  
 
 
 
Guest molecule (BetA) 
Hydrophobic cavity Hydrophilic exterior + 
Host molecule (γ-CD) 
= 
γ-CD-BetA inclusion complex 
 BetA  
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Materials  
2.1.1) Materials used in the preparation and characterization of liposomes with respective 
manufacturers:     
1,2-Dipalmitoyl-Sn-Glycero-3-Phosphocholine Sigma- Aldrich 
Acetonitrile (HPLC grade) Sigma- Aldrich 
Betulinic acid (>98%, HPLC grade and 90% grade) Sigma-Aldrich 
Chloroform (HPLC grade) Sigma- Aldrich 
Cholesterol (Sigma Grade, ≥ 99%) (Chol) Sigma-Aldrich 
Disposable folded capillary cell Malvern Ltd., Germany 
Disposable plastic cuvette 12mm Square Polystyrene Malvern Ltd., Germany 
Methanol (HPLC grade) Sigma- Aldrich 
OptiSeal polypropylene tubes (4.9 ml, 13 x 51 mm) Beckman Coulter, USA 
Whatman nuclepore track-etched polycarbonate 
membrane (0.1μm, 19 mm) 
Sigma-Aldrich 
Whatman nuclepore track-etched polycarbonate 
membrane (0.2μm, 19 mm) 
Sigma-Aldrich 
γ-cyclodextrin (powder, BioReagent, suitable for cell 
culture, ≥ 98%) 
Sigma-Aldrich 
2.1.2) Materials used in cell culture experiments with respective manufacturers:  
25 cm² Tissue culture flask Biosmart 
75 cm² Tissue culture flask Biosmart 
96-Well tissue culture treated plates Biosmart 
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Cell proliferation reagent WST-1 (25 ml) Roche 
Centrifuge tubes (15 ml and 50 ml) Biosmart 
Cryovials Biosmart 
Dimethyl sulfoxide (DMSO) Sigma 
Dulbeco’s modified eagles medium (DMEM) Life Technologies 
Ethanol  Kimix  
Fetal bovine serum  Biochrome 
Penicillin-streptomycin solution  Sigma-Aldrich 
Phosphate buffered saline (1X, without calcium or 
magnesium and pH 7.4) 
Whitehead Scientific 
Pipette tips (white tips: 2-10 μl, yellow tips: 10-200 μl 
and blue tips: 200-1000 μl) 
Biosmart 
SK-N-BE(2) and KELLY Neuroblastoma cell lines Radiobiology Department 
Stellenbosch University (gift) 
Sterile 1 ml syringes and Sterile needles (0.70 x 32 mm) Lasec 
Sterile serological pipettes (5ml single-piece extrusion) Biosmart 
Sterile syringe filters (0.20μm) Lasec 
Trypan blue Whitehead Scientific 
Trypsin-Versene (EDTA) Mixture Life Technologies 
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2.2 Experimental Design 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic overview of the experimental design. 
2.3 Methodology  
The preparation and characterisation of liposomes was performed at the University of the 
Western Cape (UWC). Liposomes were prepared in the School of Pharmacy and the 
Department of Biotechnology. Characterization of liposomes occurred at the South African 
Institute for Advanced Materials Chemistry (SAIMC), the Department of Biotechnology and 
the Department of Physics (UWC). Cell culture study was completed at the Department of 
Biotechnology and Medical Biosciences. 
2.3.1 Preparation of BetAL  
Liposomes containing BetA were prepared by the passive drug encapsulation method as 
previously described (Csuk et al., 2011; Mullauer et al., 2011) with a few alterations (Figure 
2.2, p. 55). A lipid phase was prepared by dissolving accurately weighed quantities of BetA 
and 1,2-Dipalmitoyl-Sn-Glycero-3-Phosphocholine (DPPC) lipid (Table 2.1, p. 55) in 10 ml 
of chloroform and placed in a 250 ml round bottom flask. The solvent mixture was 
evaporated using a rotary evaporator (Lasec, South Africa), with the water bath set at above 
the phase transition temperature (Tc = 55 ˚C) until a whitish thin film of lipids was obtained 
on the surface of the flask. To ensure the complete evaporation of the solvent, the thin film 
was left overnight for complete dryness. The lipid film was then hydrated for 3 hours with 5 
 
Liposome preparation using 
thin film hydration method 
Physical characterization 
• Zetasizer NanoZS: Size (diameter) 
distribution analyses, polydispersity 
index and zeta potential 
• High-resolution scanning electron 
microscopy: Shape and size 
characteristics 
 
 
Chemical characterization 
• Ultra-high pressure liquid 
chromatography: Drug entrapment 
efficiency studies 
 
Biological characterization 
• WST-1 colorimetric cell viability Assay: 
Cell viability studies 
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ml of 1 X phosphate buffered saline (PBS) (pH 7.4) at 55 ˚C in a shaking water bath (Labtec, 
Germany) allowing 10 minutes cooling cycles after each hour (Figure 2.2, p. 55). Empty 
liposomes (EL) were prepared using the same procedure, but excluding BetA (Table 2.1). 
The EL was used as a control to study the effects of the phospholipids and cholesterol (Chol) 
on the selected cell lines.  
2.3.2 Entrapment of γ-CD-BetA (Inclusion Complex) into Liposomes (γ-CD-BetAL) 
The γ-CD-BetAL was prepared as above; however in the hydration step when 1X PBS was 
added, the PBS contained the γ-CD-BetA inclusion complex (Figure 2.2, p. 55). Batch 1 (B1) 
was selected to be rehydrated with γ-CD-BetA inclusion complex in 1X PBS (pH 7.4) (Table 
2.1, p. 55) as this batch demonstrated a higher entrapment efficiency when compared to 
Batch 2 (B2) (Chapter 3, section 3.4). 
2.3.3 Preparation of the γ-CD-BetA   
The preparation of the γ-CD-BetA inclusion complex was prepared as previously described 
(Şoica et al., 2014). Briefly, γ-CD and BetA powdered form was mixed, using a mortar and a 
pestle and kneading with ethanol and double distilled water (1:1 v/v) until most of the solvent 
was evaporated; the paste-type mixture was then dried at room temperature for 24 hours and 
placed in an oven at 105 ºC for nine hours. The final product was pulverized and sieved using 
a 100μm sieve. The binary products were prepared using 1:1 molar ratios. The γ-CD-BetA 
inclusion complex was dissolved in 1X PBS (pH 7.4) to produce a final volume of 0.5 mg/ml. 
2.3.4 Size Reduction of Liposomes 
Liposomes with a size of approximately less than 200 nm were designed by manual extrusion 
using an Avanti-mini extruder (Avanti Polar Lipids, Inc., USA). The hydrated solution was 
extruded 11 times through a 200 nm polycarbonate membrane followed by 5 times through a 
100 nm polycarbonate membrane at 55 ˚C. Separate batches of BetAL (B1 and B2) and γ-
CD-BetAL was not extruded to compare un-extruded liposomes with extruded liposomes. 
Triplicate batches were prepared for each liposomal formulation. 
2.3.5 Purification  
Prepared BetAL and γ-CD-BetAL were a mixture of encapsulated and un-encapsulated 
products. The resulting liposomes were transferred to 4.9 ml Beckman Coulter Optiseal 
tubes and then purified using ultracentrifugation (Beckman Coulter Optima L-80, 
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Beckman, USA) at 30 000 rpm at 4 °C for two hours to remove un-encapsulated products. 
The supernatant was removed and the tubes were then either characterized or capped and 
stored at 4 °C until use. 
 
 
Figure 2.2 Schematic illustration of liposome preparation using thin film hydration method followed by 
downsizing and purification techniques (Adapted from Lopes et al., 2013 and modified). 
Table 2.1: Drug-lipid ratio of BetA, DPPC and Chol (Triplicate batches were prepared for 
each liposomal formulation) 
Batch BetA: DPPC: Chol (Weight ratio in mg) 
EL X : 50 : 10 
Batch 1 (B1) 2.5 : 50 : 0 
Batch 2 (B2) 5 : 50 : 0 
γ-CD-BetA L 2.5: 50: 0 
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2.4. Characterization Techniques  
Characterization of liposomes is important as it will reveal the fate of the drug-delivery 
system in vivo and in vitro. In this study, synthesized liposomes underwent physical 
characterization, chemical characterization and biological characterization. 
2.4.1  Physical Characterization 
2.4.1.1 Determination of Size and Polydispersity Index 
Photon correlation spectroscopy based on dynamic light scattering (DLS) technology and can 
be used to determine the particle size and polydispersity index (PDI). PDI refers to the width 
parameter derived from the cumulants analyses and provides information about uniformity in 
NPs size (Kale et al., 2012). This is important to consider, as particles with a PDI value close 
to 0.7 indicate that the sample has a very broad size distribution and is not suitable for DLS 
measurements. DLS measures the time-dependent fluctuations of light scattered from 
particles undergoing Brownian motion. When a particle is suspended in a solution and 
illuminated by light, it scatters light given that its index of refraction differs from that of the 
suspending solvent. Therefore DLS provides information about the size and the size 
distribution of NPs in solutions. Advantages of using this method include its sensitivity and 
minimal sample requirement (Laouini et al., 2012). 
The liposome size (diameter) distribution and polydispersity index (PDI) was measured using 
photon correlation spectroscopy techniques on a Malvern Zetasizer NanoZs (Malvern 
instruments, Ltd., UK) at 25 ºC using DLS at an angle of 173 ˚C to the laser beam. A sample 
of 1 ml was transferred to a 12 mm disposable plastic cuvette and placed into the instrument. 
The intensity-weighted mean value was measured and the average of three measurements was 
taken. DLS does not yield information about the shape of liposomes; hence other techniques 
were applied for this purpose. 
2.4.1.2 Determination of Zeta Potential (ζ-Potential) 
The presence of a net charge on a particle in solution will affect the distribution of ions 
around it; causing an increase in the concentration of counter ions. The area over which this 
layer extends is referred to as the electrical double layer (Hunter, 1981). This layer has two 
separate regions: the stern layer (inner layer of strongly bound ions) and the diffuse layer 
(outer layer of loosely associated ions) (Figure 2.3, p. 57). As particles move in solution as a 
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result of an applied voltage or gravity, the ions move as well. A boundary exists at some 
distance from the particle in which ions are stationary; this is referred to as the slipping plane 
(Figure 2.3). The potential that exists at the slipping plane of a particle in an aqueous solution 
is called the zeta potential (ζ-potential) (Domingues et al., 2008; Kaszuba et al., 2010). 
 
Figure 2.3 Schematic illustration of ions around a charged particle in solution, indicating the slipping plane. 
The potential present at the slipping plane is defined as the zeta potential (ζ-potential) (Adapted from Malvern, 
2007). 
The ζ-potential is a physical property which is exhibited by any particle in suspension and is 
a very good index of the interaction magnitude between colloidal particles (Popovska et al., 
2013). Measurements of ζ-potential are commonly used to predict the stability of colloidal 
systems (Freire et al., 2011). Colloidal particles are measured using a folded capillary cell 
containing gold electrodes on either side. A voltage is applied and charged particles are 
attracted to the oppositely charged electrode on the folded capillary cell. The particles move 
in a known electric strength in the interference pattern of two laser beams and produce 
scattered light which depends on the speed of the particles, from this the ζ-potential can be 
recorded (Popovska et al., 2013). If all the particles in suspension have a large negative or 
positive ζ-potential then they will tend to repel each other and there will be no tendency to 
aggregate. However, if the particles have low ζ-potential values, then there will be no force to 
prevent the particles from aggregating (Popovska et al., 2013). Particle suspension with ζ-
potentials > +30 mV or < −30 mV are normally considered stable (Hunter et al., 2001). 
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For this characterization technique, Malvern Zetasizer NanoZs was employed. A disposable 
folded capillary cell was rinsed with distilled water using a 1 ml syringe prior to analyses as 
recommended by the manufacturer and 700 μl of liposome solution was added to the cell. 
The samples were then analyzed with a voltage of 4 mV at 25 ºC at an angle of 173 ˚C to the 
laser beam. The intensity-weighted mean value was measured and the average of three 
measurements taken. 
2.4.1.3 Determination of Shape and Size Characteristics of Liposomes 
Scanning Electron Microscopy (SEM) is often used to study the surface morphology and 
shape characteristics of NPs (Charurvedi and Dave, 2012).  An electron beam is generated by 
an electron gun and passes through the electromagnetic lenses of a column and across the 
surface of a sample. Electrons interact with atoms on the surface of the sample, producing 
various signals that can be detected to create an image, providing information about the 
sample size topography and composition. In this study, the shape and size characteristics of 
liposomes were investigated based on a previous method with a few alterations (Odeh et al., 
2012).  
A drop of un-extruded or extruded liposomes was dispersed on carbon adhesive tape applied 
on an aluminium stub, then dried completely under fume hood. The dried liposomes was 
coated with gold palladium for 30 seconds using Emitech K550X (England) sputter coater 
and viewed with the Auriga HR-SEM F50 (Zeiss, South Africa) with a voltage of 5 KV. 
2.4.2 Chemical Characterisation   
2.4.2.1 Determination of the Concentration of BetA (in mg/ml) Entrapped in Liposomes 
and the Percentage Entrapment Efficiency (% EE) of BetA in Liposomes 
Standard solutions of BetA (0.005, 0.01, 0.04, 0.06, 0.0625, 0.08, 0.1, 0.125, 0.25, 0.5 and 1 
mg/ml) were prepared in methanol. Following ultra-centrifugation in the purification step, the 
pellet was lysed in methanol and vortexed for 10-15 minutes and diluted suitably for analyses 
with ultra-high performance liquid chromatography (Perkin Elmer Flexar FX-15 UHPLC, 
USA). All standards as well as samples were filtered through 0.2 µm filters. The HPLC 
method was adapted from Taralkar and Chattopadhyay (2012) with a modification in the 
detection time due to the use of a shorter C-18 column and an UHPLC system which offered 
a more robust and sensitive system and allowed for earlier detection of BetA (refer to 
appendix for chromatographs, section 7.2). The UHPLC experimental conditions was carried 
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out at 35 °C using a C-18 (4.5 mm x 150.5 µm) column (Phenomenex Kinetex, USA), a 
mobile phase of acetonitrile : methanol (80:20 v/v), an injection volume of 10 μl, at 0.5 
ml/min flow rate and detection at a wavelength of 205 nm at 2.5 minutes. Triplicate 
injections were performed for standards and using the averaged area under the curve/peak, a 
calibration curve was constructed (Figure 2.4) and the concentration in mg/ml of BetA in 
liposomes was determined using the linear equation. The percentage entrapment efficiency 
(% EE) of BetA in liposomal formulations was determined as previously described (Ramana 
et al., 2010 and Begum et al., 2012):  
% EE =                                                                                  X 100 
 
Figure 2.4 UHPLC calibration curve of BetA. BetA standards (0.005-1 mg/ml) were dissolved in methanol and 
analysed using ultra high performance liquid chromatography (Perkin Elmer Flexar FX-15 UHPLC, USA). The 
average area under the curve/peak for each concentration was obtained and used to construct a calibration 
curve (refer Appendixes, section 7.2). The linear equation was used to determine the concentrations (in mg/ml) 
and % entrapment efficiency (% EE) of BetA in liposomes (n = 3 for each liposomal formulation). 
2.4.3 Biological Characterization 
2.4.3.1 Cell Culture Procedures 
Established human NB brain cancer cell lines SK-N-BE(2) and KELLY were a gift from the 
Radiobiology Department at the University of Stellenbosch. The same standardized cell 
culture protocol was used to grow SK-N-BE(2) and KELLY NB cells in Dulbeco’s Modified 
Eagles Medium (DMEM) supplemented with 1% penicillin/streptomycin and 10% Fetal 
Bovine Serum (FBS). 
SK-N-BE(2) NB cell line is a sub clone from the parental cell line which was established in 
1972 from the bone marrow of a two year old Caucasian male biopsy with disseminated stage 
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4 NB after repeated courses of chemotherapy and  radiotherapy (Lee and Kim, 2004). The 
morphology presents as epithelium-like cells that are mixed adherent and suspension growth. 
They are known to exhibit moderate levels of dopamine bet hydroxylase and tyrosine 
hydroxylase activity.  
The KELLY NB cell line is derived from human brain and shows a predominantly neuronal 
morphology with adherent cell growth. The cells have a genomic amplification of the N-myc 
gene and express elevated levels of N-myc RNA or protein (nuclear DNA binding protein) 
(Beierle et al., 2007). The following procedures were followed:  
i) Thawing of Cells 
When required, frozen vials of SK-N-BE(2) NB cell line (passage number 4) and KELLY 
NB cell line (passage number 82) were removed from storage at  -80 °C and quickly thawed. 
The contents of the cryovial were slowly mixed with 9 ml of growth medium in a 15 ml 
centrifuge tube. The cells were centrifuged at 2500 rpm for 5-7 minutes; the supernatant was 
decanted and the pellet was re-suspended in 10 ml of complete media and 5 ml each was 
transferred into two 25 cm2 tissue culture flasks and  placed  in a water jacketed CO₂ 
incubator (Labtec, Germany) at 37 °C with 5% CO₂ until 70–80% confluency was reached.  
ii) Sub-culture and Trypsinization Procedure  
When the cells reached the desired confluency, the media was discarded and the cells were 
rinsed with 1 ml of 1X PBS (pH 7.4). The PBS was discarded and 1–2 ml of 2X trypsin 
EDTA was added to the flask to detach the monolayer. The flask was placed in a water 
jacketed CO₂ incubator at 37 °C with 5% CO₂ for 3-5 minutes. After incubation the cell 
suspension was removed and 5 ml of DMEM was added to deactivate trypsin. To remove 
traces of trypsin, the cells were centrifuged at 2500 rpm for 5-7 minutes and the supernatant 
was discarded. The cell pellet was then re-suspended in 5 ml growth medium and the cells 
counted using trypan blue and a Countess™ automated cell counter (Invitrogen, USA). Cells 
were seeded into 25 cm³ or 75 cm³ tissue culture flasks and placed in the water jacketed CO₂ 
incubator at 37 °C with 5% CO₂. Cells were seeded in a ratio of 1:6/1:10 for SK-N-BE(2) and 
1:4 for KELLY NB cells with media renewal occurring every 3-4 days. 
 
 
 
 
 
 
 
61 
 
iii) Trypan Blue for Cell Viability and Cell Seeding 
Live cells have intact cell membranes that exclude certain dyes, such as trypan blue whereas 
dead cells do not. Therefore trypan blue stains non-viable cells blue and viable cells will 
remain opaque or clear.  
Cell viability and cell counting for seeding into plates was conducted using trypan blue by 
mixing 10 μl cell suspension and 10 μl trypan blue and pipetting it into the countess chamber 
slide (Invitrogen) which was analysed using the Countess Automated Cell Counter 
(Invitrogen, USA). The required cell suspension and media was added and seeding for 
experimental use took place one day before exposure to dimethyl sulfoxide (DMSO), free 
BetA, free γ-CD and liposomal formulations. Only cells with a viability of 80% and higher 
were seeded. 
iv) Cryopreservation 
Once cells reached the desired confluency, cells were trypsinized as described above (section 
ii); but the final cell pellet was re-suspended in cryo-media consisting of 90% FBS and 10% 
DMSO. The resultant suspension was stored in cryovials containing 1 ml aliquots. These 
vials were stored at -80 °C for short term storage and -150 ˚C for long term storage. 
2.4.3.2 Cell Viability Studies Using the WST-1 assay 
Agents that disrupt cell membranes and destroy the respiratory chain will affect cell 
proliferation and can be detected with a cell proliferation reagent such as WST-1 proliferation 
assay. WST-1 is a stable tetrazolium salt cleaved to a soluble formazan by a complex cellular 
mechanism that occurs at the cell surface. This bioreduction depends on the glycolytic 
production of NAD(P)H in viable cells. Therefore, the amount of formazan dye formed is 
directly proportional to the number of metabolically active cells in the culture. WST-1 cell 
viability assay is considered to be more favourable when compared to other cell viability 
assays such as MTT and XTT assays as it has several advantages over older cell viability 
assays. WST-1 does not have the additional solubilisation step as MTT, but can be measured 
after 2-4 hours incubation. WST-1 is more stable than XTT and MTS and can be stored at 2 
to 8˚C for several weeks without degradation (CytoSelect™ WST-1 Cell Proliferation Assay 
Reagent Product Manual, 2013-2014). 
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Figure 2.5 The principle of WST-1 colorimetric cell viability assay. This  assay is based on the conversion of 
the metabolically active/live cells from WST-1 to formazan in the presence of cellular NADH and electron 
mediator. Live cells can be detected by the observable orange colour change and can be measured with a 
spectrophotometer with an absorbance at 450 nm and the reference absorbance at 620 nm 
(http://www.cellbiolabs.com/sites/default/files/CBA-253-cell-proliferation-assay-colorimetric.pdf). 
i) DMSO Tolerance Test for SK-N-BE(2) and KELLY NB Cells 
Following the trypsinization and cell counting procedure, 100 μl of cells were seeded into the 
inner columns and rows of 96-well plates (where n = 6 for each column treated) while 100 μl 
of 1X PBS (pH 7.4) was added to the outer rows and columns to avoid evaporation around 
the perimeter. Cells were seeded at a cell density of 1 x 10³ and 5 x 10³ for SK-N-BE(2) and 
KELLY NB cells respectively (Baik et al., 2012; Gogolin et al., 2013). Cells were allowed 24 
hours for attachment in a water jacketed CO₂ incubator at 37 °C with 5% CO₂ after which the 
media was removed and replaced with 100 μl of fresh media or DMSO concentrations (0.1%, 
0.4%, 1% and 2%) and placed back into the incubator for 24, 48 and 72 hours exposure. 
DMSO concentrations were prepared in DMEM (1% penicillin/streptomycin and 10% FBS) 
in order to obtain increasing concentrations of 0.1%, 0.2%, 1% and 2% DMSO and stored at 
4 ˚C. Following incubation, on the day of 24, 48 and 72 hours exposure the WST-1 
colorimetric assay was performed according to the manufacturer’s protocol; briefly 10 μl of 
WST-1 reagent was added to all the occupied wells, except PBS occupied wells. The plates 
were incubated in the water jacketed CO₂ incubator at 37 °C with 5% CO₂ for 4 hours.  After 
incubation, the plates were gently shaken for a minute and read with a spectrophotometer 
(BMG labotec, Germany) with an absorbance wavelength set at 450 nm and the reference 
absorbance wavelength set at 620 nm. The parameters for the plate were set as follows: Blank 
(media), negative control (media and cells) and experimental (DMSO concentrations).  
ii) Evaluation of Cell Viability Following Exposure to Free BetA  
Free BetA concentrations (5-2 μg/ml) were prepared as previously described (Damle et al., 
2013). BetA was dissolved in DMSO in order to prepare a stock solution of 5 mg/ml and 
diluted in DMEM (1% penicillin and streptomycin and 10% FBS) to obtain concentrations of 
 
 
 
 
63 
 
5 μg/ml, 10 μg/ml, 15 μg/ml and 20 μg/ml of free BetA. The stock solution of BetA was 
sterile filtered (0.2 µm filter) before being used to prepare 5-20 μg/ml free BetA. The stock 
solution and working solution were stored at 4 ˚C (Faujan et al., 2010).  
A 100 μl of cells were seeded into 96-well plates (where n = 6 for each column treated) while 
100 μl of PBS was added to the outer rows and columns to avoid evaporation. Cells were 
seeded at a cell density of 1 x 10³ and 5 x 10³ for SK-N-BE(2) and KELLY NB cells 
respectively. Cells were allowed 24 hours for attachment in a water jacketed CO₂ incubator at 
37 °C with 5% CO₂ after which the media was removed and replaced with a range of 5-20μ 
g/ml of free BetA and placed back into the incubator for 24, 48 and 72 hours. Following 
incubation, the WST-1 colorimetric assay was performed as described above (section 2.4.3.2, 
i). After incubation, the plates was gently shaken for a minute and read with a 
spectrophotometer (BMG labotec, Germany) with an absorbance wavelength set at 450 nm 
and the reference absorbance wavelength set at 620 nm. The parameters for the plates were 
set as follows: Blank (media), negative control (media and cells) and experimental (free BetA 
concentrations).  
iii) Evaluation of Cell Viability in SK-N-BE(2) and KELLY NB Cell Lines 
Following Exposure to Liposomal Formulations and Free γ-CD  
BetAL concentrations was prepared as free BetA by diluting the prepared BetAL (in PBS 
solution) with DMEM (1% penicillin and streptomycin and 10% FBS) in order to obtain 
increasing concentrations of 5 μg/ml, 10 μg/ml, 15 μg/ml, 20 μg/ml and 50 μg /ml BetAL. 
Free γ-CD was prepared based on the initial amount used in the preparation of γ-CD-BetAL. 
A stock concentration of 2.84 mg/ml of γ-CD was prepared in PBS and diluted in DMEM 
(1% penicillin and streptomycin and 10% FBS) in order to obtain increasing concentrations 
of 5 μg/ml, 10 μg/ml, 15 μg/ml, 20 μg/ml and 50 μg/ml free γ-CD. The γ-CD-BetAL 
concentration was selected based on the cell viability results obtained from free γ-CD 
exposure (5-50 μg/ml). 
A 100 μl of cells were seeded into 96-well plates as described above (where n = 6 for each 
column treated). Cells were seeded at a cell density of 1 x 10³ and 5 x 10³ for SK-N-BE(2) 
and KELLY NB cells respectively and cells were allowed 24 hours to attach in a water 
jacketed CO₂ incubator at 37 °C with 5% CO₂ after which the media was removed and 
replaced with a 100 μl of EL, BetAL (5-50 μg/ml) and free γ-CD (5-50 μg/ml) for 24, 48 and 
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72 hours. The γ-CD-BetAL concentrations were selected based on free γ-CD results (5-50 
μg/ml for 24 hours and 5-15 μg/ml for 48-72 hours for KELLY NB cell line and 5-50 μg/ml 
for 24 hours, 5-15 μg/ml for 48 hours and 5-10 μg/ml for SK-N-BE(2) NB cell line). 
Following incubation, the WST-1 colorimetric assay was performed as described above 
(section 2.4.3.2, i). Plates were gently shaken for a minute after incubation and read with a 
spectrophotometer (BMG labotec, Germany) with an absorbance at 450 nm and the reference 
absorbance at 620 nm. The parameters for the plate were set as follows: Blank (media), 
negative control (media and cells) and experimental (EL, conventional BetAL, free γ-CD and 
γ-CD-BetAL).  
2.5 Statistical Analysis 
2.5.1 Liposome data was analysed using GraphPad Prism (version 5) 
• Two-way Anova and T-test for grouped data 
• Data represented as the mean ± standard deviation (SD) 
• A probability of P < 0.05,  P < 0.01 and P < 0.001 indicates level of statistical 
significance (annotated by one, two and three asterisks respectively) 
2.5.2 Cell culture data was analysed using Medcalc Statistics Programme (version 11.6.1) 
• Student T-test was selected for parametric data 
• Data represented as the mean ± SD 
• A probability of P < 0.05 indicates statistical significance (annotated by one asterisk) 
2.5.3 IC₅₀ concentration values was determined using the linear regression analyses feature 
after plotting a X-Y graph on GraphPad Prism (version 5) 
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CHAPTER 3 
PHYSIO-CHEMICAL CHARACTERISATION OF LIPOSOMES GENERATED 
FROM THIN FILM HYDRATION METHOD 
Numerous methods of synthesising liposomes have been proposed since their discovery in the 
1960’s, however the most widely employed and convenient method for research scale 
liposome production still remains the thin film hydration method (Kraft et al., 2014). In this 
study, different liposome formulations were prepared using the thin film hydration method as 
described in Chapter 2, section 2.3.1. BetA containing liposomes (BetAL and γ-CD-BetAL) 
were synthesized using the passive drug encapsulation technique as previously described 
(Mullauer et al., 2011). Two BetAL batches were prepared with different BetA 
concentrations, while the lipid concentration remained constant: Batch 1 (B1) (50 mg DPPC: 
2.5 mg BetA) and Batch 2 (B2) (50 mg DPPC: 5 mg BetA). In order to enhance BetA loading 
into liposomes, BetA was complexed with γ-CD to produce a γ-CD-BetA inclusion complex 
(γ-CD-BetA) (Dehelean et al., 2011a; Şoica et al., 2014), subsequently double loading of 
BetA and γ-CD-BetA occurred to produce the novel γ-CD-BetAL liposomes (section 2.3.2 
and 2.3.2, Chapter 2). Empty liposomes (EL) (50 mg DPPC: 10 mg Chol) containing no BetA 
were also prepared and compared to BetAL formulations. Liposomal formulations were 
characterized based on size, polydispersity index (PI) and zeta-potential (ζ-potential) using 
photon correlation spectroscopy (Zetasizer NanoZS instrument). Shape and size characteristic 
were studied using high resolution scanning electron microscopy (HR-SEM). The 
concentration (in mg/ml) of BetA entrapped in liposomes and the percent entrapment 
efficiency (% EE) was determined using ultra-high pressure liquid chromatography 
(UHPLC). Thin film hydration method yields multilamellar vesicles (MLVs) in the μm size 
range; therefore liposomes were downsized using an Avanti-mini extruder above phase 
transition temperature (Tc = 55 ˚C) to produce liposomes in the nm size range. Un-extruded 
liposomes were compared to the extruded liposomes for each liposomal formulation. The 
data was obtained in triplicates and analysed using GraphPad Prism 5 in order to construct 
bar graphs (mean ± standard deviation, n = 3 ± SD). The error bars were calculated standard 
error of the means and the level of statistically significant differences are annotated by 
asterisk(s) (* P < 0.5; ** P < 0.01; *** P < 0.001). 
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3.1 Size Analysis of the Liposomes   
When a large multilamellar vesicle (MLV) suspension created after thin film hydration is 
forced through filters with defined pore sizes above Tc, concentric layers of the MLVs 
deform to pass through the pore. The destruction of the lipid bilayer membranes occurs as 
liposomes are reduced in size to produce unilamellar vesicles (ULVs) or small unilamellar 
vesicles (SUVs) (Mokhtarieh et al., 2013). If a liposome suspension is continually cycled 
through a filter with a specific pore size, this process will produce liposome populations with 
a mean diameter that reflects that of the filter (Hinna et al., 2015). In this study the prepared 
liposomes were extruded 11 times through a 200 nm polycarbonate membrane followed by 5 
times through a 100 nm polycarbonate membrane at 55 ˚C (section 2.3.4, Chapter 2). 
Figure 3.1 (p. 67), shows the size distribution of un-extruded liposomes (A), extruded 
liposomes (B) and the comparison of the two (C). Un-extruded EL (4194 nm ± 2260) is 
noticeably larger when compared to the other un-extruded BetA loaded liposomal 
formulations, while γ-CD-BetAL showed the smallest size (1367 nm ± 190.5). Liposomes 
loaded with BetA (B1, B2 and γ-CD-BetAL) showed a decrease in size as the concentration 
of BetA was increased. However, statistically significant differences were only noted upon 
comparison of the un-extruded EL with un-extruded B1 (BetAL) (2387 nm ± 249.2) and un-
extruded EL with un-extruded γ-CD-BetAL (* P < 0.05).  
Following extrusion (Figure 3.1, B), extruded B2 (BetAL) (179 nm ± 9.45) was visibly larger 
when compared to the other liposomal formulations, while extruded γ-CD-BetAL (116.7 nm 
± 0.95) showed the smallest size. Statistically significant differences were reported upon 
comparison of the extruded EL (149.3 nm ± 21.84) with extruded γ-CD-BetAL, extruded B1 
(BetAL) (159 nm ± 15.50) with extruded γ-CD-BetAL and extruded B2 (BetAL) with 
extruded γ-CD-BetAL (** P < 0.01 and * P < 0.05).  
As shown in Figure 3.1 (C), the un-extruded EL is noticeably larger when compared to 
extruded EL. Statistically significant differences was noted upon comparison of the un-
extruded liposomal formulations with its extruded counterpart (*** P < 0.001). The average 
size of EL before extrusion was 4194 nm and was reduced to 149.3 nm after extrusion. The 
average size of un-extruded B1 (BetAL) was 2387 nm and was reduced to 159 nm, while un-
extruded B2 (BetAL) was 1742 nm and decreased to 179 nm after extrusion (refer to 
Appendix, Table 7.1). The smallest average size before and after extrusion can be observed 
for un-extruded γ-CD-BetAL (1367 nm ± 190.5) and extruded γ-CD-BetAL (116.7 nm ± 
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1.65). Thus extrusion was successful in reducing large liposomes in the μm size range to a 
size range of less than 200 nm.  
A 
 
B 
 EL
B1
 (B
etA
L)
B2
 (B
etA
L)
-C
D-
Be
tA
L
γ 
0
2000
4000
6000
Liposomal Formulations
Si
ze
 in
 n
m
 
 EL
B1
 (B
etA
L)
B2
 (B
etA
L)
-C
D-
Be
tA
L
γ
0
50
100
150
200
Liposomal Formulations
Si
ze
 in
 n
m
 
C 
EL
B1
 (B
etA
L)
B2
 (B
etA
L)
-C
D-
Be
tA
L
γ
0
2000
4000
6000
 
Liposomal Formulations
Si
ze
 in
 n
m
 
Figure 3.1 The size (diameter) distribution of different liposomal formulations before (A) and after extrusion 
(B) was determined and compared (C). The size distribution of liposomal formulations was measured at 25 ºC 
using dynamic light scattering (DLS) at an angle of 173 ˚C to the laser beam on a Malvern Zetasizer NanoZs 
instrument (Malvern instruments, Ltd., UK). Data was obtained in triplicates and used to construct bar graphs 
(mean ± standard deviation, n = 3 ± SD). Error bars represent calculated standard error of the means. Level of 
statistically significant differences are annotated by asterisk(s) (* P < 0.05; ** P < 0.01 and *** P < 0.001). 
3.2  Polydispersity Index (PI) of Liposomes 
 The PI is the width parameter derived from the cumulants analyses and is used to evaluate 
the homogeneity of colloidal particles in solution (Iqbal et al., 2012). A PI in a range of 0.1-
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0.25 indicates uniformity in the liposome size distribution and a more monodisperse solution, 
while a PI above 0.5 and closer to 1 suggests that the sample is too polydisperse and may 
have a non-uniform size distribution (Kale et al., 2012 and Sabeti et al., 2014). 
Figure 3.2, shows the PI of un-extruded liposomes (A), the PI of extruded liposomes (B) and 
the comparison of the two (C).  
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Figure 3.2 The polydispersity index (PI) of different liposomal formulations before (A) and after extrusion 
(B) was determined and compared (C). The PI of liposomal formulations was measured at 25 ºC using dynamic 
light scattering (DLS) at an angle of 173 ˚C to the laser beam on a Malvern Zetasizer NanoZs (Malvern 
instruments, Ltd., UK) Data was obtained in triplicates and used to construct bar graphs (mean ± standard 
deviation, n = 3 ± SD). Error bars represent calculated standard error of the means. Level of statistically 
significant differences are annotated by asterisk(s) (* P < 0.05 and *** P < 0.001). 
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Un-extruded EL (0.86 ± 0.13), un-extruded B1 (BetAL) (1 ± 0.0), un-extruded B2 (BetAL) 
(0.94 ± 0.1) and un-extruded γ-CD-BetAL (0.49 ± 0.07) showed PI values in a range of 0.5-1 
(Figure 3.2, A). Statistically significance difference were only observed upon comparison of 
un-extruded B2 (BetAL) and un-extruded γ-CD-BetAL (* P < 0.05). 
After extrusion (Section 2.3.4, Chapter 2), extruded EL had the lowest PI (0.17 ± 0.03) while 
extruded γ-CD-BetAL had the highest PI. There is a noticeable increase in the PI of BetA 
loaded liposomes as the concentration of BetA increases (extruded B1: 0.22 ± 0.04, extruded 
B2: 0.23 ± 0.01 and extruded γ-CD-BetAL: 0.24 ± 0.01). Statistically significance difference 
were observed when extruded EL were compared to extruded γ-CD-BetAL (* P < 0.05). 
The results for the PI of liposomal formulations before extrusion was closer to 1 and after 
extrusion the PI was reduced to less than 0.3 (Figure 3.2, C). There were statistically 
significant differences recorded when un-extruded liposomal formulations were compared to 
its extruded counterpart (*** P < 0.001) (Figure 3.2, C). In summary, the high PI generated 
after thin film hydration method showed a liposome solution with a high degree of non-
uniformity in size distribution and extrusion was successful in producing liposomes with a 
uniform size distribution in solution.  
3.3 Zeta-potential (ζ-potential) of Liposomes 
The potential that exists at the slipping plane of a particle in an aqueous solution is called the 
ζ-potential (Domingues et al., 2008; Kaszuba et al., 2010). It is a physical property which is 
exhibited by any particle in suspension and measurements of ζ-potential are commonly used 
to assess the stability of colloidal systems (Freire et al., 2011).  
The ζ-potential before extrusion of EL (-1.205 mV ± 0.74), B1 (BetAL) (-2.25 mV ± 0.1), B2 
(BetAL) (-2.52 mV ± 0.18) and γ-CD-BetAL (-2.02 mV ± 0.21) produced negative ζ-
potential values as seen in Figure 3.3 (A), p. 70. Inclusion of BetA into un-extruded 
liposomes showed a higher negative ζ-potential when compared to un-extruded EL, with un-
extruded B2 (BetAL) demonstrating the highest negative ζ-potential. Statistically significant 
difference were noted upon comparison of EL with B1 (* P < 0.05) (Figure 3.3, A). 
After extrusion, EL showed a positive ζ-potential value close to 0 (1.05 mV ± 0.05) 
indicating a neutral surface charge on the DPPC lipid (Figure 3.3, B). Extruded B1 (BetAL) 
(-1.24 mV ± 0.04), extruded B2 (BetAL) (-1.29 mV ± 0.01) and extruded γ-CD-BetAL (-1.47 
mV ± 0.03) remained in the negative zeta range. The γ-CD-BetAL showed the highest 
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negative zeta-potential after extrusion. Statistically significant difference can be observed 
when EL is compared to all liposomal formulations (*** P < 0.001) (Figure 3.3, B). 
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Figure 3.3 The zeta potential (ζ-potential) of different liposomal formulations before (A) and after extrusion 
(B) was determined and compared (C). The ζ-potential of liposomal formulations was measured using a voltage 
of 4 mV on a Malvern Zetasizer NanoZs (Malvern instruments, Ltd., UK) at 25 ºC using dynamic light scattering 
(DLS) at an angle of 173 ˚C to the laser beam. Data was obtained in triplicates and used to construct bar graphs 
(mean ± standard deviation, n = 3 ± SD). Error bars represent calculated standard error of the means. Level of 
statistically significant differences are annotated by asterisk(s) (* P < 0.05; ** P < 0.01 and *** P < 0.001). 
The ζ-potential of BetA loaded liposomal formulations before extrusion was in the negative 
range and became slightly less negative after extrusion (Figure 3.3, C). Statistically, 
significant differences were only observed for un-extruded EL compared to extruded EL (** 
* 
*** 
** 
*** 
*** 
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P < 0.01) (Figure 3.3, C). Therefore changes in ζ-potential are related to size and BetA 
loading. 
3.4 Physical Morphology of Liposomes 
Size distribution (diameter) studies of liposomes from the Zetasizer nanoZS instrument uses 
dynamic light scattering (DLS) which provides statistical information about the size 
distribution of liposomes in solutions only. DLS does not yield information about the shape 
morphology of NPs; hence other techniques are usually applied for this purpose. SEM is 
often used to study surface morphology and shape characteristics of NPs (Charurvedi and 
Dave, 2012). In this study, the investigation of size and shape morphology was studied using 
HR-SEM. 
Figure 3.4 (p. 72) are HR-SEM micrographs of the prepared liposomes. Figure 3.4 shows the 
size and physical morphology of un-extruded EL (A and B), extruded B1 (BetAL) (C and D) 
and extruded γ-CD-BetAL (E and F). Un-extruded EL revealed a non-uniform size 
distribution of spherical like vesicles in a size range of ± 300 nm (different sizes of vesicles 
indicated by white arrows in A and B). Extruded B1 (BetAL) and extruded γ-CD-BetAL 
showed a more narrow uniform size distribution of spherical-like vesicles in a size range of 
less than 200 nm (indicated by arrows in C, D and F). Black arrows in un-extruded EL (A and 
B) and γ-CD-BetAL (F) indicate aggregation of liposomes as electrostatic forces present on 
the surface of liposomes are low and cannot prevent clumping of particles together, relating 
to the low negative ζ-potential results obtained. Un-extruded EL size analyses from Malvern 
Zetasizer NanoZs showed a size distribution of > 4000 nm (4194 nm ± 2260); this does not 
correlate with the size distribution of un-extruded EL using HR-SEM analyses (vesicles are < 
4000 nm). The uniform vesicles in extruded B1 (BetAL) (indicated by white arrows in C and 
D) and extruded γ-CD-BetAL (indicated by the white arrow in F) correlates with the PI study 
in a range of less than 0.25 for extruded B1 (BetAL) (0.22 ± 0.04) and extruded γ-CD-BetAL 
(0.24 ± 0.01), indicating uniformity in the liposome size distribution and a monodisperse 
solution after extrusion.  
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Figure 3.4 HR-SEM micrographs of un-extruded EL (A and B), extruded B1 (BetAL) (C and D) and 
extruded γ-CD-BetAL (E and F). A drop of un-extruded or extruded liposomes was dispersed on carbon 
adhesive tape applied on an aluminium stub and then left overnight to completely dry under fume hood. The 
dried liposomes were coated with gold palladium for 30 seconds using Emitech K550X (England) sputter coater 
and viewed with the Auriga HR-SEM F50 (Zeiss, South Africa) at a voltage of 5 KV. A scale-bar in nm, Extra 
high tension (EHT), Working distance (WD) and Magnification (Mag) is provided for each image. Black arrows 
indicate features of aggregation and white arrows show different sizes of un-extruded and extruded vesicles. 
A B 
C D 
E F 
 
 
 
 
73 
 
3.5 Determination of the Concentration of BetA Entrapped in Liposomes and the 
Percentage Entrapment Efficiency (% EE) of BetA in Liposomes 
The % EE refers to the total amount of drug or compound entrapped within liposomes (in 
mg/ml) divided by the total starting concentration (in mg/ml) multiplied by 100. Several 
factors such as the affinity of the drug to the lipid membrane, the lipid composition of the 
membrane, the volume of internal aqueous phase and the lipid bilayer, the concentration of 
the liposomes formed, drug-to-lipid ratio and the method of downsizing of liposomes have 
influences on the % EE of liposomes (Muppidi et al., 2012). In this study it was important to 
evaluate the amount of BetA entrapped within the liposomes in order to select the most 
appropriate liposomal formulations for further biological characterization of prepared 
liposomes. 
The concentration in mg/ml of BetA and the % EE of BetA in liposomes was determined 
using a UHPLC system (Flexar FX-20 UHPLC) (as described in section 2.4.2.1, Chapter 2). 
BetA was dissolved in methanol in order to prepare standards (0.005-1 mg) (section 2.4.2.1, 
Chapter 2). A calibration curve with standards plotted against the area under the peak/curve 
was constructed (Figure 2.4, Chapter 2). The linear equation was obtained to determine the 
concentration (in mg/ml) of BetA entrapped in the liposomes.  From this, the % EE of BetA 
in liposomes was calculated using the following equation: 
% Entrapment efficiency =                          X 100 
The amount of BetA entrapped in the formulations was dependent on the amount of BetA 
added while the DPPC remained constant. Table 3.1 shows the concentration of BetA in 
mg/ml entrapped in the different liposomal formulations. Thin film hydration method yielded 
a low entrapment of BetA before and after extrusion as seen in Table 3.1 
Table 3.1 The concentrations (in mg/ml) of BetA entrapped in liposomes (in mg/ml) (n = 3) 
 
B1 (BetAL) B2 (BetAL) γ-CD-BetAL 
Starting concentration of BetA 0.5 mg/ml 1 mg/ml 1 mg/ml 
Total entrapped BetA  before extrusion 0.17 mg/ml 0.22 mg/ml 0.31 mg/ml 
Total entrapped BetA  after extrusion 0.04 mg/ml 0.05 mg/ml 0.13 mg/ml 
 
Amount of drug in liposomes (pellet) (mg/ml)    
Total amount of drug used (mg/ml) 
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Table 3.2 shows the % EE of BetA in different liposomal formulations before and after 
extrusion. B1 (BetAL) shows the highest % EE (34.14% ± 2.86), while B2 (BetAL) shows 
the lowest % EE (22.78% ± 2.83). Incorporation of γ-CD-BetA into liposomes showed a 
decrease in γ-CD-BetAL (30.57% ± 1.74) when compared to B1 (BetAL). Statistically 
significant differences were observed when the % EE of un-extruded B1 (BetAL) was 
compared to the % EE of un-extruded B2 (BetAL) (* P < 0.05). This indicates that the lowest 
starting concentration of BetA loaded into liposomes (0.5 mg/ml) produced the highest 
entrapment before extrusion and employing a starting concentration of 1 mg/ml BetA (Table 
3.1) could not entrap more than 30% BetA.  
The % EE of BetA in different liposomal formulations after extrusion (section 2.3.4, Chapter 
2) showed a noticeable decrease. Extruded γ-CD-BetAL (13.20% ± 4.58) showed the highest 
% EE of BetA when compared to extruded B1 (BetAL) (8.50% ± 1.22) and extruded B2 
(BetAL) (5.14% ± 1.12), however no statistically significant differences were reported upon 
comparison of the % EE of different extruded liposomal formulations. 
Table 3.2 The percentage entrapment efficiency (% EE) of different liposomal formulations 
before extrusion and after extrusion (n = 3) 
 
B1 (BetAL) B2 (BetAL) γ-CD-BetAL 
% EE of BetA  before extrusion 34.14% ± 2.86 22.78% ± 2.83 30.57% ± 1.74 
% EE of BetA  after extrusion 8.50% ± 1.22 5.14% ± 1.12 13.24% ± 4.58 
 
Figure 3.5 (p. 75) shows the comparison of % EE of BetA in liposomes before and after 
extrusion. The % EE of un-extruded B1 (BetAL) was higher than the % EE of un-extruded 
B2 (BetAL), therefore in this case BetA loaded liposomes decreased with an increase in BetA 
concentration as the phospholipid composition remained the same (P < 0.05). Since B1 
(BetAL) showed a higher % EE than B2 (BetAL), this batch was selected to load γ-CD-BetA 
to form the γ-CD-BetAL. The incorporation of γ-CD-BetA into B1 (BetAL) liposomal 
formulation showed no increase in % EE of un-extruded γ-CD-BetAL when compared to un-
extruded B1 (BetAL), however an increase in % EE of extruded γ-CD-BetAL was noticeable 
when compared to both extruded B1 (BetAL) and extruded B2 (BetAL). Statistically 
significantly differences were not reported when the % EE of extruded γ-CD-BetAL was 
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compared with the % EE of extruded B1 (BetAL) and extruded B2 (BetAL). Statistically 
significant differences were observed upon comparison of un-extruded liposomal 
formulations with its extruded counterpart (Figure 3.5) (** P < 0.01 and * P < 0.05). In 
summary, the size of liposomes formed using thin film hydration method influenced the 
initial entrapment of BetA in liposomes and BetA loss after extrusion was significant. 
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Figure 3.5 The percentage entrapment efficiency (% EE) of different liposomal formulations before 
extrusion and after extrusion was determined and compared. The % EE of BetA and γ-CD-BetA into 
liposomes was obtained using Ultra High Performance Liquid Chromatography (UHPLC) (Perkin Elmer 
Flexar FX-15 UHPLC, USA). UHPLC conditions were as follows: C-18 (4.5 mm x 150. 5µm) column 
(Phenomenex Kinetex, USA), mobile phase of acetonitrile: methanol (80:20 v/v), triplicate injections with an 
injection volume of 10 μl and 0.5 ml/min flow rate. Detection occurred at 2.5 minutes using a wavelength of 
205 nm. Data were obtained in triplicates and used to construct bar graphs (mean ± standard deviation, n = 3 
± SD). Error bars represent calculated standard error of the means. Level of statistically significant 
differences are annotated by asterisk(s) (** P < 0.01 and * P < 0.05). 
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CHAPTER 4 
CYTOTOXICITY STUDIES OF THE SELECTED LIPOSOMAL FORMULATIONS 
ON NEUROBLASTOMA BRAIN CANCER CELL LINES 
For liposomes to be considered as a drug-delivery system, they must be evaluated in vitro for 
cytotoxicity on cell cultures and, subsequently, in vivo in pre-clinical and clinical trials. In 
vitro evaluation could assist in establishing the biocompatibility of the liposomal design, 
optimal liposomal formulation and reveal mechanisms of cell-liposome interaction. There are 
numerous methods used to analyze the cytotoxicity, which involve different aspects of cell 
function, such as cell viability and proliferation, cell morphology, loss of membrane integrity, 
decrease in cell adhesion etc. Following the physio-chemical characterization of liposomes 
(Chapter 3), B1 (BetAL) and γ-CD-BetAL was selected to evaluate their effect on the cell 
viability of two NB cell lines. This Chapter presents the results on the effects of free BetA 
(non-liposomal BetA), BetAL, γ-CD-BetAL and free γ-CD (non-liposomal γ-CD) on the 
viability of SK-N-BE(2) and KELLY NB cells in vitro. It is known from literature that 
certain concentrations of DMSO and γ-CD induce cytotoxicity into cell cultures. Free BetA 
was prepared from a working stock solution of 5 mg/ml BetA dissolved in DMSO. Therefore 
a DMSO tolerance test was conducted at concentrations of 0.1 to 2% in order to establish the 
final concentration of DMSO that is tolerable in both cell lines. In order to evaluate the 
cytotoxicity of free γ-CD in cells, treatment with 5-50 μg/ml free γ-CD occurred in both cell 
lines and based on this results, the concentration range of γ-CD-BetAL to treat SK-N-BE(2) 
and KELLY NB cells was selected. Cells were subjected with treatment of free BetA at a 
concentration range of 5-20 μg/ml, while BetAL treatment was performed at a concentration 
range of 5-50 μg/ml. The concentration of BetAL was increased due to the low entrapment of 
BetA in BetAL (section 3.5, Chapter 3). Empty liposomes (liposomes not containing BetA) 
were used as a control to evaluate the effect of the DPPC lipid and cholesterol (Chol) in both 
NB cell lines. The cell viability was evaluated using the WST-1 colorimetric cell viability 
assay. Control cells were untreated cells represented as 100% viability. The data was 
obtained and analysed using Medcalc Statistics Programme (version 11.6.1) in order to 
construct bar graphs (mean ± SD; n = 6). Error bars represent calculated standard error of the 
means. A probability of P < 0.05 indicates statistical significance (annotated by one asterisk). 
The % cell viability values and P values are included (refer to Appendixes). The half 
maximal inhibitory concentration (IC₅₀) values, represents the drug concentration required 
for 50% inhibition of cell viability in vitro.  IC₅₀ concentration values was obtained using 
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linear regression analyses feature on GraphPad Prism 5 for SK-N-BE(2) and KELLY NB cell 
lines exposed to free BetA, BetAL and γ-CD-BetAL after 24, 48 and 72 hours exposure. 
4.1 DMSO Tolerance Test for SK-N-BE(2) and KELLY NB Cell Lines 
DMSO is usually used as a cryo-protective agent for storing cells as it is added to cell 
freezing media to prevent the formation of ice crystals during the freezing process (Chen and 
Thibeault, 2013). It is also often used as a delivery vehicle for most non-soluble compounds 
and drugs and is usually tolerated with little or no observable effects at 0.1% final 
concentration (v/v) (Chen and Thibeault, 2013). At 1% or higher concentrations, depending 
on the cell line, its effects in vitro on cell viability have been reported to be selectively 
cytotoxic (Kim et al., 2001; Da Violante et al., 2002; Kvasnica et al., 2005; Qi et al., 2008; 
Chen and Thibeault, 2013; Galvao et al., 2014). DMSO tolerance test for SK-N-BE(2) and 
KELLY NB cell lines using the WST-1 cell viability assay is not reported in literature, 
therefore a DMSO tolerance test was performed on these two cell lines before treatment with 
free BetA as the free BetA concentrations (5-20 μg/ml ) was prepared from a stock solution 
of 5 mg/ml BetA (dissolved in DMSO). 
Figure 4.1 (p. 78) illustrates the DMSO tolerance test for SK-N-BE(2) (A) and KELLY (B) 
NB cell lines with control (untreated cells) represented as 100% cell viability. For DMSO 
treatment of SK-N-BE(2) NB cell line for all exposure time points, there was a general 
increase in cell viability above control at 0.1-0.4% DMSO exposure and a sharp linear 
decrease in cell viability from 1-2% DMSO exposure showing a noticeable trend (Figure 4.1, 
A and refer to Appendixes, Table 7.3.1). When compared to control, there was a 23% 
increase in cell viability at 72 hours for 0.1% DMSO treatment (123% cell viability), showing 
the highest increase while the 2% DMSO treatment at 72 hours produced the lowest cell 
viability (53% cell viability).  
The DMSO tolerance test for KELLY NB cell line (Figure 4.1, B, p. 78) did not show a 
noticeable trend as the cell viability showed variations across the exposure durations. At 24 
hours for 0.1-2% DMSO treatment, cell viability remained similar to controls and then 
decreased slightly from 0.4-2% DMSO exposure (Table 7.3.4, refer to Appendixes) as 
observed in the general trend with SK-N-BE(2) NB cells exposed to DMSO (Figure 4.1, A). 
Treatment with 0.1-2% DMSO showed a decrease below controls at 48 hours. Cell viability 
at 0.2-0.4% DMSO exposure for 72 hours showed a slight increase with the highest cell 
viability being reported at 1% DMSO treatment (111% cell viability). At 24 hours exposure  
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to 2% DMSO, cell viability decreased by 29%, showing the lowest cell viability (71% cell 
viability) (Table 7.3.4, refer to Appendixes). 
A 
 
B 
   
Figure 4.1 DMSO tolerance test for SK-N-BE(2) (A) and KELLY (B) NB cell lines. Cells were subjected to 
treatment with 0.1-2% DMSO for 24-72 hours. Control cells are untreated cells represented as 100% cell 
viability. Cell viability was evaluated using the WST-1 colorimetric cell viability assay. The data was obtained and 
used to construct bar graphs (mean ± SD, n = 6). Error bars represent calculated standard error of the means. 
Statistically significant differences are annotated by asterisks (* P < 0.05). 
For both cell lines, no statistically significant differences were reported upon comparison of 
untreated cells with 0.1-1% DMSO treated cells for all exposure durations. However, cells 
treated with 2% DMSO showed statistically significant differences (annotated by one 
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asterisk) when compared to controls for all exposure durations (P < 0.05) (Figure 4.1, Table 
7.3.2 and Table 7.3.5, refer to Appendixes). No statistically significant differences were 
reported for NB cells treated with 0.1-2% DMSO compared between the selected time 
intervals (24 hours compared to 48 hours, 48 hours compared to 72 hours and 24 hours 
compared to 72 hours) as seen in Table 7.3.3 and Table 7.3.6 (refer to Appendixes). In 
general, DMSO at low concentrations (0.1 and 0.4%) promoted cell growth in SK-N-BE(2) 
NB cells at 24-72 hours exposure while in KELLY NB cells it promoted cell growth only at 
72 hours with no statistically significant differences being reported when compared to 
controls. DMSO exposure at high concentrations (1% and 2%) was toxic to both cell lines. 
Therefore these results reveal that DMSO kept below 0.4% as a final concentration will not 
be toxic to SK-N-BE(2) and KELLY NB cells. 
4.2 Evaluation of Cytotoxicity for Free BetA and BetAL treatment in SK-N-BE(2) and 
KELLY NB Cell Lines 
BetA has demonstrated anti-cancer capabilities in vitro for numerous cancer cell lines with 
established IC₅₀ concentration values reported to fall in the rage of 0.5–17 μg/ml depending 
on the type of cell lines and cell viability assay methods used (Faujan et al., 2010; Suresh et 
al., 2012). The sensitivity of neuroectodermal derived tumour cells to free BetA was 
established previously with IC₅₀ concentration values for human NB cell lines starting at 14-
17 µg/ml and the underlying molecular apoptotic pathways were also studied (Fulda et al., 
1997 and Schmidt et al., 1997). Other brain tumour cell lines sensitive to free BetA (such as 
glioblastoma and medulablastoma) have also been reported to show IC₅₀ concentration values 
at 3-13.5 µg/ml and 2-17 µg/ml, respectively whereas no cytotoxic signs in non-malignant 
murine neuronal cells were observed (Wick et al., 1999 and Fulda et al., 1999). Head and 
neck squamous cellular carcinoma cells were also reported to be sensitive to BetA (Thurnher 
et al., 2003). 
The high lipophilic character associated with BetA shows that it cannot be dissolved and 
administered in most aqueous solutions, posing a difficulty in its efficacy in vivo and 
hampering a pharmaceutical formulation. Studies have modified BetA derivatives in an 
attempt to increase their solubility to address this issue (Liu et al., 2004; Huang et al., 2007; 
Rajendran et al., 2008), however it seems as though the lipophilic character of BetA is 
important in its pluripotent mechanism of action, which is responsible for its broad activity 
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profile (Mullauer et al., 2010). Therefore different liposomal formulations of BetA were 
prepared. 
Originally synthesized large BetAL (> 1 μm) was downsized (< 200 nm) for treatment of SK-
N-BE(2) and KELLY NB cell lines, thus leading to a decrease in the total percentage 
entrapment efficiency (% EE) of BetA. Therefore the concentration of extruded BetAL (% 
EE: 8.50 % ± 1.22) and extruded γ-CD-BetAL (% EE: 13.24 % ± 4.58) was increased from 
5-20 μg/ml  used in free BetA to 5-50 μg/ml due to the low entrapment of BetA and to 
evaluate if higher concentrations would have a statistically significant effect on cell viability. 
Figure 4.2.1 (p. 81) demonstrates the sensitivity of SK-N-BE(2) NB cell line subjected to 5-
20 μg/ml  free BetA treatment (A) and 5-50 μg/ml BetAL (B) treatment when compared to 
control (untreated cells). For all exposure durations to free BetA, there appeared to be a 
noticeable time and concentration dependent decrease in the cell viability (Figure 4.2.1, A). 
This is evident for 5-20 μg/ml treatment at 24 hours exposure and 5-15 μg/ml treatment at 
both 48 and 72 hours exposure. The lowest cell viability can be observed at 72 hours 
exposure at 15 μg/ml (7% cell viability), while the highest cell viability was observed at 5 
μg/ml treatment with free  BetA at 48 hours exposure (83% cell viability). Cell viabilities at 
48 hours and 72 hours showed a decrease at 5-10 μg/ml and then an increase at 15-20 μg/ml  
(Figure 4.2.1 and Table 7.4.1, refer to Appendixes). The estimated IC₅₀ values for SK-N-
BE(2) NB cells treated with free BetA were reported as follows: 13.10 μg/ml (24 hours 
exposure); 14.03μg/ml (48 hours exposure) and 7.85 μg/ml (72 hours exposure) (Table 4.1, 
Chapter 4,  p. 91).  
SK-N-BE(2) NB cells treated with BetAL compared to control (untreated cells) showed a 
similar trend in viability when compared to free BetA treatment as cells exposed to BetAL 
showed a concentration (5-50 μg/ml) and time (24-72 hours) dependent decrease for all hours 
of exposure (Figure 4.2.1, B, p. 81). The lowest cell viability can be observed at treatment 
with 50 μg/ml BetAL at 72 hours exposure (31% cell viability). EL (liposomes without BetA) 
showed a viability similar to untreated cells at 24 hours exposure (99% cell viability), but 
increased at 48 and 72 hours (110% cell viability and 102% cell viability, respectively). The 
estimated IC₅₀ values for SK-N-BE(2) NB cells treated with BetAL were reported as follows: 
53.45 μg/ml (24 hours exposure); 38.73 μg/ml (48 hours exposure) and 18.30 μg/ml (72 
hours exposure) (Table 4.2, Chapter 4, p. 91).  
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Figure 4.2.1 The evaluation of SK-N-BE(2) NB cell viability following exposure to free BetA (A) and BetAL (B) 
for 24-72 hours.  Cells were subjected to treatment with 5-20 μg/ml free BetA and 5-50 μg/ml BetAL for 24-72 
hours. Control cells are as follows: untreated cells (100% cell viability), DMSO control (0.4%) and empty 
liposomes (EL). Cell viability was measured using the WST-1 cell viability assay. The data was obtained and used 
to construct bar graphs (mean ± SD, n = 6). Error bars represent calculated standard error of the means. 
Statistically significant differences are annotated by asterisks (* P < 0.05) 
Statistically significant differences (annotated by the asterisks) were noted upon comparison 
of controls with 5-20 μg/ml free BetA treated cells (Figure 4.2.1, A) and with 5-50 μg/ml 
BetAL treated cells (Figure 4.2.1, B) (P < 0.05). Statistically significant differences were also 
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evident across time points for both free BetA and BetAL (refer to Appendixes, Table 7.4.3 
and Table 7.5.3). This suggests that treatment with 5-20 μg/ml  free BetA for 24-72 hours and 
5-50 μg/ml exposure of BetAL for 24-72 hours induces cytotoxicity in SK-N-BE(2) NB cells 
in a time and concentration dependent manner. DMSO control (Figure 4.2.1, A)  and  EL 
control (Figure 4.2.1, B) for 24-72 hours exposure showed no statistically significant 
differences when compared to untreated cells, indicating its safety profile in NB cells (Table 
7.5.2, refer to Appendixes). 
The sensitivity of KELLY NB cell line exposed to 5-20 μg/ml  free BetA (Figure 4.2.2, A) 
and 5-50 μg/ml BetAL (Figure 4.2.2, B) for 24-72 hours compared to controls (untreated 
cells) represented as 100% cell viability was determined (p. 83). When compared to the 
controls, for all exposure durations, there appeared to be a noticeable time and concentration 
dependent decrease in the cell viability of KELLY NB cells exposed to free BetA (Figure 
4.2.2, A). This is evident at 5-20 μg/ml free BetA treatment for 24-48 hours exposure. The 
lowest cell viability was observed at 72 hours exposure to 10 μg/ml free BetA (14% cell 
viability) (Table 7.4.4, refer to Appendixes). Cell viability at 72 hours exposure to free BetA 
showed a decrease from 5-10 μg/ml and then a slight increase at 15-20 μg/ml suggesting that 
cells are starting to recover at the highest concentrations; however it was still lower than 50% 
cell viability. The estimated IC₅₀ concentration values for KELLY NB cells treated with free 
BetA were reported as follows: 24.00 μg/ml (24 hours exposure); 14.50 μg/ml (48 hours 
exposure) and 76.05 μg/ml (72 hours exposure) (Table 4.2, p. 91).  
The effect of BetAL exposure (5-50μg/ml) to KELLY NB cells compared to untreated cells 
showed variations in cell viability across the exposure time points, however there seems to be 
a trend as cell viability decreases with an increase in exposure time (Figure 4.2.2, B, p. 83). 
This can be observed at 10-50 μg/ml BetAL treatment at 24 hours and 5-20 μg/ml exposure at 
48 and 72 hours. The lowest cell viability was reported at 15 μg/ml BetAL treatment at 72 
hours (41% cell viability). Cells treated with EL showed a 5% increase in cell viability at 24 
hours (105% cell viability) and a slight decrease at 48 and 72 hours (98% cell viability) 
(Table 7.5.4, refer to Appendixes). The estimated IC₅₀ values for KELLY cells treated with 
BetAL were reported as: 68.65 μg/ml (24 hours exposure), 61.52μg/ml (48 hours exposure) 
and 21.42μg/ml (72 hours exposure) (Table 4.2, p. 91). 
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Figure 4.2.2 The evaluation of KELLY NB cell viability following exposure to free BetA (A) and BetAL (B) for 
24-72 hours. Cells were subjected to treatment with 5-20 μg/ml free BetA and 5-50 μg/ml BetAL for 24-72 hours. 
Control cells are as follows: untreated cells (100% cell viability), DMSO control (0.4%) and EL. Cell viability 
was measured using the WST-1 cell viability assay. The data was obtained and used to construct bar graphs 
(mean ± SD, n = 6). Error bars represent calculated standard error of the means. Statistically significant 
differences are annotated by asterisks (* P < 0.05) 
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Statistically significant differences (annotated by the asterisks) for KELLY NB cells were 
observed upon comparison of untreated cells and cells treated with 5-20 μg/ml  free BetA 
(Figure 4.2.2, A, p. 83) and 5-50 μg/ml BetAL (Figure 4.2.2, B, p. 83) (P < 0.05). Statistically 
significant differences were also evident across time points for both free BetA and BetAL 
(refer to Appendixes, Table 7.4.6 and Table 7.5.6). This suggests that treatment with 5-20 
μg/ml free BetA for 24-72 hours and treatment with 5-50 μg/ml BetAL for 24-72 hours 
induces cytotoxic effects in KELLY NB cells. DMSO control (Figure 4.2.2, A)  and  EL 
control can be considered safe as they had (Figure 4.3, B) no statistically significant effect on 
cell viability compared to untreated cells (Table 7.5.5, refer to Appendixes). 
4.3 Evaluation of Cytotoxicity For Free γ-CD and γ-CD-BetAL Exposure in SK-N-BE(2) 
and KELLY NB Cell Lines 
It was reported in literature that certain cyclodextrin (CD) groups demonstrate toxicity such 
as α-CD, β-CD and a number of alkylated CDs are known to show renal toxicity and 
disruption of biological membranes, while γ-CD and some of its derivatives (HP-γ-CD), as 
well as HP-β-CD and SBE-β-CD, appear to be much safer (Stella and He et al., 2008; 
Hanumegowda et al., 2014). A limited amount of studies have been done on the effect of γ-
CD interaction with brain cancer cell lines, however studies have shown the effect of 
different CD including γ-CD on an in vitro BBB model (Monnaert et al., 2004). Monnaert et 
al., (2004) studied the toxicity and endothelial permeability for α-, β- and γ-CDs on the 
blood-brain barrier (BBB). The study revealed that the α-CD series is the most toxic, closely 
followed by β-CD series, whereas the γ-CD presents the lowest toxicities. As more products 
using CDs are approved or undergoing evaluation by regulatory agencies for use in 
pharmaceuticals, toxicity studies become essential in establishing their safety profile 
especially for neuroscience research.  
Incorporation of γ-CD-BetA into liposomes did enhance the % EE in extruded liposomes 
(13.24 % ± 1.22) and therefore the free γ-CD was prepared based on the initial amount used 
in the preparation of γ-CD-BetAL. A stock concentration of 2.84 mg/ml of γ-CD was 
prepared (dissolved in PBS) and diluted in DMEM (1% penicillin and streptomycin and 10% 
FBS) in order to obtain concentrations of 5-50 μg/ml free γ-CD. The γ-CD-BetAL 
concentration was selected based on the cytotoxicity results obtained from free γ-CD 
exposure (5-50 μg/ml). 
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Figure 4.3.1 (p. 86) shows the effects on the cell viability of SK-N-BE(2) NB cell line when 
exposed to free γ-CD (A) and γ-CD-BetAL (B) for 24-72 hours. The cell viability of SK-N-
BE(2) cells with treatment of 5-50 μg/ml free γ-CD showed variation in cell viability across 
the exposure time points (24-72 hours) when compared to controls (untreated cells) (Figure 
4.3.1, A and Table 7.6.1, refer to Appendixes). At 48 hours, statistically significant 
differences were noted at 20 μg/ml and 50 μg/ml free γ-CD exposure compared to controls 
(85% cell viability and 87% cell viability, respectively) (P < 0.05) (refer to Appendixes: 
Table 7.6.1 and Table 7.6.2, refer to Appendixes). At 72 hours, it is evident that free γ-CD 
exposure causes an increase in cell proliferation above controls with exposure to 15 μg/ml 
free γ-CD showing the highest increase in cell viability (121% cell viability), while at 20 
μg/ml and 50 μg/ml free γ-CD exposure cell viability decreased to below 50% (48% and 40% 
cell viability, respectively) (Figure 4.3.1, A, p. 86 and refer to Appendixes: Table 7.6.2). No 
statistically significant differences were reported for 24 hours exposure with 5-50 μg/ml free 
γ-CD when compared to controls, however statistically significant differences were observed 
when compared across different time points (Table 7.6.3, refer to Appendixes). Therefore 
free γ-CD at 24 hours exposure to 5-50 μg/ml, at 48 hours exposure to 5-15 μg/ml and at 72 
hours exposure to 5-10 μg/ml did not induce cytotoxicity into SK-N-BE(2) NB cells and was 
safe to use in γ-CD-BetAL cell viability experiments. 
Figure 4.3.1 (B) shows the sensitivity of the SK-N-BE(2) NB cell line to γ-CD-BetAL 
exposure concentrations. The cell viability of SK-N-BE(2) cells with treatment of γ-CD-
BetAL showed a concentration dependent decrease in viability for all exposure times with 
statistically significant differences being reported (annotated by the asterisks) (P < 0.05) 
(Figure 4.3.1 and refer to Appendixes: Table 7.7.1 and Table 7.7.2). SK-N-BE(2) NB cells 
treated with γ-CD-BetAL showed estimated IC₅₀ concentration values at: 44.90 μg/ml (24 
hours exposure); 32.10 μg/ml (48 hours exposure) and 12.12 μg/ml (72 hours exposure) 
(Table 4.3, p.91.). 
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Figure 4.3.1 The evaluation of SK-N-BE(2) NB cell viability following exposure to free γ-CD (A) and γ-CD-
BetAL (B) for 24-72 hours. Cells were subjected to treatment with: 5-50 μg/ml free γ-CD for 24-72 hours, 5-50 
μg/ml γ-CD-BetAL for 24 hours, 5-15 μg/ml γ-CD-BetAL for 48 hours and 5-10 μg/ml γ-CD-BetAL for 72 hours. 
Control cells are untreated cells represented as 100% cell viability. Cell viability was evaluated using the WST-1 
cell viability assay. The data was obtained and used to construct bar graphs (mean ± SD, n = 6). Error bars 
represent calculated standard error of the means. Statistically significant differences are annotated by  asterisks 
(* P < 0.05) 
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Figure 4.3.2 (A) shows the sensitivity of KELLY NB cell line to free γ-CD (5-50 μg/ml) 
exposure with controls represented as 100% cell viability. Similarly to the SK-N-BE(2) cells, 
the cell viability of KELLY cells with treatment of free γ-CD showed variation in cell 
viability across the exposure time (24-72 hours) (Figure 4.3.2, p.88 and Table 7.6.4, refer to 
Appendixes). At 24 hours exposure to 5-50 μg/ml free γ-CD, statistically significant 
differences was only  reported at 50 μg/ml free γ-CD compared to controls (untreated cells), 
however at 48 and 72 hours statistically significant differences were noted at 20 μg/ml 
(94.65% and 94.94% cell viability, respectively  viability) and 50 μg/ml (86.42% and 91.94% 
cell viability, respectively) when compared to controls (P < 0.05) (Figure 4.3.2, B, and Table 
7.6.5, refer to Appendixes). No statistically significant differences were reported when the 
different time points were compared (Table 7.6.6, refer to Appendixes). Therefore treatment 
with 5-20 μg/ml free γ-CD at 24 hours and 5-15 μg free γ-CD treatment at 48 and 72 hours 
did not confer cytotoxicity into KELLY NB cells and was safe to use in γ-CD-BetAL cell 
viability experiments. 
KELLY NB cells treated with γ-CD-BetAL (Figure 4.3.2, B) showed a concentration 
dependent decrease in viability for all exposure times similar to γ-CD-BetAL treated SK-N-
BE(2) cells (Figure 4.3.1, B). At 24 hours cells were subjected to treatment with 5-20 μg/ml  
γ-CD-BetAL and at 48 and 72 hours cells were subjected to treatment with 5-15 μg/ml γ-CD- 
BetAL. Statistically significant differences were reported for all concentrations (P < 0.05) 
(Table 7.7.5, refer to Appendixes). KELLY NB cells exposed to γ-CD-BetAL showed 
estimated IC₅₀ concentration values to be: 49.17 μg/ml (24 hours), 40.63 μg/ml (48 hours) 
and 38.25 μg/ml (72 hours) (Table 4.3, p. 91).  
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Figure 4.3.2 The evaluation of KELLY NB cell viability following exposure to free γ-CD (A) and γ-CD-BetAL 
(B) for 24-72 hours. Cells were subjected to treatment with: 5-50 μg/ml free γ-CD for 24-72 hours, 5-20 μg/ml γ-
CD-BetAL for 24 hours and 5-15 μg/ml γ-CD-BetAL for 48-72 hours. Control cells are untreated cells 
represented as 100% cell viability. Cell viability was evaluated using the WST-1 cell viability assay. The data was 
obtained and used to construct bar graphs (mean ± SD, n = 6). Error bars represent calculated standard error of 
the means. Statistically significant differences are annotated by one asterisk (* P < 0.05) 
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4.4 Comparison of Selected Concentrations of Free BetA, BetAL and γ-CD-BetAL at 
Specific Time Points in SK-N-BE(2) and KELLY NB Cell Lines 
Figure 4.4 (A), p. 90, shows the comparison of free BetA, BetAL and γ-CD-BetAL at the 
same concentrations and exposure time points in the SK-N-BE(2) NB cell line. For all 
concentrations and exposure durations, cell viability showed a significant drop for free BetA 
when compared to BetAL and γ-CD-BetAL. The γ-CD-BetAL was more effective in 
reducing the cell viability when compared to BetAL at all hours and concentrations, except at 
24 hours, 5-10 μg/ml treatment. Statistically significant differences were noted when the 
same concentrations of free BetA was compared to BetAL (i.e. 5 μg/ml free BetA compared 
to 5 μg/ml BetAL etc.) for all concentrations at 24 and 72 hours exposure (Figure 4.1, A, 
Table 7.8.1, refer to Appendixes). This was also noted for free BetA compared to γ-CD-
BetAL (Figure 4.1, A, Table 7.8.2, refer to Appendixes) for all concentrations being 
compared at 24 and 72 hours exposure. At 48 hours exposure, statistically significant 
differences can be observed when 5 μg/ml free BetAL was compared to 5 μg/ml γ-CD-BetAL 
and at 72 hours at 5 μg/ml free BetA treatment compared to 5 μg/ml BetAL.  
The comparison of free BetA, BetAL and γ-CD-BetAL at the same concentrations and 
exposure time points in KELLY NB cell line was studied (Figure 4.4, B). Free BetA showed 
the lowest cell viabilities when compared to the same concentrations of BetAL and γ-CD-
BetAL for all hours, except at 24 hours treatment with 5-10 μg/ml free BetA. Free BetA was 
also reported to show statistically significant differences when compared to liposomal 
formulations for all hours (P < 0.05) (Figure 4.1, B, Table 7.8.4 and Table 7.8.5, refer to 
Appendixes). The γ-CD-BetAL was more effective in reducing the cell viability when 
compared to BetAL at all hours and concentrations, except at 24 hours, 5-10 μg/ml treatment.  
In summary, both cell lines show a noticeable concentration dependent decrease in cell 
viability for exposure durations. Free BetA is more effective in inducing cytotoxicity when 
compared to the same concentrations of BetAL and γ-CD-BetAL for both NB cell lines. 
Treatment with-γ-CD-BetAL induced a higher cytotoxicity than BetAL in SK-N-BE(2) as 
seen at 24 hours (15-20 μg/ml ), 48 hours (5-15 μg/ml) and 72 hours (5-10 μg/ml). KELLY 
cells were more sensitive to treatment with BetAL at 48 hours (5-20 μg/ml ) and 72 hours (5-
20 μg/ml ), except at 24 hours (10-20 μg/ml) when compared γ-CD-BetAL. SK-N-BE(2) NB 
cells appear to be more sensitive to free BetA at 24 hours when compared to KELLY NB 
cells, however they show a similar decrease in cell viability at 72 hours (10-20 μg/ml).  
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Figure 4.4 Comparison of the same concentrations of free BetA, BetAL and γ-CD-BetAL at 24-72 hours 
treatment in SK-N-BE(2) (A) and KELLY NB (B) NB cell lines. SK-N-BE(2) and KELLY NB cells were 
subjected to treatment with free BetA, BetAL and γ-CD-BetAL. Cell viability was measured using the WST-1 
cell viability assay. The data was obtained and used to construct bar graphs (mean ± SD, n = 6). Error bars 
represent calculated standard error of the means. Statistically significant differences are annotated by one 
asterisk (* P < 0.05) 
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Table 4.1: Estimated half maximal inhibitory concentration values (IC₅₀) for free BetA.  
Cell line Time (Hours) IC₅₀ values (μg/ml) 
 
SK-N-BE(2) 
24 13.10 
48 14.03 
72 7.85 
 
KELLY 
24 24.00 
48 14.50 
72 76.05 
 
Table 4.2: Estimated half maximal inhibitory concentration values (IC₅₀) for BetAL.  
Cell line Time (Hours) IC₅₀ values (μg/ml) 
 
SK-N-BE(2) 
24 53.45 
48 38.73 
72 18.30 
 
KELLY 
24 68.65 
48 61.52 
72 21.42 
 
Table 4.3: Estimated half maximal inhibitory concentration values (IC₅₀) for γ-CD-
BetAL.  
Cell line Time (Hours) IC₅₀ values (μg/ml) 
 
SK-N-BE(2) 
24 44.90 
48 32.10 
72 12.12 
 
KELLY 
24 49.17 
48 40.63 
72 38.25 
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CHAPTER 5 
DISCUSSION  
5.1 Introduction 
More than half of children diagnosed with high-risk NB will either not respond to 
conventional therapies or relapse after treatment (London et al., 2011). There are various 
complicating factors associated with the treatment of NS and CNS cancers. The delivery of 
drugs in CNS cancers is mainly limited by the presence of anatomical barriers: the blood–
brain barrier (BBB), blood–cerebrospinal fluid barrier (BCSFB) and the cerebrospinal fluid 
brain barrier (CSF) (Engelhardt and Sorokin, 2009). These barriers are highly selective and 
regulate the passage of certain substances into the brain. The crossing of any molecule 
through these barriers is dependent upon its physicochemical properties, and pharmacokinetic 
profile in plasma and therefore, a large number of drugs with low vesicular transport and high 
metabolic activity or molecules such as nucleic acids, peptides, proteins and antibiotics 
cannot cross the BBB (Balda and Matter, 1998). In addition to the anatomical barriers 
presented by the CNS, normal brain vasculature differs when compared to tumour 
vasculature of the brain, as tumour vasculature comprises abnormal blood vessels; distended 
capillaries with leaky walls, leading to inconsistent drug delivery at the tumour site (Van 
Meir, et al., 2010). The diminished therapeutic value of many potent anticancer drugs is also 
greatly impacted by the lack of specificity of anticancer drugs to pathological diseased sites, 
resulting in very low amounts of administered drug that can ultimately reach the brain 
(Begley and Brightman, 2003). This is responsible for the systemic toxicity associated with 
chemotherapeutic agents. The long term toxic side effects of chemotherapeutic drugs to 
adjacent healthy brain structures usually include cognitive deficits and epilepsy due to 
neuronal damage (Wen and Kesari, 2008), as neurons present in the CNS do not present 
regenerative capacity, therefore damaged neurons are not capable of dividing and replacing 
themselves under normal circumstances (Buga et al., 2011), this compromises the CNS 
greatly. Growth reduction, thyroid function disorders, learning difficulties and an increased 
risk of secondary cancers continue to affect survivors of high-risk NB (Trahair et al., 2007). 
It has been proposed that one of the mechanisms contributing to the aggressive behaviour of 
advanced-stage NB in older children is resistance to the extrinsic apoptosis pathway 
activation (George et al., 2010). Hence, research in recent years has focused on the activation 
of apoptosis via the mitochondrial pathway (Ferrin et al., 2011; Posadas et al., 2012).  
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The medicinal use of plant-derived bioactive compounds for the treatment of many disease 
conditions including cancer predates recorded human history. BetA, a natural plant-derived 
compound belonging to the prominent class of triterpenoids, has emerged as a highly 
promising anti-cancer compound due to its ability to directly target the mitochondrial 
pathway of apoptosis (Mullauer et al., 2010). Its efficacy in many in vitro and in vivo systems 
has been widely studied with minimal to no cytotoxic effects in healthy cells and rodents 
(Zuco et al., 2002; Fulda and Kroemer 2009; Mullauer et al., 2010). However, the 
formulation of a pharmaceutical product from this compound has been hampered by its 
highly lipophilic character and weak hydrosolubility (Mullauer et al., 2011). Many studies 
have tried to modify BetA derivatives to enhance their solubility such as modifications at the 
C-3 and C-28 positions which were found to be promising in addressing the solubility issues 
(Lui et al., 2004; Huang et al., 2007; Rajendran et al., 2008). However, since the lipophilic 
character of BetA is likely to be crucially involved in its pluripotent mechanism of action, 
which is responsible for its broad activity profile, novel formulations of BetA are needed. 
Owing to the challenges faced with BetA and drug delivery to the brain, advancement in 
science has lead to the discovery of specialized drug delivery techniques using 
nanotechnology. 
Nanotechnology utilizes particles in the 1-100 nm size range in at least one dimension; this 
allows them to cross biological barriers through small capillaries into individual cells, thereby 
permitting efficient drug accumulation at the target site and reducing the residual toxicity 
imposed by most chemo-therapeutic agents (Fisher and Ho, 2002, Lockman et al., 2002; Peer 
et al., 2007). This offers numerous novel possibilities for the treatment of cancer.  
Liposomes, a class of NPs, were discovered by Dr Bangham and colleagues in 1965 and have 
generated much enthusiasm due to their unique potential to improve the efficacy of current 
drugs (Paliwal et al., 2011). They are considered to be self-assembled closed colloidal 
structures composed of one or more concentric lipid bilayers surrounding a central aqueous 
core (Parveen et al., 2012). The unique ability of liposomes to entrap hydrophilic molecules 
into the core and hydrophobic molecules into the bilayers renders them attractive for drug 
delivery systems (Akbarzadeh et al., 2013). Cyclodextrins (CDs) are non-reducing cyclic 
oligosaccharides with features of a hydrophilic outer surface and lipophilic interior cavity, 
allowing for the improvement of poorly water soluable molecules by entrapping  guest 
molecules (lipophilic molecules) inside the internal cavity and acting as complexing agents 
(Laza-Knoerr et al., 2010; Nasir et al., 2012). CDs and liposomes have recently gained 
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interest as novel drug delivery vehicles by forming complexes that can be incorporated into 
the aqueous core of liposomes, hence improving therapeutic load, bioavailability and efficacy 
of many poorly water-soluble drugs (Arun et al., 2008; Li et al., 2011; Nasir et al., 2012; 
Chordiya and Senthilkumaran, 2012; Vafaei et al., 2014). This present study focuses on a 
novel drug delivery system for BetA using liposomes and γ-CDs and applying it for the 
treatment of human NB cancer cells. 
5.2 Size Analysis of the Liposomes 
The effects on size distribution of the EL, BetAL (B1 and B2) and γ-CD-BetAL generated 
from thin film hydration, before and after extrusion was studied (Figure 3.1, Chapter 3). In 
this study thin film hydration generated multilamellar vesicles (MLVs) (> 0.1μm). Thin film 
hydration is known to yield MLVs; liposomes with a diameter of approximately 0.1-20 µm 
with more than 4 bilayers present (Elhissi et al., 2006; Raman et al., 2007; Al-Zubaidi et al., 
2014). As shown in Figure 3.1, A (Chapter 3), the size of un-extruded EL (4194 nm ± 2260) 
was larger than un-extruded BetAL (B1 and B2) (2387 nm ± 249.2 and 1742 nm ± 959.9, 
respectively) and γ-CD-BetAL (1367 nm ± 190.5). As the concentration of BetA was 
increased, the size of the un-extruded BetA liposomal formulations decreased. Statistically 
significant differences were noted upon comparison of the un-extruded EL with un-extruded 
B1 (BetAL) and un-extruded γ-CD-BetAL (* P < 0.05). This suggests that cholesterol (Chol) 
might be included in the bilayer of liposomes more efficiently than BetA which allowed for 
larger size distribution of un-extruded liposomes. The presence of the hydroxyl group (OH) 
attached to the end of the Chol makes that part weakly hydrophilic therefore it inserts itself in 
the bilayer with its OH-group towards the aqueous core, and the rigid hydrophobic tail 
toward the phospholipid bilayers (Cooper and Hausman; 2009; Perrie and Rades, 2010). It 
could also be attributed to the high hydrophobicity of the long acyl chains present in DPPC 
phospholipid and repulsive interactions between water molecules at the interface; causing 
them to aggregate (Zhao and Feng, 2004; Zhao and Feng, 2005), therefore DLS could have 
measured these agglomerated particles as singular large particles. It is also important to note 
that 2 mg/ml of Chol was used in EL preparation, 0.5 and 1 mg/ml of BetA were used in 
BetAL preparations while the DPPC lipid remained constant. Increasing the concentration of 
BetA did not however cause the size of liposomes to increase (Figure 3.1, A, Chapter 3). The 
size of liposomes appears to depend largely on the interaction of DPPC lipids with either 
Chol or BetA during the formation process of liposomes and it seems as though Chol has a 
higher affinity for the DPPC bilayers than BetA. 
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It is suggested in the literature that the incorporation of both cholesterol (Chol) and BetA into 
liposome bliayers worked together to contribute to a highly rigid bilayer, a phenomenon of 
cooperative membrane rigidification also observed for Chol together with carotenoids (Reddy 
and Couvreur, 2008; Mullauer et al., 2011). BetAL was prepared without Chol to avoid 
rigidification and allow for easier extrusion (Mullauer et al., 2011) however, extrusion in this 
study was still difficult due to the viscosity of the liposome solution after thin film hydration 
and the desired SUVs (small unlamellar vesicles) in a range of less than 100 nm was 
therefore not achieved when studied with DLS (Figure 3.1, B). However, DLS measurements 
from Zetasizer NanoZS reveal that extrusion was successful in reducing MLVs in the μm size 
range, to large unilamellar vesicles (LUVs) in a size range of less than 200 nm (Figure 3.1.3, 
Chapter 3). Extrusion through a 100 nm filter did not work initially; therefore a 200 nm filter 
was used first and then a 100 nm filter (Section 2.3.4, Chapter 2). This could explain why the 
size distribution after extrusion for BetAL (B1 and B2) was larger when compared to EL as 
these two batches had a very viscous whitish medium after hydration making extrusion 
particularly difficult in both 200 nm and 100 nm filters (Figure 3.1.2, Chapter 3). A recent 
study revealed that extrusion through different sized filter pores and increasing the amount of 
passes through filters when extruding is more effective in achieving smaller liposomes 
(Hinna et al., 2015). Therefore it’s possible that increasing the amount of passes through the 
filter during extrusion and employing a smaller filter size (80 nm) in this study could have 
resulted in liposomes with a size of less than 100 nm.  
5.3 Polydispersity Index (PI) of liposomes 
PI for all liposomes before extrusion (Figure 3.2, A, Chapter 3) was closer to 1 and after 
extrusion PI was reduced to less than 0.3 (Figure 3.2, B, Chapter 3) indicating that the 
process of extrusion generated liposomes with a relatively narrow size distribution 
irrespective of BetA loading. The PI of B1 (BetAL) (1 ± 0.0) and B2 (BetAL) (0.94 ± 0.1) 
before extrusion shows a relationship with the large size distribution obtained for un-extruded 
B1 (BetAL) (2387 nm ± 143.9) and un-extruded B2 (BetAL) (1742 nm ± 959.9). After the 
hydration step, the lipid suspension should contain a heterogeneous mixture of MLVs, LUVs 
and SUVs (Laouini et al., 2012). This was noted in this study by the turbid whitish viscous 
lipid suspension before extrusion and therefore after extrusion this lipid suspension became 
more transparent. The low PI (0.1-0.24) after extrusion correlates to the nm size range 
obtained after extrusion, indicating that the transparent liposome solution observed after 
extrusion is monodisperse with a narrow uniform size distribution of liposomes in solution. 
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This also relates to previous studies where reported PI range of 0.2-0.4, yielded uniform sized 
liposomes in the nm size range (Cabral et al., 2004; Saha et al., 2011). 
5.4)      ζ-potential of Liposomes 
The ζ-potential of EL (-1.205 mV ± 0.74), B1 (BetAL) (-2.25 mV ± 0.1), B2 (BetAL) (-2.52 
mV ± 0.18) and γ-CD-BetAL (-2.02 mV ± 0.21) before extrusion was in the negative range 
(3.3, A, Chapter 3). The average un-extruded BetAL (B1 and B2) and un-extruded γ-CD-
BetAL showed a higher negative ζ-potential upon comparison to the extruded liposomes 
(Figure 3.3, C, and Chapter 3). When BetA was loaded into liposomes, the ζ-potential was 
more negative than EL (Figure 3.3, A) and remained in the negative range even after 
extrusion (Figure 3.3, C). BetA has a hydroxyl group which makes the compound slightly 
negative, which could explain why the ζ-potential remains negative after BetA loading and 
extrusion, as the BetA contributes to the negative ζ-potential of liposomes. This low ζ-
potential for BetA does not correlate to previous studies, BetA incorporated in flax-seed oil 
containing a nanoemulsion formulation showed higher negative ζ-potential values (−39.1 ± 
1.2), however this could be due to a different nanoparticle drug delivery system (Dehelean et 
al., 2011b). EL showed a positive ζ-potential value before extrusion (Figure 3.3, A) and a low 
negative ζ-potential after extrusion (Figure 3.3, B), with both values being closer to 0 mV, 
thus indicating a neutral surface charge. The surface charge of the EL was influenced by the 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) phospholipid used in the liposome 
preparation. DPPC lipid consists of a hydrophilic head group with a quaternary ammonium 
moiety choline, which is linked to a glycerol via a phosphoric ester (Brandl, 2001). The 
permanent positive charge on the choline of the head group counteracts the negative charge 
of the phosphate to give a neutral hydrophilic head group (Philippot and Schuber, 1994).  
The size of un-extruded BetAL (B1 and B2) was larger than un-extruded γ-CD-BetAL 
(Figure 3.1, A, Chapter 3) and higher negative ζ-potential values was evident when 
comparing the ζ-potential of un-extruded BetAL (B1 and B2) with un-extruded γ-CD-BetAL 
(Figure 3.3, A, Chapter 3). B2 (BetAL), which had a higher BetA loading compared to B1 
(BetAL), showed the highest ζ-potential before extrusion. These support the suggestion by 
Howard and Levi (2010) that the ζ-potential is related to size and drug loading. Higher BetA 
concentrations made the surface charge on the DPPC liposomes more intense before 
extrusion but when extruded, the intensity of the BetAL (B1 and B2) and γ-CD-BetAL was 
similar to that of un-extruded EL, suggesting that the stability of liposomes decreases as the 
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size decreases (Figure 3.3, C, Chapter 3). According to literature, liposomes with a ζ-
potential in a range of  > +30 mV or < −30 mV are normally considered stable for biological 
applications (Hunter et al., 2001; Laouini et al., 2012; Monteiro et al., 2014; Sabeti et al., 
2014); however the lipid-to-drug ratio used will influence the ζ-potential values (Honary and 
Zahir, 2013). The lipid-to-drug ratio of the neutral charged DPPC lipid and the slightly 
negatively charged BetA contributed to the low ζ-potential observed in this study. Liposomal 
formulations with ± 30 mV is superior in dispersion stability than the reported ranges in this 
study due to the fact that such formulations will have stronger electrostatic repulsion 
interaction forces present, thereby preventing aggregation of liposomes. This could explain 
the low ζ-potential values of liposomal formulations as the electrostatic repulsion is weak 
causing agglomeration. Furthermore ζ-potential with ± 30 mV has been shown to have higher 
drug encapsulation efficiency, due to stronger ζ-potential contributing to unilamellar 
liposome formation (Sou et al., 2011). Surface potential plays an important role in the 
behaviour of liposomes in vivo and in vitro. The ζ-potential of liposomes will affect the 
interaction with cells as most cancer cells are negatively charged due to the translocation of 
negatively charged constituents of the inner layer of the cell membrane to the cell surface 
(Ran et al., 2002). The BBB has also been reported to be negatively charged due to anionic 
sites located on the luminal surfaces of brain capillaries (Béduneau et al., 2007). More 
positively charged NPs could facilitate in crossing biological membranes and the BBB 
(Honary and Zahir, 2013). Therefore even though liposomal formulations in this study 
revealed low negative ζ-potential values, this could assist in the mechanism of liposome-cell-
interaction and drug delivery to cells. 
5.5 Size and Physical Morphology of Liposomes 
HR-SEM micrographs of un-extruded EL, extruded B1 (BetAL) and extruded γ-CD-BetAL 
revealed spherical-shaped vesicles (Figure 3.4, Chapter 3). The spherical shape was 
maintained even after the incorporation of BetA into liposomes. Un-extruded EL had a 
heterogeneous size distribution of spherical vesicles as some were in the size range of less 
than 300 nm and a few vesicles were larger than 300 nm (A and B). This did not correlate 
with the size results obtained from the Zetasizer NanoZs instrument which showed a size 
distribution of more than 4000 nm for un-extruded EL (4194 nm ± 2260). However it did 
relate to the PI studies of un-extruded EL, as the PI was above 0.5, indicating a 
heterogeneous solution, suggesting that liposomes in solution are non-uniform in shape. 
Extruded B1 (BetAL) (C and D) and extruded γ-CD-BetAL (E and F) showed a more 
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homogeneous size distribution, thus extrusion was successful in converting large liposomes 
into a uniform and narrow liposome population. This also corresponds with the PI results 
obtained from the Zetasizer NanoZs instrument for extruded B1 (BetA) (0.22 ± 0.04) and 
extruded y-CD-BetAL (0.24 ± 0.01) as the PI was in a range of less than 0.25, indicating a 
monodisperse solution. The reported size distribution of extruded B1 (BetAL) and extruded 
γ-CD-BetAL after analyses with the Zetasizer NanoZs was larger when compared with the 
sizes observed in the HR-SEM micrographs (Figure 3.4, Chapter 3). This is largely related to 
the different techniques used in the analysis of size. The Zetasizer NanoZs instrument uses 
dynamic light scattering (DLS) techniques to measure particles in solution undergoing 
Brownian motion and hydrodynamic size whereas in HR-SEM analyses, the sample 
requirement is smaller and must be completely dried under a fume hood prior to analyses 
(Elsayed and Cevc, 2011). Liposomes dispersed in liquid would have different properties 
compared to the liposomes that are air-dried. It is possible that the larger sizes reported in un-
extruded EL (Figure 3.1, A) using DLS was attributed to aggregation of liposomes as seen in 
un-extruded EL HR-SEM micrographs (black arrows in Figure 3.4, A, B and E). This relates 
to the low ζ-potential reported for un-extruded EL (Figure 3.3, A) observed as electrostatic 
repulsion forces prevent NPs from agglomerating and low ζ-potential values have been 
reported to result in agglomeration of NPs (Hunter et al., 2001, Jiang et al., 2009; Sabeti et 
al., 2014). In this study, the repulsive forces present was weak and forces of agglomeration 
prevailed causing the clumping together of vesicles as observed in Figure 3.4 (A, B and E). 
Aggregation of liposomes may contribute to leakage of entrapped agents (Torchilin et al., 
1992; Matteucci and Thrall, 2000; Pedroso de Lima et al., 2003) which was evident in the 
low % EE in this study and the significant loss of BetA after extrusion (Figure 3.5.2, Chapter 
3). Colloidal particles (size range of 1 μm) in solution often pose challenges in accurate 
characterization and measurement as they are constantly transitioning between Brownian 
movement and the fluid-induced movement (Elimelech, 1995). HR-SEM could give accurate 
information about size of liposomes, but the size of liposomes is also important in solution as 
this is the medium used to treat cells.  
SEM is less frequently used to image liposomes as the sample must be air dried/ freeze dried/ 
fixed before imaging and these prior steps cause liposomal vesicles to collapse during drying 
stages and burst or crack under the intensity of the electron beam as the magnification is 
increased (Ruozi et al., 2011). Liposomes in this study suffered structural perturbations as a 
result of the high-vacuum conditions of the HR-SEM instrument (images not shown) and 
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many vesicles collapsed during the air-drying step. The intensity of the electron beam caused 
the destruction of liposomes at higher magnifications; therefore images had to be taken 
quickly. This also explains why some images may seem out of focus (Figure 3.4, C and F). 
Liposomes, unlike cells, do not have pumps to enable the transfer of water out and therefore 
liposomes cannot tolerate a high osmotic pressure. When samples are diluted excessively 
during the sample preparation, the osmotic pressure could cause the liposomes to swell and 
burst. Freeze drying of samples using cryo-transmission electron microscopy (Cryo-TEM) 
could assist in improving the quality of images (Fox et al., 2014). Cryo-TEM imaging could 
also provide lamellarity characteristics (Farhang et al., 2012). However we were successful in 
imaging liposomes that are spherical in shape, as most liposomes imaged using SEM reported 
in literature are spherical (Nirale et al., 2009; Yousefi et al., 2009; Ramana et al., 2010; Odeh 
et al., 2012). Smooth external surfaces of liposomes in SEM images have been reported to 
demonstrate that the structure is a self-assembled and a closed membrane of lipid bilayers in 
contrast to agglomeration of lipids or fragments of lipid bilayers (Stamm et al., 2012). 
Smooth surfaces of un-extruded EL and extruded BetAL can be observed on the surfaces of 
spherical vesicles (white arrows in Figure 3.4, A and D). The shape and size morphology is 
an essential component in understanding and elucidating the mechanisms involved in drug 
release from liposomes and the biological analyses of liposome-cell-interaction.  
5.6 The Concentration (mg/ml) and the Percentage Entrapment Efficiency (% EE) 
of BetA in Liposomes 
The results presented in Table 3.1, Table 3.2 and Figure 3.5 (Chapter 3) indicates that BetA 
loading achieved using the thin film hydration method was poor and BetA loss in the 
extrusion process was significant (*** P < 0.01 and * P < 0.05). Statistically significant 
differences was reported when the % EE of un-extruded B1 (BetAL) was compared with the 
% EE of un-extruded B2 (BetAL) (* P < 0.05) but did not differ statistically when compared 
to un-extruded γ-CD-BetAL (Table 3.2, Chapter 3). This suggests that loading low amounts 
of BetA (0.5 mg/ml) was more effective in entrapping higher amounts of BetA in the DPPC 
bilayers. It’s possible that DPPC bilayers may have reached a limit in the capacity to entrap 
BetA at higher concentrations (1 mg/ml). Since the concentration of DPPC remained the 
same, increasing DPPC concentrations could have enhanced drug loading as shown by 
Chorachoo et al., (2013). The initial entrapment of BetA in un-extruded liposomes was 
generally low (Table 3.2 and Figure 3.5, Chapter 3); indicating that passive loading using thin 
film hydration method produced a poor entrapment of BetA as a lipophilic molecule (Figure 
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3.5, Chapter 3). This relates to previous studies which reported on the low entrapment of non-
polar derivatives and hydrophilic molecules into liposomes using thin film hydration method 
(Patel et al., 2010; Vyas et al., 2011; Muppidi et al., 2012).  
The initial size of liposomes generated from thin film hydration and liposomes subjected to 
extrusion shows a relationship with the % EE of BetA. It’s possible if the size of BetA loaded 
liposomes was increased, the % EE could be increased as shown by Mullauer et al., (2011) 
where large liposomes (1.5µm), assembled without Chol, contained a fivefold-enhanced 
BetA incorporation (approximately 6 mg/ml) (Mullauer et al., 2011). The researchers did 
conclude that the larger liposomes would not be feasible for human application.  Extrusion 
has also been reported to decrease drug entrapment in liposomes (Jousma et al., 1987; Berger 
et al., 2001, Mokhtarieh et al., 2013) as observed in this study. Previous studies suggested 
that BetA orients itself in the bilayer of liposomes (Mullauer et al., 2011). As extrusion took 
place, it appears that BetA was being discarded as the bilayers were being destroyed, thus the 
extruded liposome had an even lower % EE (Figure 3.5, Chapter 3). This resulted in less than 
1 mg/ml BetA in extruded B1 (BetAL), extruded B2 (BetAL) and extruded γ-CD-BetAL 
(Table 3.2).This finding corroborated a previous study by Mullauer et al., (2011), where they 
prepared long circulating liposomes in the size range of 100-200 nm which entrapped less 
than 1 mg/ml BetA. In the current study, long circulating liposomes (< 200 nm) was prepared 
because of their small size and prolonged circulatory half-life that could potentially enter into 
the tumour tissue by virtue of the local enhanced permeability retention (EPR) effect, thereby 
delivering BetA to the tumour tissue (Maeda et al., 2000).  
Chol is known to improve membrane stability for liposome formulations and hydrophobicity 
in the bilayers, especially for non-polar molecules. Chol does this by inserting itself into the 
membrane with its hydroxyl groups oriented towards the aqueous core and aliphatic chain 
aligned parallel to the acyl chains in the centre of the bilayer (Perrie and Rades, 2010). 
However Chol was not added to BetAL (B1 and B2) and γ-CD-BetAL in this study in order 
to avoid rigidification. The incorporation of Chol and BetA in the bilayer of liposomes 
renders an extremely rigid membrane, causing difficulty in downsizing of liposomes and 
slow or sustained drug release, as reported previously (Mullauer et al., 2011), 
Previous studies showed that there are variations in the % EE of molecules due to the 
increasing or decreasing amount of Chol, in some cases increasing the amount of Chol 
showed an increasing drug encapsulation efficiency, as reported by Bhatia et al., (2004) 
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where 30% Chol addition lead to an increased % EE of tamoxifen from 45.2% to 57.5%. 
There is variation in the % EE of hydrophobic molecules due to the increasing or decreasing 
amount of Chol. These effects may be due to molecular interaction between the 
phospholipids, Chol and drug. Chol enhances the hydrophobicity region of the bilayered 
membrane which may favour the entrapment of hydrophobic molecules (Subczynski et al., 
1994; Pasenkiewicz-Gierula et al., 2000). Addition of Chol in this study could have enhanced 
BetA loading and prevented BetA leakage; however considering the conflicting fact that Chol 
may favour incorporation into the limited hydrophobic bilayer, there might be a competition 
for space between the alkyl chains of DPPC, cholesterol and BetA resulting in an overall 
lower encapsulation with an increasing Chol content.  
It is known from literature that employing a lipid with a long alkyl chain length, increases 
partitioning of the non-polar or lipophilic derivatives into the bilayer and could help to avoid 
poor encapsulation and retention of drug which is one of the common disadvantages 
associated with liposomal drug delivery systems prepared using natural phospholipid such as 
the commonly used soy derived EPC (1,2-dioleoyl-sn-glycero-3-ethylphosphocholine) 
(Begum et al., 2012). In this study, a synthetic EPC lipid called DPPC, a 16 alkyl chain lipid, 
was used due to its reported high entrapment of hydrophobic drugs (Begum et al., 2012 and 
Odeh et al., 2012), however the % EE of BetA was still low. Using heating (above Tm) and 
cooling cycles in the hydration step was suggested as a means to increase the entrapment of 
BetA in the bilayer of liposomes, as this induced opening and closing of liposomes which 
would entrap more BetA. It is suggested in literature that after forming a thin film of lipids on 
a 250 ml round bottom flask, purging with nitrogen can reduce lipid oxidation (Achim et al., 
2009; Popovska et al., 2013). It is possible that some form of lipid peroxidation prevented 
BetA loading in the final prepared liposomes as no nitrogen purging for thin films with 
nitrogen was done, but stored immediately at -4˚C and cooling and heating cycles took place 
in the hydration step which was suppose to enhance BetA loading. Changes in temperature is 
one of the factors that can cause lipid peroxidation in DPPC liposomes as these changes can 
alter certain properties of lipids and the way in which they arrange themselves in order to 
enclose molecules and form liposomes during the hydration step (Cubillos et al., 2006). It is 
known from literature that the % EE of lipophilic molecules in liposomes depends largely on 
the affinity of drug to the lipid membrane (Muppidi et al., 2012).Therefore in this study, the 
ability of BetA to entrap in liposomes depended largely on the interaction and affinity of 
BetA in the DPPC bilayers of liposomes.  
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The interaction between BetA and DPPC lipid could be seen as non-specific as it is 
dependent on the hydrophobic (or van der Waals) force (Mullauer et al., 2011). Upon 
analyses of the molecular structure of BetA and DPPC lipid, low % EE of BetA in DPPC 
liposomes could be attributed to the absence or weakness of the van der Waals forces 
between the two compounds, hence hindering and acting as a physical barrier for the 
movement of BetA into the bilayers and forming unstable systems at the air/water interface 
during preparation. In chemistry, van der Waals forces are defined as the sum of the attractive 
or repulsive forces between molecules (or between parts of the same molecule) other than 
those due to covalent bonds, or the electrostatic interaction of ions with one another, with 
neutral molecules, or with charged molecules. There are three types of van der Waals’ forces- 
dipole-dipole forces, dispersion forces and hydrogen bonding. Chol could have been better 
oriented in the DPPC lipid bilayer than BetA, since it can form a hydrogen bond with 3β-
hydroxyl and the sn-2 carbonyl of DPPC (Sankaram and Thompson, 1991), this also 
correlates to the large sizes reported for un-extruded EL and the smaller un-extruded sizes for 
BetA loaded liposomes in this study. Partitioning of molecules into DPPC bilayers of 
liposomes is attributed to increasing hydrophobicity (Ojogun et al., 2010); hence it is possible 
that with BetA and DPPC having weak van der Waals forces between them, there are no 
strong electrostatic forces retaining BetA within DPPC bilayers. This correlates with the low 
negative ζ-potential values reported in this study before and after extrusion and the significant 
loss in BetA observed after extrusion. Further work using differential scanning calorimetry 
(DSC) is required to elucidate this. It could be assumed that some sort of adsorption took 
place inside the bilayers, where BetA incorporated in the bilayer of liposomes are in between 
the alkly chain lengths of DPPC and not held in place by electrostatic forces, as retention 
within the bilayers of BetA was weak. These factors could have contributed to BetA leakage 
from the liposome.  
The γ-CD-BetA did enhance BetA loading in γ-CD-BetAL but it was not statistically 
significant when compared to B1 (BetAL), BetA might have been entrapped in the core of 
liposomes when complexed with γ-CD but it  was a very low amount as it only differed from 
B1 (BetAL) by 5% (Table 3.2, Chapter 3). Forces such as van der Waals, hydrogen bonds 
and hydrophobic effects contribute to the formation of a stable complex of drugs in the non-
polar cavity of CDs (Nasir et al., 2012). These forces could have been really poor or 
complexation was weak, therefore contributing to poor loading of γ-CD-BetA into liposomes. 
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The % EE of BetA loading in DPPC liposomes reported in this study was dependent on size 
and ζ-potential. Decreasing the size of liposomes caused a decrease in BetA entrapment and 
therefore a decrease in ζ-potential of liposomes. This gives an indication that the 
accommodation of BetA within the liposome bilayers could be responsible for the slight 
negative ζ-potential values. The ζ-potential values with ± 30 mV has been shown to have 
higher drug encapsulation efficiency, due to stronger ζ-potential contributing to the formation 
of unilamellar stable liposomes (Sou et al., 2011). The low ζ-potential in this study matches 
with the low % EE. The ζ-potential for extruded γ-CD-BetAL showed the highest negative ζ-
potential after extrusion and the highest % EE after extrusion. 
The selected method and drug-to-lipid ratio were two important factors considered when 
analyzing the low entrapment of BetA in DPPC liposomes for this study as optimization of 
drug-to-lipid ratios will influence the entrapment of drugs in liposomes (Muppidi et al., 
2012). Thin film hydration method is the oldest and simplest method for preparing liposomes 
and usually yields poor entrapment efficiency (Gubernator, 2011; Prathyusha et al., 2013). 
The method of BetA loading used in this study is known as the passive loading method where 
BetA was included during the preparation of liposomes. Recently, active loading methods for 
producing liposomes have become more popular, as they demonstrate higher % EE (Sur et 
al., 2014). In this method, empty liposomes are first created and then the drug/compound is 
loaded using transmembrane pH gradients where drugs can cross membrane layers to enter 
into the liposome. This method however seem to increase the % EE of hyrophilihc drugs 
more than hydrophobic/lipophilic drugs. Particulate-based proliposome technology is 
becoming more synonymous with improving hydrophobic and lipophilic drugs entrapped in 
liposomes. The method involves carbohydrates as soluble carrier materials layered with 
phospholipids to form MLVs upon addition of the aqueous phase above Tc (Payne et al., 
1986). Liposomes are prepared by attaching a flask containing carrier particles to a rotary 
evaporator followed by the addition of the organic solution in a portion wise manner through 
a feed-line under reduced pressure to coat the carrier particles. Evaporation of the organic 
solvent under vacuum using rotary evaporation causes the formation of particulate based 
proliposome (Payne et al., 1986; Elhissi et al., 2006). Lipophilic drugs incorporated in 
liposomes prepared from this method demonstrated high entrapment efficiency such as 
Amphotericin B (100%) (Payne et al., 1987), Nimodipine (84.70%) (Sun et al., 2013), CM3 
peptide (100%) and Ciprofloxacin (96%) (Desai et al., 2002).  
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The amount of hydrophobic/ lipophilic drug that can be introduced in a liposome is highly 
dependent on packing restrictions in the lipid bilayers and, as a result, liposomal formulations 
for this type of drug may differ significantly from one drug to the next (Mayer et al., 1986). 
Packaging restrictions of liposomes are influenced by factors such as the technique used and 
drug-to-lipid ratio. The water solubility of lipophilic drugs or hydrophobic compounds 
incorporated into the conventional liposome bilayer is often limited in terms of drug-to-lipid 
ratio (Dhule et al., 2012). It has also been reported that some lipophilic drugs may interfere 
with the formation of the liposome bilayer, limiting the dose which can be incorporated into 
the liposome (Chordiya and Senthilkumaran et al., 2012). This could have occurred when 
higher starting concentrations of BetA (1 mg/ml) loaded into liposomes were unable to be 
entrapped efficiently and therefore lower starting concentrations of BetA (0.5 mg/ml) was 
more efficient in entrapping BetA. In addition, both incomplete and rapid release and have 
been reported for lipophilic drugs entrapped within liposomes (Otero-Espinar et al., 2010), 
therefore we proceeded to evaluate the effect of B1 (BetAL) liposomes and γ-CD-BetA 
liposomes in two NB cell lines. 
5.7) DMSO Tolerance Test for SK-N-BE(2) and KELLY NB Cell Lines 
The results of this study revealed that DMSO at low concentrations (0.1 and 0.4%) promoted 
cell growth in SK-N-BE(2) NB cells for 24-72 hours while in KELLY NB cells, it promoted 
cell growth only at 72 hours with no statistically significant difference reported when 
compared to controls. It is evident that exposure to 1-2% DMSO is toxic in both cell lines (P 
< 0.05). It has been reported that different reagents generally dissolved with a final DMSO 
concentration in a range of 0.1-0.6% and less than 1% did not have significant effects on the 
viability of NB cancer cell lines, in some cases even up to 72 hours exposure (Jadhav et al., 
2007; Ponthan et al., 2007; Wickstro et al., 2007; Xia et al., 2008; Fallarini et al., 2009; 
Götte et al., 2010; More et al., 2011; Frumm et al., 2013; Tsutsumimoto et al., 2014). 
Therefore, in this study, the highest concentration of free BetA (5-20 μg/ml) prepared from a 
stock solution of 5 mg/ml BetA (dissolved in DMSO) contained 0.4% DMSO. 
5.8) Evaluation of Cytotoxicity for Free BetA and BetAL Treatment in SK-N-BE(2) 
and KELLY NB Cell Lines 
In this study, free BetA treatment (5-20 μg/ml) induced cytotoxic effects on SK-N-BE(2) 
(Figure 4.2.1, A and B) and KELLY NB (Figure 4.2.2, A and B) cell lines. SK-N-BE(2) NB 
cells subjected to 5-20 μg/ml  free BetA treatment, demonstrated a time and concentration 
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dependent decrease in the cell viability for all exposure hours (Figure 4.2.1, A, Chapter 4). 
KELLY NB cells treated with free BetA only showed a concentration dependent decrease at 
24 hours exposure (Figure 4.2.2, A, Chapter 4). The lowest cell viability for SK-N-BE(2) NB 
cell line were observed at 15 μg/ml exposure at 72 hours (7% cell viability) and in KELLY 
NB cell line at 10 μg/ml (14% cell viability) (P < 0.05, annotated by asterisks). Statistically 
significant differences were noted for treated cells compared to untreated cells. Estimated 
IC₅₀ concentration values for treatment with free BetA were reported to be 13.10 μg/ml (24 
hours), 14.03 μg/ml (48 hours) and 7.85 μg/ml (72 hours) for SK-N-BE(2) NB cells and 24 
μg/ml (24 hours), 14.50 μg/ml (48 hours) and 76.05 μg/ml (72 hours) for KELLY NB cells 
(Table 4.1, Chapter 4). Therefore the reported IC₅₀ concentration values for this study 
corresponded to the established IC₅₀ values for NB and other brain cancer cell lines reported 
in literature (Fulda et al., 1997; Schmidt et al., 1997; Steele et al., 1999; Wick et al., 1999; 
Thurnher et al., 2003; Moghaddam et al., 2012; Suresh et al., 2012).  
SK-N-BE(2) NB cells treated with BetAL (Figure 4.2.1, B, Chapter 4) showed a time and 
concentration dependent decrease in the cell viability, similar to the treatment of SK-N-BE(2) 
NB cells with free BetA (Figure 4.2.1, A). However cell viability results reported for free 
BetA were lower when compared to BetAL treated cells as concentration and exposure 
duration increased (Table 7.4.1 and Table 7.5.1, refer to Appendix). The estimated IC₅₀ 
concentration values for SK-N-BE(2) cells treated with BetAL (53.45 μg/ml for 24 hours 
38.73 μg/ml for 48 hours and 18.30 μg/ml for 72 hours) was higher when compared to the 
IC₅₀ concentration values reported for free BetA exposure (Table 4.1 and Table 4.2, Chapter 
4). KELLY cells treated with BetAL shows variability in the cell viability across 
concentrations, this is seen at 48 hours as viability decreases from 5-20 μg/ml  (74%, 60%, 
56% and 52% cell viability, respectively) and then an increase at 50 μg/ml (57% cell 
viability) (Figure 4.3.2, Chapter 4). This could suggest that KELLY NB cells demonstrate 
recovery at higher concentrations and exposure times. The estimated IC₅₀ concentration 
values for KELLY NB cells treated with BetAL were higher at 24 and 48 hours (68.65 μg/ml 
and 61.52 μg/ml, respectively) but lower at 72 hours (21.42 μg/ml) when compared to the 
reported IC₅₀ concentration values for free BetA. The estimated IC₅₀ concentration values for 
SK-N-BE(2) and KELLY NB cell line reported in this study suggests that free BetA is more 
effective in inhibiting cell growth in vitro at lower concentrations and shorter exposure 
durations than BetAL. The cytotoxic activity of free drug might have been more effective in 
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reducing the proliferation of NB cells; however BetAL was still successful in reducing the 
cell viability even if the BetA entrapment was poor. 
For all hours with EL exposure in both cell lines, no statistically significant differences was 
observed when compared to untreated cells, suggesting that EL did not confer any cytotoxic 
effects on the cell viability which is in agreement with previous studies (Mitsopoulos and 
Suntres 2011; Dhule et al., 2012; Venegas et al., 2012). This may be due to the phospholipid 
and Chol used in the preparation of EL, which are major components found in biological 
membranes and essential for cellular functions. Liposomes are usually composed of 
biocompatible and biodegradable lipids and should not have any cytotoxic effects in cell 
culture at concentrations up to 200 µM final lipid concentration (Puapermpoonsiri et al., 
2005). This could also be due to the fact that the lipids used exhibited a neutral charge.  
5.9) Evaluation of Cytotoxicity for Free γ-CD and γ-CD-BetAL Treatment in SK-N-
BE(2) and KELLY NB Cell Lines 
Treatment with free γ-CD did not show any statistically significant difference when 
compared to the control at 24 hours for SK-N-BE(2) NB cells, however statistically 
significant differences were noted in KELLY NB cells at 50 μg/ml. Both cell lines showed 
statistically significant differences at 48 and 72 hours exposure to 20 and 50 μg/ml free γ-CD 
suggesting that free γ-CD induces cytotoxicity only after 24 hours exposure at higher 
concentrations. Studies reporting on the in vitro toxicity of free CDs are contradictory as 
some studies report that free CD is toxic and others report no toxicity, however the toxicity 
seems to be related to the type of CDs molecule. CDs are classified based on the amount of 
glucose units present: α-, β-, and γ-CDs (with 6, 7 or 8 glucose units respectively) (Das et al., 
2013) subsequently relating to how they would interact with cells in vitro. The β-CD series is 
the most widely studied CD type and has revealed that it can modulate Chol in cell 
membranes due to their high affinity for Chol, affecting the structure of the cell membrane 
(Zidovetzki and Levitan, 2007), α-CD are most efficient in extracting phospholipids from 
cells (Monnaert et al., 2004) and γ-CD is less lipid selective compared to the other two CDs 
(Monnaert et al., 2004). This is noted in a study investigating CD toxicity in an in vitro 
endothelial BBB model, where the researchers concluded that the α-CD and β-CD series are 
the most toxic CDs whereas the γ-CD series are less toxic (Monnaert et al., 2004). CDs have 
also demonstrated cell toxicity in fibroblasts (Pitha et al., 1988). Abu-Dahab et al., (2013) 
synthesized thymoquine-β-CD self assembling NPs and demonstrated that free CDs (which 
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was the control) had no cytotoxic effects on MCF-7 cells after 72 hours exposure. In this 
study for both cell lines, as the concentration increased from 10-50 μg/ml free γ-CD, the cell 
proliferation decreased. This was observant for both cell lines of 24 and 72 hours. This could 
be due to the aggregation of CD molecules, as previous studies demonstrated that higher CDs 
concentrations, including γ-CDs, have been reported to form aggregates with a diameter of 
100 nm in solution which contributes to toxicity in vitro (Arun et al., 2008; Messner et al., 
2010; Messner et al., 2011). The cytotoxicity induced by free γ-CD was an important factor 
to consider when preparing γ-CD-BetAL, especially in the SK-N-BE(2) NB cell line at 20-50 
μg/ml treatment for 72 hours . Therefore concentrations where the final amount of γ-CD in γ-
CD-BetAL were below 20 μg/ml for 48 and 72 hours exposure in KELLY cell and SK-N-
BE(2) cells was prepared.   
SK-N-BE(2) NB cells treated with γ-CD-BetAL (Figure 4.3.1, Chapter 4) showed a time and 
concentration dependent decrease in cell viability, similar to the trend noticed in both free 
BetA and BetAL exposure. The cell viability was moderately lower in SK-N-BE(2) with γ-
CD-BetAL treatment when compared with BetAL for the same concentrations and time 
points. The estimated IC₅₀ concentration values for γ-CD-BetAL exposure in SK-N-BE(2) 
cells for 24-72 hours were lower when compared to BetAL treated cells for 24-72 hours, 
suggesting that γ-CD-BetAL was more effective in inhibiting cell growth at lower 
concentrations when compared to BetAL as demonstrated by the lower cell viabilities. This 
corresponds to γ-CD-BetAL having a 5% higher BetA entrapment than BetAL, however free 
BetA was still more effective than both liposomal formulations in reducing cell growth 
(Table 4.1, Table 4.2 and Table 4.3, Chapter 4). Similar results were observed in KELLY 
cells treated with γ-CD-BetAL (Figure 4.3.2, Chapter 4), as the cell viability showed a time 
and concentration dependent decrease. KELLY cells treated with γ-CD-BetAL showed 
estimated IC₅₀ concentration values for 24 and 48 hours that were lower than BetAL, 
however free BetA is the most effective in producing lower IC₅₀ concentration values.  
5.10) Conclusive Findings of Liposomal BetA Formulations Compared to Free BetA in 
SK-N-BE(2) and KELLY NB Cell Lines 
BetA is insoluble in most aqueous solutions, hence it was prepared as previously described 
(Damle et al., 2013) by dissolving BetA in DMSO to produce a stock concentration of 5 
mg/ml BetA and further diluted in media to obtain 5-20 μg/ml free BetA concentrations. 
BetAL and γ-CD-BetAL concentrations were prepared in the same manner in defined cell 
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culture media (Section 4.2.3.2, Chapter 2). The amount of BetA in the final concentrations of 
BetAL and γ-CD-BetAL were not equivalent to the amount of BetA found in free BetA even 
though the concentrations were the same (e.g. 5 μg/ml free BetA and 5 μg/ml BetAL/ γ-CD-
BetAL). This is due to the fact that liposomes were subjected to extrusion to produce a final 
concentration of 0.04 mg/ml BetA entrapped in BetAL (B1) and 0.13 mg/ml BetA entrapped 
in γ-CD-BetAL. This is significantly lower when compared to the 1 mg/ml free BetA 
prepared in DMSO. Concentrations were prepared in the same manner from these working 
stock solutions; however the 5-20 μg/ml used in free BetA was increased to 5-50 μg/ml for 
BetAL. This could be the main reason that free BetA conferred a higher cytotoxicity in NB 
cells when compared to BetAL and γ-CD-BetA. The entrapment of BetA in liposomes was 
poor (< 1 mg/ml BetA entrapped in extruded liposome) and therefore did not match the 
cytotoxicity induced by free BetA treatment (Figure 4.4, Chapter 4). Free BetA compared to 
the same concentration of BetAL and γ-CD-BetAL showed statistically significant 
differences (P < 0.05), suggesting that free BetA is more effective in decreasing cell 
proliferation and inducing cytotoxicity into NB cells, especially at 72 hours (10-20 μg/ml) 
(Figure 4.4, Chapter 4). Treatment with-γ-CD-BetAL induced a higher cytotoxicity than 
BetAL in SK-N-BE(2), while treatment with BetAL in KELLY cells induced higher 
cytotoxicity than γ-CD-BetAL as the exposure duration increased. The estimated IC₅₀ values 
for free BetA was lower when compared to BetAL and  γ-CD-BetAL, however the IC₅₀ 
values for γ-CD-BetAL was lower when compared to BetAL suggesting that γ-CD-BetAL 
was more toxic than BetAL. This could be attributed to the higher BetA entrapment in γ-CD-
BetAL.  
Additionally, the less cytotoxic nature of liposomes could also be attributed to sustained drug 
release upon using liposomes, especially in the case of the γ-CD-BetAL as there is double 
loading of BetA and γ-CD. This could have a delayed release of BetA as seen at 48 and 72 
hours in Figure 4.3.2 (Chapter 4). CDs have been reported to demonstrate a delayed release 
of drugs referred to as ‘sustained’ or ‘controlled’ drug release (Sotthivirat et al., 2007; 
Sotthivirat et al., 2009; Daoud-Mahammed et al., 2008; Weifen et al., 2008; Otero-Espinar et 
al., 2012, Mignet et al., 2013). This is especially noticed in CD liposome drug delivery 
systems (Singh et al., 2010; Cui et al., 2011; Nasir et al., 2012; Vafaei et al., 2014). 
Lipophilic plant derivatives within the bilayer of liposomes may cause rigidity of the bilayers, 
resulting in the decreased release of the contents or uptake of liposome by the cell in vitro 
(Gao et al., 2012; Odeh et al., 2012). The nutritional value of the phospholipids of the 
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liposomes could also account for the low cytotoxicity induced by the liposomal formulations 
(Crosasso et al., 2000). 
It is a known fact that the cytoplasmic membranes of cancer cells are more fluid when 
compared to normal cells (Leth-Larsen et al., 2010) and this could be one of the mechanisms 
to facilitate liposome-cell interaction. Although the mechanism of liposome cell interaction 
was not ascertained in this study, previous studies have shown mechanisms in which cells 
would internalize liposomes and other nanoparticles (NPs) through receptor-mediated 
endocytosis. The entire liposome enters the cell via an endosome and then into the lysosome 
or the liposome can cause endosome destabilization resulting in drug liberation into the cell 
cytoplasm (Torchilin, 2005; Dobrovolskaia and McNeil, 2007; Hess and Tseng 2007). In the 
event where the liposome does not enter the cell, liposomes come into close proximity with 
the cell surface and liposome-cell-lipid exchange could occur and the contents are 
automatically released into the cytoplasm (Torchilin, 2005). Low ζ-potentials reported in this 
study indicate low stability in BetAL and γ-BetAL and the fact that BetA was not strongly 
retained within the bilayer by strong van der Waals forces, undesirable BetA leakage might 
have occurred impacting on the results obtained. Therefore cytotoxicity could also be due to 
low concentrations of free BetA uptake that leaked from liposomes. As observed in the SEM 
micrographs of liposomes (Figure 3.4, A and E), aggregation could have also contributed to 
the low cytotoxicity induced by the BetA liposomes. The presence of electrolytes and high 
ionic strength of biological media can result in aggregation of NPs and this may influence 
their ability to interact with or enter cells (Vesaratchanon et al., 2007; Alkilany and Murphy, 
2010). 
Regardless of the delayed effect of BetAL and γ-CD-BetAL on the SK-N-BE(2) and KELLY 
NB cells, the cell viability showed a noticeable concentration and time decrease in cell 
proliferation, similar to free BetA. The cytotoxicity exhibited by BetAL and γ-CD-BetAL 
correlates with the % EE studies. Increasing the amount of BetA in liposomes through 
complexing BetA with γ-CD for enhanced entrapment into γ-CD-BetAL was more effective 
in decreasing cell viability at higher concentrations when compared to BetAL. However both 
BetAL and γ-CD-BetAL could not measure up to the cytotoxicity induced by free BetA 
treatment for both cell lines, suggesting that liposomal formulation were both weak when 
compared to free BetA treatment. This is also seen with the lower estimated IC₅₀ 
concentration values for free BetA in both cell lines when compared to BetAL and γ-CD-
BetAL. 
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CHAPTER 6 
CONCLUSION AND FUTURE RECOMMENDATIONS 
6.1) CONCLUSION 
This study was conducted in order to develop a novel drug delivery system in addressing the 
solubility issues associated with the lipophilic anti-cancer plant extract BetA. This was done 
by preparing BetAL and improving the % EE through double entrapment of BetA and γ-CD-
BetA inclusion complex forming a novel γ-CD-BetAL. The drug delivery system was then 
characterized based on physio-chemical characteristics and evaluated in two NB cancer cell 
lines, compared to free BetA treatment in order to investigate cytotoxicity.  
In this study, liposomal formulations: EL, BetAL (B1 and B2) and γ-CD-BetAL, were 
prepared using the thin film hydration method. Liposomal formulations yielded a 
heterogeneous size distribution of approximately 1-4 μm and manual extrusion was 
successful in reducing the size of liposomes to less than 200 nm for biological systems 
application. HR-SEM images revealed aggregated vesicles of different sizes before extrusion 
and a uniform size distribution of spherical-like vesicles in a size range of less than 200 nm 
after extrusion, matching with size distribution and PI studies obtained from Zetasizer 
NanoZS instrument. HR-SEM micrographs of un-extruded EL did not match with results 
obtained from Zetasizer NanoZS instrument, as HR-SEM images revealed a smaller size 
distribution of liposomes. This was suggested to be due to the differences in techniques and 
aggregated liposomes being measured as large single particles by DLS. Extrusion of 
liposomes caused a decrease in size, PI and ζ-potential. Increasing the concentration of BetA 
into liposomes did not cause an increase in size or ζ-potential before extrusion; however as 
the size decreased the ζ-potential decreased contributing to a less stable liposomal 
formulation. The EL showed a ζ-potential close to 0 mV, indicating that the lipid is neutral; 
this suggested that incorporation of BetA in the lipid bilayers contributed to the negative ζ-
potential values reported for BetA loaded liposomes. 
The % EE results indicate that passive loading of BetA using the thin film hydration method 
was poor and BetA loss after extrusion process was significant. Partitioning of BetA into 
DPPC bilayers of liposomes was dependent upon the hydrophobicity induced by the DPPC 
bilayers and the affinity of BetA to the membrane bilayers. Hence it is possible that with 
BetA and DPPC having weak van der Waals forces between them as no hydrogen bond can 
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be formed, there are no strong electrostatic forces retaining BetA in the DPPC bilayers, 
causing drug leakage. This correlates with the low negative ζ-potential values reported in this 
study before and after extrusion and the significant loss in BetA observed during the 
preparation process. Inclusion of low starting concentrations of BetA (0.5 mg/ml) was more 
effective in entrapping higher amounts of BetA in the DPPC bilayers. Incorporation of γ-CD-
BetA inclusion complex into liposomes to form γ-CD-BetAL did enhanced the % EE by 5% 
when compared to B1 (BetA); however this was not statistically significant. Nevertheless the 
therapeutic efficacy of EL, BetAL (Batch 1) and γ-CD-BetAL in SK-N-BE(2) and Kelly NB 
cell lines was still substantiated. A DMSO tolerance test (0.1%-2%) was performed and the 
sensitivity of free BetA and free γ-CD in both cell lines was determined. Cell viability was 
evaluated using the WST-1 colorimetric cell viability assay. 
DMSO tolerance test revealed that 0.4% DMSO as a final concentration used in free BetA 
preparation did not confer any cytotoxic effects on cell viability. Treatment with free γ-CD at 
20-50 μg/ml at 48 hours and 72 hours in both cell lines showed cytotoxicity. The EL had no 
cytotoxic effects on both cell lines for all exposure durations. Free BetA, BetAL and γ-CD-
BetAL showed a time and concentration dependent decreases in the cell viability of SK-N-
BE(2) NB cell line. The estimated IC₅₀ concentration values in SK-N-BE(2) and KELLY NB 
cell lines for free BetA were lower when compared to BetAL and γ-CD-BetAL. This is 
noticeable with the higher cytotoxicity induced by free BetA when compared with BetAL and 
γ-CD-BetAL. BetA was more effective in inhibiting cell proliferation at lower concentrations 
and at earlier exposure durations. This could be due to the low % EE of BetA into liposomes, 
poor liposomal stability, weak γ-CD-BetA complexion, sustained drug release, liposome-cell-
interaction and the nutritional value of phospholipids of the liposomes.  
In conclusion, the estimated IC₅₀ concentration values for free BetA produced from this study 
matched with established IC₅₀ concentration values reported in previous studies. The 
objectives of preparing and characterizing different liposomal formulations of BetA and the 
novel γ-CD-BetAL were achieved. In this study, the loading of γ-CD-BetA into BetAL to 
produce the novel γ-CD-BetAL exhibited the highest % EE when compared to the other 
liposomal formulations in line with the hypothesis of the study. However, owing to the 
overall low % EE of BetA (< 1 mg/ml), low ζ-potential after extrusion and aggregation the 
liposomal designs became unstable. Weak electrostatic forces were unable to retain BetA in 
liposomes, therefore drug leakage and loss was significant in the preparation of liposomes. 
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These results influenced the evaluation of liposomal formulations in SK-N-BE(2) and Kelly 
NB cell lines. BetAL and γ-CD-BetAL did not measure up to the cytotoxicity induced by free 
BetA. However, γ-CD-BetAL was more effective in reducing cell viability in SK-N-BE(2) 
NB cells than BetAL and BetAL was more effective than γ-CD-BetAL in KELLY NB cells 
at 48-72 hours. Pronounced decrease in cell viability of SK-N-BE(2) and Kelly NB cells 
treated with free BetA, BetAL and γ-CD-BetAL still provides a basis for new hope for the 
effective management of NB using BetA.  
6.2) FUTURE WORK AND RECOMMENDATIONS 
Despite the many advantages posed by liposomes, the main drawback experienced in this 
study was the poor % EE of BetA, as drug loading was poor and drug loss in the initial 
preparation process was significant. Future studies aimed at investigating an active method or 
particulate-based proliposome technology for entrapping BetA as an alternative to the passive 
method used in this study are recommended. Previous studies have shown that these methods 
are more advantageous in promoting a higher % EE than passive loading (Akbarzadeh et al., 
2013; Sun et al., 2013). Extrusion has also been reported to decrease drug entrapment in 
liposomes (Jousma et al., 1987; Berger et al., 2001, Mokhtarieh et al., 2013). Therefore 
creating liposomes of a specific size range first and then optimizing drug loading for efficient 
entrapment into liposomes is also recommended. 
 Drug-to-lipid optimization and the use of a longer alkyl chain length lipid instead of DPPC 
(a 16 alkyl chain length) are recommended (e.g., 18 alkyl chain length) as this could enhance 
the % EE. The use of different lipids in combination or alone could facilitate more strongly 
the retention of BetA in the bilayer of liposomes through strong electrostatic forces/ van der 
Waals forces. To improve BetA entrapment within the DPPC bilayers of liposomes, it was 
recommended to increase the electrostatic forces or van der Waals force by employing 
hydrogen bonding. This could be achieved by preserving the positive charge on the DPPC 
lipid, through increasing the carbon chain between the phosphoric group and amine group, 
the amine group could still have a positive charge and could assist in maintaining BetA in the 
bilayer. The amine group in DPPC could also be substituted with a stronger negatively 
charged group to form van der Waals forces between the BetA and the DPPC lipid. 
Modification of liposomal surfaces with phosphatidylinositol or polyethylene glycol (PEG) 
has been known to improve the stability of liposomes and prevent aggregation (Goa et al., 
2012). The addition of charged lipids to the neutral DPPC such as phosphatidylglycerol (PG) 
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or phosphatidylserine (PS) that is negatively charged could also enhance drug loading and 
increase negative ζ-potential values thereby increasing stability properties of liposomes. 
Drug release kinetics studies are recommended, a drug release study over 24-72 hours would 
be ideal in investigating whether sustained drug release occurred and whether or not γ-CD 
hampered the release of BetA from liposomes, providing further insight into the mechanism 
of liposome-cell-interaction. Differential scanning calorimetry (DSC) would be performed in 
order to evaluate the complexation of BetA with γ-CD. Cryo-TEM for lamellarity structure 
analyses would provide insight into the amount of bilayers present in prepared liposomes and 
further insight into drug loss after the extrusion process. 
Futher cell viability studies to evaluate the effects of the liposomal formulations in non-
malignant human or murine neuronal cell line are recommended. Further investigation of 
estimated IC₅₀ concentration values and determining the selectivity index for free BetA and 
liposomal BetA is also recommended. The integrity of the blood-brain barrier can be 
evaluated in vitro before and after treatment of liposomal formulations using transendothelial 
electrical resistance (TEER). An apoptosis study to evaluate the cytochrome C release could 
validate whether apoptosis is occurring via the intrinsic pathway as reported in literature 
(Fulda and Debatin, 2000, Fulda et al, 2010). 
Chlorotoxin (CTX) is a 36-amino acid peptide found in the venom of the deathstalker 
scorpion (Leiurus quinquestriatus) which blocks small-conductance chloride channels 
(DeBin and Strichartz, 1991) and has emerged as a promising targeting agent due to its ability 
to specifically recognize over expressed tumour receptors in a broad spectrum of cancers 
including tumours of neuroectodermal origin such as human NB and some glioblastoma cell 
lines (Kievit et al., 2010). Future studies for improving the liposomal BetA would investigate 
the development of a targeted drug delivery BetAL system using CTX. 
Animal model of NB are recommended to investigate the in vivo effects of liposomes, in 
terms of drug release, clearance and biodistribution to ascertain whether there is a correlation 
with in vitro findings.  
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APPENDIXES: SUPPLEMENTARY DATA 
7.1 Liposome Results 
Table 7.1 Average size (diameter) distribution, PI and ζ-potential analyses of liposomal 
formulations (n = 3 ± SD) from Malvern Instruments’ Zetasiser Nano Zs 
 EL Batch 1 Batch 2 
Un-extruded γ-CD-
BetA L 
Average size 
before extrusion 
4194 nm ± 2260 2387 nm ± 249.2 1742 nm ± 959.9 1367 nm ± 190.5 
Average size after 
extrusion 
149.30 nm ± 37.82 159.0 nm ± 26.85 179.0 nm ± 16.37 116.70 nm ± 1.650 
PI before extrusion 0.86 ± 0.2361 1.00 ± 0.0 0.94 ± 0.11 0.49 ± 0.07 
PI after extrusion 0.17 ± 0.03 0.22 ± 0.07 0.23 ± 0.03 0.24 ± 0.01 
ζ-potential before 
extrusion 
-1.21 mV ± 1.28 mV -2.25 mV ± 0.16 mV -2.52 mV ± 0.32 mV -2.02 mV ± 0.36 mV 
ζ-potential after 
extrusion 
1.06 mV ± 0.09 mV -1.24 mV ± 0.07 mV -1.29 mV ± 0.03 mV -1.48 mV ± 0.06 mV 
 
7.2 UHPLC Chromatographs  
 
Figure 7.2.1 UHPLC chromatogram of methanol (blank) detected at wavelength of 205 nm. Retention time 
was 2.6 minutes and separation was achieved at 35 °C using the following chromatographic conditions: C-18 
(4.5 mm x 150.5 µm) column (Phenomenex Kinetex, USA), mobile phase of acetonitrile: methanol (80:20 v/v), 
an injection volume of 10 ul and 0.5 ml/min flow rate. 
Methanol 
(Blank) 
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Figure 7.2.2 UHPLC chromatogram of Betulinic acid standard (0.0625 mg/ml) detected at wavelength of 205 
nm. Retention time was 2.5 minutes and separation was achieved at 35 °C using the following chromatographic 
conditions: C-18 (4.5 mm x 150.5µm) column (Phenomenex Kinetex, USA), mobile phase of acetonitrile: 
methanol (80:20 v/v), an injection volume of 10 ul and 0.5 ml/min flow rate. 
 
Figure 7.2.3 UHPLC chromatogram of Betulinic acid standard (0.125 mg/ml) detected at wavelength of 205 
nm. Retention time was 2.5 minutes and separation was achieved at 35 °C using the following chromatographic 
conditions: C-18 (4.5 mm x 150.5 µm) column (Phenomenex Kinetex, USA), mobile phase of acetonitrile: 
methanol (80:20 v/v), an injection volume of 10 ul and 0.5 ml/min flow rate 
 
Figure 7.2.4 UHPLC chromatogram of Betulinic acid standard (0.250 mg/ml) detected at wavelength of 205 
nm. Retention time was 2.5 minutes and separation was achieved at 35 °C using the following chromatographic 
conditions: C-18 (4.5 mm x 150.5µm) column (Phenomenex Kinetex. USA), mobile phase of acetonitrile: 
methanol (80:20 v/v), an injection volume of 10 ul and 0.5 ml/min flow rate. 
Betulinic 
Acid 
Betulinic 
Acid 
Betulinic 
Acid 
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Figure 7.2.5 UHPLC chromatogram of Betulinic acid standard (1 mg/ml) detected at wavelength of 205 nm. 
Retention time was 2.5 minutes and separation was achieved at 35 °C using the following chromatographic 
conditions: C-18 (4.5 mm x 150.5µm) column (Phenomenex Kinetex, USA), mobile phase of acetonitrile: 
methanol (80:20 v/v), an injection volume of 10 ul and 0.5 ml/min flow rate. 
 
Figure 7.2.6 UHPLC chromatogram of BetAL detected at wavelength of 205 nm. Retention time was 2.5 
minutes and separation was achieved at 35 °C using the following chromatographic conditions: C-18 (4.5 mm x 
150.5µm) column (Phenomenex Kinetex, USA), mobile phase of acetonitrile: methanol (80:20 v/v), an injection 
volume of 10 ul and 0.5 ml/min flow rate. 
 
Figure 7.2.7 UHPLC chromatogram of γ-CD-BetAL detected at wavelength of 205 nm. Retention time was 2.5 
minutes and separation was achieved at 35 °C using the following chromatographic conditions: C-18 (4.5 mm x 
150.5µm) column (Phenomenex Kinetex, USA), mobile phase of acetonitrile: methanol (80:20 v/v), an injection 
volume of 10 ul and 0.5 ml/min flow rate. 
Betulinic 
Acid 
Betulinic 
Acid 
Betulinic 
Acid 
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7.3 DMSO Tolerance Test of SK-N-BE(2) and KELLY NB Cells 
Table 7.3.1 Percentage cell viability of SK-N-BE(2) NB cells exposed to 0.1-2% DMSO 
concentrations at the selected time intervals (24-72 hours) compared to control (untreated 
cells, represented as 100% cell viability).  
Cell viability of DMSO tolerance test for SK-N-BE(2) NB cells (n = 6) 
Hours Control (Untreated) 0.1% DMSO 0.4% DMSO 1% DMSO 2% DMSO 
24 100% 122% 118% 97% 66% 
48 100% 117% 116% 91% 56% 
72 100% 123% 121% 117% 53% 
 
Table 7.3.2 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 0.1-2% DMSO 
compared to control (untreated cells) at the selected time intervals (24-72 hours). 
P values (* P < 0.05) of DMSO tolerance test for SK-N-BE(2) NB cells ( n = 6) 
Hours 0.1% DMSO 0.4% DMSO 1% DMSO 2% DMSO 
24 P = 0.1211 P = 0.1695 P = 0.6789 P = 0.0008 
48 P = 0.0947 P = 0.0921 P = 0.2724 P < 0.0001 
72 P = 0.2164 P = 0.5159 P = 0.2164 P < 0.0001 
 
Table 7.3.3 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 0.1-2% DMSO 
compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) of DMSO tolerance test for SK-N-BE(2) NB cells (n = 6) 
Comparison between hours 0.1% DMSO 0.4% DMSO 1% DMSO 2% DMSO 
24 & 48 P = 0.7996 P = 0.8680 P = 0.554 P = 0.8805 
48 & 72 P = 0.7780 P = 0.7408 P = 0.1172 P = 0.0957 
24 & 72 P = 0.9329 P = 0.8827 P = 0.3917 P = 0.0594 
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Table 7.3.4 Percentage cell viability of KELLY NB cells exposed to 0.1-2% DMSO 
concentrations at the selected time intervals (24-72 hours) compared to control (untreated 
cells represented as 100% cell viability). 
Cell viability of DMSO tolerance test for KELLY NB cells (n = 6) 
Hours Control  0.1% DMSO 0.4% DMSO 1% DMSO 2% DMSO 
24 100% 100% 99% 92% 71% 
48 100% 95% 99% 91% 75% 
72 100% 106% 111% 111% 77% 
 
Table 7.3.5 P values (* P < 0.05) for KELLY NB cells exposed to 0.1-2% DMSO compared 
to control (untreated cells) at the selected time intervals (24-72 hours). 
P values (* P < 0.05) of DMSO tolerance test for KELLY NB cells (n = 6) 
Hours 0.1% DMSO 0.4% DMSO 1% DMSO 2% DMSO 
24 P = 0.9323 P = 0.9424 P = 0.2774 P < 0.0001 
48 P = 0.2809 P = 0.9007 P = 0.3090 P = 0.0045 
72 P = 0.5749 P = 0.3268 P = 0.6349 P = 0.0006 
 
Table 7.3.6 P values (* P < 0.05) for KELLY NB cells exposed to 0.1-2% DMSO compared 
between the selected time intervals (24-72 hours). 
P values (* P < 0.05) of DMSO tolerance test for KELLY NB cells (n = 6) 
Comparison between hours 0.1% DMSO 0.4% DMSO 1% DMSO 2% DMSO 
24 & 48 P = 0.5367 P = 0.9848 P = 0.9367 P = 0.6362 
48 & 72 P = 0.6372 P = 0.7024 P = 0.5744 P = 0.2002 
24 & 72 P = 0.7689 P = 0.7413 P = 0.5875 P = 0.2568 
 
 
 
 
 
 
 
 
119 
 
7.4 Free BetA Exposure to SK-N-BE(2) and KELLY NB Cells 
Table 7.4.1 Percentage cell viability of SK-N-BE(2) NB cells exposed to 5-20 μg/ml free 
BetA concentrations at the selected time intervals (24-72 hours) compared to control 
(untreated cells, represented as 100% cell viability 
Cell viability of SK-N-BE(2) NB cells exposed to free BetA (5-20 μg/ml) for 24-72 hours (n = 6) 
Hours Control  5 μg/ml BetA 10 μg/ml BetA 15 μg/ml BetA 20 μg/ml BetA 
24 100% 80% 68% 33% 31% 
48 100% 83% 53% 40% 42% 
72 100% 59% 12% 7% 15% 
 
Table 7.4.2 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-20 μg/ml free BetA 
compared to control (untreated cells) at the selected time intervals (24-72 hours). 
P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to free BetA (5-20 μg/ml) (n = 6) 
Hours 5 μg/ml BetA 10 μg/ml BetA 15 μg/ml BetA 20 μg/ml BetA 
24 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 
48 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 
72 P < 0.0010 P < 0.0001 P < 0.0001 P < 0.0001 
 
Table 7.4.3 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-20 μg/ml free BetA 
compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to free BetA (5-20 μg/ml ) (n = 6) 
Hours 5 μg/ml BetA 10 μg/ml BetA 15 μg/ml BetA 20 μg/ml BetA 
24 & 48 P = 0.1484 P = 0.0051 P = 0.1767 P = 0.0305 
48 & 72 P = 0.5122 P < 0.0001 P < 0.0001 P = 0.0003 
24 & 72 P = 0.0841 P < 0.0001 P < 0.0001 P < 0.0001 
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Table 7.4.4 Percentage cell viability of KELLY NB cells exposed to 5-20 μg/ml free BetA 
concentrations at the selected time intervals (24-72 hours) compared to control (untreated 
cells, represented as 100% cell viability).  
Cell viability of KELLY NB cells exposed to free BetA (5-20 μg/ml) for 24-72 hours (n = 6) 
Hours Control  5 μg/ml BetA 10 μg/ml BetA 15 μg/ml BetA 20 μg/ml BetA 
24 100% 95% 92% 75% 66% 
48 100% 69% 50% 50% 45% 
72 100% 17% 14% 17% 22% 
 
Table 7.4.5 P values (* P < 0.05) for KELLY NB cells exposed to 5-20 μg/ml free BetA 
compared to control (untreated cells) at the selected time intervals (24-72 hours). 
P values (* P < 0.05) for KELLY NB cells exposed to free BetA (5-20 μg/ml) (n = 6) 
Hours 5 μg/ml BetA 10 μg/ml BetA 15 μg/ml BetA 20 μg/ml BetA 
24 P = 0.0031 P = 0.0362 P = 0.0011 P = 0.0003 
48 P = 0.0294 P < 0.0001 P < 0.0001 P < 0.0001 
72 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 
 
Table 7.4.6 P values (* P < 0.05) for KELLY NB cells exposed to 5-20 μg/ml free BetA 
compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for KELLY NB cells exposed to free BetA (5-20 μg/ml) (n = 6) 
Hours 5 μg/ml BetA 10 μg/ml BetA 15 μg/ml BetA 20 μg/ml BetA 
24 & 48 P = 0.0009 P < 0.0001 P = 0.0267 P < 0.0001 
48 & 72 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0002 
24 & 72 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 
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7.5 BetAL Exposure to SK-N-BE(2) and KELLY NB Cells 
Table 7.5.1 Percentage cell viability of SK-N-BE(2) NB cells exposed to EL and 5-50 μg/ml 
BetAL at the selected time intervals (24-72 hours) compared to control (untreated cells, 
represented as 100% cell viability).  
Cell viability of SK-N- BE (2) NB cells exposed to BetAL (5-50 μg/ml) for 24-72 hours (n = 6) 
Hours Control  EL 5 μg/ml 
BetAL 
10 μg/ml 
BetAL 
15 μg/ml 
BetAL 
20 μg/ml 
BetAL 
50 μg/ml 
BetAL 
24 100% 99% 92% 81% 79% 68% 55% 
48 100% 110% 93% 77% 62% 54% 47% 
72 100% 102% 76% 51% 50% 36% 31% 
 
Table 7.5.2 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to EL and 5-50 μg/ml 
BetAL compared to control (untreated) cells at the selected time intervals (24-72 hours). 
P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to BetAL (5-50 μg/ml) (n = 6) 
Hours EL 5 μg/ml 
BetAL 
10 μg/ml 
BetAL 
15 μg/ml 
BetAL 
20 μg/ml 
BetAL 
50 μg/ml 
BetAL 
24 P = 0.5062 P < 0.0001 P < 0.0001 P = 0.0090 P = 0.0002 P < 0.0001 
48 P = 0.1062 P = 0.0124 P = 0.0306 P = 0.0114 P < 0.0001 P < 0.0001 
72 P = 0.1836 P < 0.0001 P = 0.0002 P < 0.0001 P < 0.0001 P < 0.0001 
 
Table 7.5.3 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to EL and 5-50 μg/ml 
BetAL compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to BetAL (5-50 μg/ml) (n = 6) 
Hours EL 5 μg/ml 10 μg/ml 15 μg/ml 20 μg/ml 50 μg/ml 
24 & 48 P = 0.1065 P = 0.8898 P = 0.6420 P = 0.2380 P = 0.0203 P = 0.0006 
48 & 72 P = 0.0522 P = 0.3170 P = 072200 P = 0.3980 P = 0.0002 P = 0.7030 
24 & 72 P = 0.2002 P = 0.0022 P = 0.0073 P = 0.0053 P = 0.0001 P = 0.0120 
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Table 7.5.4 Percentage cell viability of KELLY NB cells exposed to EL and 5-50 μg/ml 
BetAL at the selected time intervals (24-72 hours) compared to control (untreated cells, 
represented as 100% cell viability).  
Cell viability of KELLY NB cells exposed to BetAL (5-50 μg/ml) for 24-72 hours (n = 6) 
Hours Control  EL 5 μg/ml 
BetAL 
10 μg/ml 
BetAL 
15 μg/ml 
BetAL 
20 μg/ml 
BetAL 
50 μg/ml 
BetAL 
24 100% 105% 83% 86% 80% 75% 61% 
48 100% 98% 74% 60% 56% 52% 57% 
72 100% 98% 65% 57% 41% 42% 47% 
 
Table 7.5.5 P values (* P < 0.05) for KELLY NB cells exposed to 5-50 μg/ml BetAL 
compared to control (untreated) cells at the selected time intervals (24-72 hours). 
P values (* P < 0.05) for KELLY NB cells exposed to BetAL (5-50 μg/ml) (n = 6) 
Hours EL 5 μg/ml 
BetAL 
10 μg/ml 
BetAL 
15 μg/ml 
BetAL 
20 μg/ml 
BetAL 
50 μg/ml 
BetAL 
24 P = 0.1604 P < 0.0001 P = 0.0125 P = 0.0001 P < 0.0001 P < 0.0001 
48 P = 0.5818 P = 0.0003 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 
72 P = 0.05613 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 
 
Table 7.5.6 P values (* P < 0.05) for KELLY NB cells exposed to 5-50 μg/ml BetAL 
compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for KELLY NB cells exposed to BetAL (5-50 μg/ml) (n = 6) 
Hours EL 5 μg/ml 10 μg/ml 15 μg/ml 20 μg/ml 50 μg/ml 
24 & 48 P = 0.1604 P = 0.1731 P = 0.4342 P < 0.0001 P < 0.0001 P = 0.1661 
48 & 72 P = 0.9656 P = 0.1357 P = 0.4593 P < 0.0001 P = 0.1667 P = 0.0002 
24 & 72 P = 0.1547 P = 0.0759 P = 0.0017 P < 0.0001 P = 0.0007 P = 0.0002 
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7.6 Free γ-CD Exposure to SK-N-BE(2) and KELLY NB Cells 
Table 7.6.1 Percentage cell viability of SK-N-BE(2) NB cells exposed to 5-50 μg/ml free γ-
CD at the selected time intervals (24-72 hours) compared to control (untreated cells, 
represented as 100% cell viability). Values are rounded off to two decimal places. 
Cell viability of SK-N- BE (2) NB cells exposed to free γ-CD (5-50 μg/ml) for 24-72 hours (n = 6) 
Hours Control  5 μg/ml γ-
CD 
10 μg/ml γ-
CD 
15 μg/ml γ-
CD 
20 μg/ml γ-
CD 
50 μg/ml γ-
CD 
24 100% 100% 100% 98% 96% 97% 
48 100% 101% 105% 99% 85% 87% 
72 100% 111% 116% 121% 48% 40% 
 
Table 7.6.2 P values (* P < 0.05) for SK-N-BE NB (2) cells exposed to 5-50 μg/ml free γ-CD 
compared to control (untreated) cells at the selected time intervals (24-72 hours).                    
P values (* P < 0.05) for  SK-N-BE(2) NB cells exposed to free γ-CD (5-50 μg/ml) (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 50 μg/ml γ-CD 
24 P = 0.9534 P = 0.8704 P = 0.7225 P = 0.4125 P = 0.1148 
48 P = 0.5794 P = 0.0821 P = 0.7945 P = 0.0006 P = 0.0002 
72 P = 0.2820 P = 0.0773 P = 0.0353 P < 0.0001 P < 0.0001 
 
Table 7.6.3 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-50 μg/ml free γ-CD 
compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to free γ-CD (5-50 μg/ml) (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 50 μg/ml γ-CD 
24 & 48 P = 0.7564 P = 0.3727 P = 0.8914 P = 0.5763 P = 0.8498 
48 & 72 P = 0.6380 P = 0.2639 P = 0.0379 P < 0.0001 P < 0.0001 
24 & 72 P = 0.4901 P = 0.1311 P = 0.0400 P < 0.0001 P < 0.0001 
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Table 7.6.4 Percentage cell viability of KELLY NB cells exposed to 5-50 μg/ml free γ-CD at 
the selected time intervals (24-72 hours) compared to control (untreated cells, represented as 
100% cell viability). Values are rounded off to two decimal places. 
Cell viability of KELLY NB cells exposed to free γ-CD (5-50 μg/ml) for 24-72 hours (n = 6) 
Hours Control  5 μg/ml γ-
CD 
10 μg/ml γ-
CD 
15 μg/ml γ-
CD 
20 μg/ml γ-
CD 
50 μg/ml γ-
CD 
24 100% 105% 104% 105% 99% 94% 
48 100% 104% 105% 99% 95% 86% 
72 100% 107% 102% 104% 95% 92% 
 
Table 7.6.5 P values (* P < 0.05) for KELLY NB cells exposed to 5-50 μg/ml free γ-CD 
compared to control (untreated) cells at the selected time intervals (24-72 hours).                    
P values (* P < 0.05) for  KELLY NB cells exposed to free γ-CD (5-50 μg/ml) (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 50 μg/ml γ-CD 
24 P = 0.2855 P = 0,2753 P = 0,2673 P = 0,5908 P = 0,0112 
48 P = 0.2327 P = 0,7913 P = 0,7913 P = 0,01169 P = 0.0001 
72 P = 0.2585 P = 0,3319 P = 0,1161 P = 0,00932 P = 0.0153 
 
Table 7.6.6 P values (* P < 0.05) for KELLY NB cells exposed to 5-50 μg/ml free γ-CD 
compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for KELLY NB cells exposed to free γ-CD (5-50 μg/ml) (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 50 μg/ml γ-CD 
24 & 48 P = 0.8577 P = 0.8502 P = 0.9604 P = 0.1785 P = 0.0224 
48 & 72 P = 0.5826 P = 0.3791 P = 0.9999 P = 0.9935 P = 0.1300 
24 & 72 P = 0.7018 P = 0.6589 P = 0.9469 P = 0.2748 P = 0.5472 
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7.7 γ-CD-BetAL Exposure to SK-N-BE(2) and KELLY NB Cells 
Table 7.7.1 Percentage cell viability of SK-N-BE(2) NB cells exposed to 5-50 μg/ml γ-CD-
BetAL at the selected time intervals (24-72 hours) compared to control (untreated cells, 
represented as 100% cell viability).  
Cell viability of SK-N- BE (2) NB cells exposed to γ-CD-BetAL (5-50 μg/ml) for 24-72 hours (n = 6) 
Hours Control 5 μg/ml γ-
CD-BetA L 
10 μg/ml γ-
CD-BetA L 
15 μg/ml γ-
CD-BetA L 
20 μg/ml γ-
CD-BetA L 
50 μg/ml γ-
CD-BetA L 
24 100% 94% 85% 77% 64% 49% 
48 100% 87% 75% 57% - - 
72 100% 65% 50% - - - 
Table 7.7.2 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-50 μg/ml γ-CD-
BetAL compared to control (untreated) cells at the selected time intervals (24-72 hours). 
P values (* P < 0.05) for  SK-N-BE(2) NB cells exposed to γ-CD-BetAL (5-5 μg/ml) (n = 6) 
Hours 5 μg/ml γ-CD-
BetA L 
10 μg/ml γ-CD-
BetA L 
15 μg/ml γ-CD-
BetA L 
20 μg/ml γ-CD-
BetA L 
50 μg/ml γ-CD-
BetA L 
24 P = 0.0406 P < 0.0001 P < 0.0001 P = 0.0010 P = 0.0003 
48 P = 0.0010 P = 0.0001 P < 0.0001 - - 
72 P = 0.0117 P < 0.0001 - - - 
Table 7.7.3 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-5 μg/ml γ-CD-
BetAL compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to γ-CD-BetAL (5-50 μg/ml) (n = 6) 
Hours 5 μg/ml γ-CD-
BetA L 
10 μg/ml γ-CD-
BetA L 
15 μg/ml γ-CD-
BetA L 
20 μg/ml γ-CD-
BetA L 
50 μg/ml γ-CD-
BetA L 
24 & 48 P = 0.1288 P = 0.0018 P = 0.0025 P = 0.0757 P = 0.3669 
48 & 72 P = 0.1598 P = 0.0309 P = 0.0436 - - 
24 & 72 P = 0.0314 P = 0.0002 - - - 
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Table 7.7.4 Percentage cell viability of KELLY NB cells exposed to 5-50 μg/ml γ-CD-BetAL 
at the selected time intervals (24-72 hours) compared to control (untreated cells, represented 
as 100% cell viability).  
Cell viability of KELLY NB cells exposed to γ-CD-BetAL (5-50 μg/ml ) for 24-72 hours (n = 6) 
Hours Control 5 μg/ml γ-
CD-BetA L 
10 μg/ml γ-
CD-BetA L 
15 μg/ml γ-
CD-BetA L 
20 μg/ml γ-
CD-BetA L 
24 100% 87% 79% 73% 63% 
48 100% 73% 66% 59% - 
72 100% 68% 62% 59% - 
Table 7.7.5 P values (* P < 0.05) for KELLY NB cells exposed to 5-50 μg/ml γ-CD-BetAL 
compared to control (untreated) cells at the selected time intervals (24-72 hours). 
P values (* P < 0.05) for  KELLY NB cells exposed to γ-CD-BetAL (5-50 μg/ml) (n = 6) 
Hours 5 μg/ml γ-CD-
BetA L 
10 μg/ml γ-CD-
BetA L 
15 μg/ml γ-CD-
BetA L 
20 μg/ml γ-CD-
BetA L 
24 P = 0.0038 P < 0.0001 P = 0.0017 P < 0.0001 
48 P < 0.0001 P < 0.0001 P < 0.0001 - 
72 P < 0.0001 P = 0.0001 P = 0.0002 - 
Table 7.7.6 P values (* P < 0.05) for KELLY NB cells exposed to 5-50 μg/ml γ-CD-BetAL 
compared between the selected time intervals (24-72 hours). 
P values (* P < 0.05) for KELLY NB cells exposed to γ-CD-BetAL (5-50 μg/ml) (n = 6) 
Hours 5 μg/ml γ CD- 
BetAL 
10 μg/ml γ CD- 
BetAL 
15 μg/ml γ CD- 
BetAL 
20 μg/ml γ CD-
BetAL 
24 & 48 P = 0.0089 P = 0.0024 P = 0.2755 P = 0.1952 
48 & 72 P = 0.2924 P = 0.7707 P = 0.0590 - 
24 & 72 P = 0.0030 P = 0.0351 P = 0.0308 - 
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7.8 Comparison of Selected Concentrations of Free BetA, BetAL and γ-CD-BetAL at 
Specific Time Points in SK-N-BE(2) and KELLY NB Cell Lines 
Table 7.8.1 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-20 μg/ml free BetA 
compared to 5-20 μg/ml  free BetAL at the selected time intervals (24-72 hours).
P values (* P < 0.05) for the comparison of free BetA with BetAL in SK-N-BE(2) NB (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 
24 P = 0.0133 P = 0.006 P = 0.0001 P < 0.0001 
48 P = 0.3457 P = 0.038 P = 0.1372 P = 0.0543 
72 P = 0.0075 P = 0.001 P < 0.0010 P < 0.0001 
Table 7.8.2 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-20 μg/ml free BetA 
compared to 5-20 μg/ml  free γ-CD-BetAL at the selected time intervals (24-72 hours).        
P values (* P < 0.05) for the comparison of free BetA with γ-CD-BetAL in SK-N-BE(2) NB (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 
24 P = 0.0061 P = 0.0008 P < 0.0001 P = 0.0016 
48 P = 0.4815 P = 0.0180 P = 0.0302 - 
72 P = 0.0471 P < 0.0001 - - 
Table 7.8.3 P values (* P < 0.05) for SK-N-BE(2) NB cells exposed to 5-20 μg/ml BetAL 
compared to 5-20 μg/ml  free γ-CD-BetAL at the selected time intervals (24-72 hours).
P values (* P < 0.05) for the comparison of BetAL with γ-CD-BetAL in SK-N-BE(2) NB (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 
24 P = 0.6550 P = 0.1354 P = 0.7824 P = 0.0792 
48 P < 0.0001 P = 0.4630 P = 0.7131 - 
72 P = 0.3894 P < 0.0001 - - 
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Table 7.8.4 P values (* P < 0.05) for KELLY NB cells exposed to 5-20 μg/ml free BetA 
compared to 5-20 μg/ml  free BetAL at the selected time intervals (24-72 hours).
P values (* P < 0.05) for the comparison of free BetA with BetAL in KELLY NB (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 
24 P < 0.0001 P = 0.0030 P = 0.0002 P < 0.0001 
48 P = 0.0042 P = 0.0185 P < 0.0001 P < 0.0001 
72 P = 0.0003 P < 0.0001 P < 0.0001 P = 0.0239 
Table 7.8.5 P values (* P < 0.05) for KELLY NB cells exposed to 5-20 μg/ml free BetA 
compared to 5-20 μg/ml  free γ-CD-BetAL at the selected time intervals (24-72 hours).
P values (* P < 0.05) for the comparison of free BetA with γ-CD-BetAL in KELLY NB (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 
24 P = 0.0003 P < 0.0001 P = 1.0000 P < 0.0001 
48 P = 0.0001 P = 0.0365 P = 0.0001 - 
72 P < 0.0001 P < 0.0001 P = 0.0005 - 
Table 7.8.6 P values (* P < 0.05) for KELLY NB cells exposed to 5-20 μg/ml BetAL 
compared to 5-20 μg/ml  free γ-CD-BetAL at the selected time intervals (24-72 hours).
P values (* P < 0.05) for the comparison of BetAL with γ-CD-BetAL in KELLY NB (n = 6) 
Hours 5 μg/ml γ-CD 10 μg/ml γ-CD 15 μg/ml γ-CD 20 μg/ml γ-CD 
24 P = 0.5015 P = 0.2115 P = 0.2901 P = 0.0007 
48 P = 0.0843 P = 0.6840 P = 0.0063 - 
72 P = 0.7835 P = 0.5769 P = 0.1751 - 
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